<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        30-887-18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TEMOL 140 mg capsule
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TEMOZOLOMIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        140
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Sachet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1607.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="EirGen Pharma" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            EirGen Pharma
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ASPEN PHARMA TRADING LIMITED (APTL)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01AX03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>1. WHAT TEMOL IS AND WHAT IT IS USED FOR</strong><br />Temol contains a medicine called temozolomide. This medicine is an antitumour agent.<br />Temol is used for the treatment of specific forms of brain tumours:<br />- In adults with newly-diagnosed glioblastoma multiforme. Temol is first used together with radiotherapy (concomitant phase of treatment) and after that alone (monotherapy phase of treatment).<br />- In children 3 years and older and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma. Temol is used in these tumours if they return or get worse after standard treatments.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>2. BEFORE YOU TAKE TEMOL<br />Do not take TEMOL</strong><br />- If you are allergic (hypersensitive) to Temolozomide or any of the other ingredients of Temol.<br />- If you have had an allergic reaction to dacarbazine (an anticancer medicine sometimes called DTIC). Signs of allergic reaction include feeling itchy, breathlessness or wheezing, swelling of the face, lips, tongue or throat.<br />- If certain kinds of blood cells are severely reduced (myelosuppression), such as your white blood cell count and platelet count. These blood cells are important for fighting infection and for proper blood clotting. Your doctor will check your blood to make sure you have enough of these cells before you begin treatment.</p><p>&nbsp;</p><p><strong>Take special care with TEMOL</strong><br />- You should be observed closely for the development of a serious form of pneumonia called Pneumocystis carinii pneumonia (PCP). If you are a newly-diagnosed patient (glioblastoma multiforme) you may be receiving Temol for 42 days in combination with radiotherapy. In this case, your doctor will also prescribe medicine to help you prevent this type of pneumonia (PCP).<br />- If you have low counts of red blood cells (anaemia), white blood cells and platelets, or blood clotting problems before starting the treatment, or if you develop them during treatment. Your doctor may decide to reduce the dose, interrupt, stop or change your treatment. You may also need other treatments. In some cases, it may be necessary to stop treatment with Temol. Your blood will be tested frequently during treatment to monitor the side effects of Temol on your blood cells.<br />- You may have a small risk of other changes in blood cells, including leukaemia.<br />- If you have nausea (feeling sick in your stomach) and/or vomiting which are very common side effects of Temol (see section 4 &ldquo;Possible side effects&rdquo;), your doctor may prescribe you a medicine (an anti-emetic) to help prevent vomiting. If you vomit frequently before or during treatment, ask your doctor about the best time to take Temol until the vomiting is under control. If you vomit after taking your dose, do not take a second dose on the same day.<br />- If you develop fever or symptoms of an infection contact your doctor immediately.<br />- Do not open, crush or chew the capsules. If a capsule is damaged, avoid contact of the powder with your skin, eyes or nose. Avoid inhaling the powder. If you accidentally get some in your eyes or nose, flush the area with water.<br />- If you are older than 70 years of age, you might be more prone to infection, bruising or bleeding.<br />- If you have liver or kidney problems, your dose of Temol may need to be adjusted.<br />- If you have ever had or might now have a hepatitis B infection. This is because Temol could cause hepatitis B to become active again, which can be fatal in some cases. Patients will be carefully checked by their doctor for signs of this infection before treatment is started.</p><p><br />Due to lack of experience, Temol should not be used in children younger than 3 years.</p><p><br />Temol may cause permanent infertility. Male patients should use effective contraceptions and not father a child for up to 6 months after stopping treatment. It is recommended to seek advice on conservation of sperm prior to treatment.</p><p>&nbsp;</p><p><strong>Using other medicines</strong><br />Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p><br /><strong>Pregnancy and breast-feeding</strong><br />Tell your doctor if you are pregnant, think you might be or are planning to get pregnant. You must not be treated with Temol during pregnancy unless clearly indicated by your doctor.<br />Effective contraceptive precautions must be taken by both male and female patients who are taking Temol (see also &ldquo;Take special care with Temol&rdquo; above). You should stop breast-feeding while receiving treatment with Temol.</p><p><br /><strong>Driving and using machines</strong></p><p>Temol may make you feel tired or sleepy. In this case, do not drive or use any tools or machines.</p><p><strong>Important information about some of the ingredients of TEMOL</strong><br />Temol hard capsules contain lactose. If you have been told by yourdoctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>3. HOW TO TAKE TEMOL</strong><br /><u>Dosage and duration of treatment</u><br />Your doctor will work out your dose of Temol. This is based on your size (height and weight) and if you have a recurrent tumour and have had chemotherapy treatment in the past.<br />You may be given other medicines (anti-emetics) to take before and/or after taking Temol to prevent or control nausea and vomiting.</p><p><br /><u><em>Patients with newly-diagnosed glioblastoma multiforme:</em></u><br />If you are a newly-diagnosed patient, treatment will occur in two phases:<br />- Treatment together with radiotherapy (concomitant phase) first<br />- Followed by treatment with only Temol (monotherapy phase).</p><p><br />During the concomitant phase, your doctor will start Temol at a dose of 75 mg/m2 (usual dose). You will take this dose every day for 42 days (up to 49 days) in combination with radiotherapy. The Temol dose may be delayed or stopped, depending on your blood counts and how you tolerate your medicine during the concomitant phase. Once the radiotherapy is completed, you will interrupt treatment for 4 weeks. This will give your body a chance to recover. Then, you will start the monotherapy phase.</p><p><br />During the monotherapy phase, the dose and way you take Temol will be different. Your doctor will work out your exact dose. There may be up to 6 treatment periods (cycles). Each one lasts 28 days. You will take your new dose of Temol alone once daily for the first 5 days (&ldquo;dosing days&rdquo;) of each cycle. The first dose will be 150 mg/m2. Then you will have 23 days without Temol. This adds up to a 28- day treatment cycle. After Day 28, the next cycle will begin. You will again take Temol once daily for 5 days followed by 23 days without Temol. The Temol dose may be adjusted, delayed or stopped depending on your blood counts and how you tolerate your medicine during each treatment cycle.</p><p><br /><em><u>Patients with tumours that have returned or worsened (malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma) taking Temol only:</u></em></p><p><br />A treatment cycle with Temol lasts 28 days. You will take Temol alone once daily for the first 5 days. This daily dose depends on whether or not you have received chemotherapy before.</p><p><br />If you have not been previously treated with chemotherapy, your first dose of Temol will be 200 mg/m2 once daily for the first 5 days. If you have been previously treated with chemotherapy, your first dose of Temol will be 150 mg/m2 once daily for the first 5 days. Then, you will have 23 days without Temol. This adds up to a 28-day treatment cycle.</p><p><br />After Day 28, the next cycle will begin. You will again receive Temol once daily for 5 days, followed by 23 days without Temol.</p><p><br />Before each new treatment cycle, your blood will be tested to see if the Temol dose needs to be adjusted. Depending on your blood test results, your doctor may adjust your dose for the next cycle.</p><p>&nbsp;</p><p><strong>How to take Temol</strong><br />Take your prescribed dose of Temol once a day, preferably at the same<br />time each day.</p><p><br />Take the capsules on an empty stomach; for example, at least one hour before<br />you plan to eat breakfast. Swallow the capsule(s) whole with a glass of water. Do not open or chew the capsules. If a capsule is damaged, avoid contact with<br />your skin, eyes or nose. If it occurs, wash the affected area thoroughly.</p><p><br />Depending on the prescribed dose, you may have to take more than one capsule together, eventually with different strengths (content of active substance, in mg). The colour of the capsule cap is different for each strength<br />(see in the table below).</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>Strength</td><td>Colour of the cap</td></tr><tr><td>Temol 5 mg hard capsules</td><td>Green</td></tr><tr><td>Temol 20 mg hard capsules</td><td>Orange</td></tr><tr><td>Temol 100 mg hard capsules</td><td>Purple</td></tr><tr><td>Temol 140 mg hard capsules</td><td>Blue</td></tr><tr><td>Temol 180 mg hard capsules</td><td>Chocolate brown</td></tr><tr><td>Temol 250 mg hard capsules</td><td>White</td></tr></tbody></table><p>You should make sure you fully understand and remember the following:<br />&bull; How many capsules you need to take every dosing day. Ask your doctor or pharmacist to write it down (including the colour).<br />&bull; Which days are your dosing days.</p><p><br />Review the dose with your doctor each time you start a new cycle, since it may be different from the last cycle.</p><p><br />Always take Temol exactly as your doctor has told you. It is very important to check with your doctor or pharmacist if you are not sure.</p><p>Errors in how you take this medicine may have serious health consequences.</p><p>&nbsp;</p><p><strong>If you take more TEMOL than you should</strong><br />If you accidentally take more Temol capsules than you were told to,<br />contact your doctor or pharmacist immediately.</p><p><br /><strong>If you forget to take TEMOL</strong><br />Take the missed dose as soon as possible during the same day. If a full day has gone by, check with your doctor. Do not take a double dose to make up for a forgotten dose, unless your doctor tells you to do so.</p><p><br />If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>4. POSSIBLE SIDE EFFECTS</strong><br />Like all medicines, Temol can cause side effects, although not everybody gets them.<br /><u>Contact your doctor immediately if you have any of the following:</u><br />- A severe allergic (hypersensitive) reaction (hives, wheezing or other breathing difficulty),<br />- Uncontrolled bleeding,<br />- Seizures (convulsions),<br />- Fever,<br />- A severe headache that does not go away.</p><p>&nbsp;</p><p>Temol treatment can cause a reduction in certain kinds of blood cells.<br />This may cause you to have increased bruising or bleeding, anaemia (a shortage of red blood cells), fever, and reduced resistance to infections. The reduction in blood cell counts is usually short-lived. In some cases, it may be prolonged and may lead to a very severe form of anaemia (aplastic anaemia). Your doctor will monitor your blood regularly for any changes, and will decide `if any specific treatment is needed. In some cases, your Temol dose will be reduced or treatment stopped.<br /><u>Side effects from clinical studies:</u><br />Side effects may occur with certain frequencies, which are defined as follows:<br />&bull; Very common: affects more than 1 user in 10<br />&bull; Common: affects 1 to 10 users in 100<br />&bull; Uncommon: affects 1 to 10 users in 1,000<br />&bull; Rare: affects 1 to 10 users in 10,000<br />&bull; Very rare: affects less than 1 user in 10,000<br />&bull; Not known: frequency cannot be estimated from the available data.</p><p>&nbsp;</p><p><u>Temol in combination treatment with radiotherapy in newly-diagnosed glioblastoma</u><br />Patients receiving Temol in combination with radiotherapy may experience different side effects than patients taking Temol alone.<br />The following side effects may occur, and may require medical attention.</p><p><br /><strong>Very common: </strong>loss of appetite, headache, constipation (difficulty passing stools), nausea (feeling sick in your stomach), vomiting, rash, hair loss, tiredness.</p><p><br /><strong>Common:</strong> oral infections, wound infection, reduced number of blood cells (neutropenia, thrombocytopenia, lymphopenia, leukopenia), increased sugar in the blood, loss of weight, change in mental status or alertness, anxiety/ depression, sleepiness, difficulty speaking, impaired balance, dizziness, confusion, forgetfulness, difficulty concentrating, inability to fall asleep or stay asleep, tingling sensation, bruising, shaking, abnormal or blurry vision, double vision, hearing impairment, shortness of breath, cough, blood clot in the legs, fluid retention, swollen legs, diarrhoea, stomach or abdominal pain, heartburn, upset stomach, difficulty swallowing, dry mouth, skin irritation or redness, dry skin, itching, muscle weakness, painful joints, muscle aches and pains, frequent urination, difficulty with holding your urine, allergic reaction, fever, radiation injury, face swelling, pain, abnormal taste, abnormal liver function tests.</p><p><br /><strong>Uncommon:</strong> flu-like symptoms, red spots under the skin, appearance of a swollen face or muscle weakness, low potassium level in the blood, weight gain, mood swings, hallucination and memory impairment, partial paralysis, impaired coordination, difficulty swallowing, impaired sensations, partial loss of vision, dry or painful eyes, deafness, infection of the middle ear, ringing in the ears, earache, palpitations (when you can feel your heart beat), blood clot in the lung, high blood pressure, pneumonia, inflammation of your sinuses, bronchitis, a cold or the flu, swollen stomach, difficulty controlling your bowel movements, haemorrhoids, peeling skin, increased skin sensitivity to sunlight, change in skin colour, increased sweating, muscle damage, back pain, difficulty in urinating, vaginal bleeding, sexual impotence, absent or heavy menstrual periods, vaginal irritation, breast pain, hot flushes, shivering, discolouration of your tongue, change in your sense of smell, thirst, tooth disorder.</p><p><br /><u>Temol monotherapy in recurrent or progressive glioma</u><br />The following side effects may occur, and may require medical attention.</p><p><br /><strong>Very common: </strong>reduced number of blood cells (neutropenia or lymphopenia, thrombocytopenia), loss of appetite, headache, vomiting, fatigue, nausea (feeling sick in your stomach), constipation (difficulty passing stools).</p><p><br /><strong>Common: </strong>loss of weight, dizziness, tingling sensation, shortness<br />of breath, diarrhoea, abdominal pain, upset stomach, rash, itching, hair loss,<br />fever, weakness, shivering, feeling unwell, pain, change in taste Somnolence, increase in liver enzyme.</p><p><br /><strong>Uncommon: </strong>reduced number of blood cell counts (pancytopenia, anaemia,<br />leukopenia), cytomegalovirus infection, infection reactivation such as cytomegalovirus, hepatitis B virus, diabetes insipidus.</p><p><br /><strong>Rare: </strong>cough, infections including pneumonia.</p><p><br /><strong>Very rare:</strong> skin redness, urticaria (hives), skin eruption, allergic reactions.</p><p>&nbsp;</p><p><u>Other side effects:</u><br />Very rare cases of severe rash with skin swelling, including on the palms of the hands and soles of the feet, or painful reddening of the skin and/or blisters on the body or in the mouth have been observed. Tell your doctor immediately if this occurs.</p><p><br />Very rare cases of lung side effects have been observed with Temol.<br />Patients usually present with shortness of breath and cough. Tell your doctor if you notice any of these symptoms.</p><p><br />In very rare cases, patients taking Temol and medicines like it may have a small risk of developing secondary cancers, including leukaemia.</p><p><br />If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>5. HOW TO STORE TEMOL</strong><br />Keep out of the reach and sight of children</p><p><br />Do not use Temol after the expiry date which is stated on the label and carton. The expiry date refers to the last day of that month.</p><p><br /><u>HDPE Bottle presentation</u><br />Store below 30 &deg;C<br />Store in the original bottle in order to protect from moisture.<br />Keep the bottle tightly closed.</p><p><br /><u>Sachet presentation</u><br />Store below 30 &deg;C<br />Medicines should not be disposed via wastewater or household waste. Ask you pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>6. FURTHER INFORMATION<br />a. What Temol contains<br />- The active substance is temozolomide. Each capsule contains 5 mg temozolomide.<br />- The active substance is temozolomide. Each capsule contains 20 mg temozolomide.<br />- The active substance is temozolomide. Each capsule contains 100 mg temozolomide.</p><p>- The active substance is temozolomide. Each capsule contains 140 mg temozolomide.<br />- The active substance is temozolomide. Each capsule contains 180 mg temozolomide.<br />- The active substance is temozolomide. E ach capsule contains 250 mg temozolomide.<br />- The other ingredients are:<br /><u>Capsule content</u><br />Lactose Anhydrous<br />Colloidal silicon dioxide<br />Sodium Starch Glycollate (Type A)<br />Tartaric Acid<br />Stearic Acid<br /><u>Capsule shell, Size 0:</u><br />5 mg: gelatin, titanium dioxide (E 171). yellow iron oxide (E 172), Indigotine-FD&amp; C Blue2 (E132)<br />20 mg: gelatin, titanium dioxide (E 171), red iron oxide (E 172), yellow iron oxide (E 172)<br />100 mg: gelatin, titanium dioxide (E 171), indigotine FD&amp;C blue2 (E 132), red iron oxide (172)<br />140 mg: Gelatin, titanium dioxide (E 171), indigotine FD&amp;C blue 2 (E 132)<br />180 mg: Gelatin, titanium dioxide (E 171), yellow iron oxide (E 172), red iron oxide (E 172), black iron oxide (E 172)<br />250 mg: gelatin, titanium dioxide (E 171).</p><p><u>Printing ink</u><br />Black ink:Shellac, Propylene glycol, Purified water, Sodium ammonia solution, Potassium hydroxide, Black iron oxide (E 172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                b. What TEMOL looks like and the contents of the pack
5 mg: Hard gelatin capsules size 0 (green opaque cap/white opaque body) with 5 printed on the body.
20 mg: Hard gelatin capsules size 0 (orange opaque cap /white opaque body)
with 20 printed on the body.
100 mg: Hard gelatin capsules size 0 (purple opaque cap /white opaque body)
with 100 printed on the body.
140 mg: Hard gelatin capsules size 0 (blue opaque cap /white opaque body)
with 140 printed on the body.
180mg: Hard gelatin capsules size 0 (chocolate brown opaque cap /white
opaque body) with 180 printed on the body
250 mg: Hard gelatin capsules size 0 (white opaque cap /white opaque body)
with 250 printed on the body.

HDPE Bottle presentation
White opaque High Density Polyethylene Bottles with Polppropylene push lock
assembly closure, with polyester coil containing 5 capsules.

Sachet presentation
Sachets composed of paper on linear low density polyethylene (outermost layer), aluminium and ethylene acrylic acid co-polymer (innermost layer). Each sachet contains 1 hard capsule and is dispensed in a cardboard carton. The carton contains 5 or 20 hard capsules, individually sealed in sachets.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>c. Marketing Authorisation Holder and Manufacturer</strong></p><p><br /><strong>Manufacturered by:</strong><br />EirGen Pharma Ltd.,<br />Westside Business Park,<br />Old Kilmeaden Road,<br />Waterford, Ireland.</p><p><br /><strong>1ry Packager: </strong>Millmount Healthcare Ltd, Navan, Ireland.<br /><strong>2ry Packager</strong>: Millmount Healthcare Ltd, City North, Ireland</p><p><br /><strong>Marketing Authorization Holder:</strong><br />Aspen Pharma Trading Limited<br />3016 Lake Drive Citywest Business Campus. Dublin 24, Ireland<br />For any information about this medicinal product, please contact the local representative of the Marketing Authorization Holder:</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                d. This leaflet was last approved in {01/2016}; version number {1}
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>1. ما المقصود بالدواء تيمول؟ وما دواعي استخدامه؟</strong><br />يحتوى تيمول على الدواء المسمى تيموزولوميد. هذا دواء مضاد للأورام. يستخدم تيمول لعلاج أنواع<br />بعينها من أورام المخ:<br />- في البالغين الذين شخصت حديثًا إصابتهم بالورم الدباقي الأرومي متعدد الأشكال. يستخدم تيمول أو مع العلاج الإشعاعي (المرحلة المتزامنة من العلاج) ثم وحده بعد ذلك (مرحلة العلاج الأحادي من العلاج).<br />- في الأطفال الذين تبلغ أعمارهم 3 سنوات فما فوق وفي البالغين المرضى بالورم الدباقي الخبيث مثل الورم الدباقي الأرومي متعدد الأشكال أو ورم الخلايا النجمية اللاتنسجي. يستخدم تيمول في هذه الأورام إن تكررت الإصابة بها أو إن تفاقمت بعد العلاج القياسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>2. قبل تعاطي تيمول<br />موانع استخدام تيمول</strong><br />- إذا كنت تعاني من الأرجية (فرط الحساسي) تجاه مادة تيمولوزومايد أو أيٍ من المكونات الأخرى في هذا الدواء.<br />- إذا كنت أُصبت برد فعل أرجي تجاه مادة دكاربازين (عقار مضاد للسرطان ويُسمى &quot;دي تي آي سي&quot; أحياناً). تشمل أعراض رد الفعل الأرجي الشعور بحكة أو انقطاع النفس أو أزيز في الصدر أو تورم الوجه أو الشفتين أو اللسان أو الحلق.<br />- في حالة الانخفاض الشديد في أنواع معينة من خلايا الدم (حالة كبت النِّقْي)، مثل انخفاض عدد خلايا الدم البيضاء وعدد الصفيحات. هذه الخلايا الدموية مهمة لمكافحة العدوى والتجلط السليم للدم. سيقوم الطبيب بعمل اختبارات دم لك للتأكد من وفرة هذه الخلايا لديك قبل بدء العلاج.</p><p><strong>اتخاذ العناية الخاصة مع تيمول</strong><br />- تجب مراقبة حالتك عن قرب للتحري عن تطور نوع خطير من الالتهاب الرئوي يُسمى &quot;الالتهاب الرئوي بالمتكيسة الجؤجؤية&quot; (بي سي بي). إذا كانت حالتك مُشخَّصة حديثاً (الورم الأرومي الدبقي متعدد الأشكال)؛ فيمكن أن تتعاطي تيمول لمدة 42 يوماً بالتزامن مع العلاج الإشعاعي. في هذه الحالة؛ سوف يصف لك الطبيب دواءً للمساعدة على عدم إصابتك بذلك النوع من الالتهاب الرئوي (بي سي بي).<br />- إذا كنت تعاني من نقص عدد خلايا الدم الحمراء (فقر دم) أو خلايا الدم البيضاء والصفيحات أو تعاني من مشكلات في تجلط الدم قبل بدء العلاج، أو إذا أُصبت بهذه المشكلات أثناء العلاج. يمكن أن يقرر الطبيب خفض الجرعة لك أو قطع العلاج أو إيقافه أو تغييره. وقد تحتاج إلى علاجات أخرى أيضًا. في بعض الحالات ؛قد يكون من الضروري إيقاف العلاج بالعقار تيمول. ستجرى لك اختبارات دم بشكل متكرر أثناء العلاج لمراقبة الآثار الجانبية للعقار تيمول على خلايا دمك.<br />- هناك احتمال صغير لحدوث تغيرات أخرى في خلايا دمك بما فيها ابيضاض الدم.<br />- إذا أُصبت بالغثيان (الشعور برغبة في التقيؤ) و/أو القيء، وهما من الآثار الجانبية الشائعة جداً للعقار تيمول (انظر القسم 4 &quot;الآثار الجانبية الممكنة&quot;)، فقد يصف لك الطبيب دواءً (مضاداً للقيء) للمساعدة على منع القيء لديك. إذا كنت تتقيأ بشكل متكرر قبل العلاج أو أثنائه، فاسأل الطبيب عن أفضل وقت لتعاطي تيمول حتى تتم السيطرة على القيء. إذا تقيأت بعد أخذ الجرعة؛ فلا تأخذ جرعة ثانية في اليوم نفسه.<br />- إذا أُصبت بحمى أو أعراض عدوى؛ فاتصل بالطبيب على الفور.<br />- لا تفتح الكبسولات ولا تسحقها ولا تمضغها. في حالة تلف كبسولة؛ تجنب ملامسة المسحوق الموجود داخلها لجلدك أو عينيك أو أنفك. تجنب استنشاق المسحوق. إذا لامس بعض المسحوق عينيك أو أنفك بدون قصد؛ فاغسل المنطقة المصابة بالماء.<br />- إذا كنت تجاوزت 70 سنة من العمر؛ فقد تكون أكثر عرضة للعدوى أو الكدمات أو النزيف.<br />- إذا كنت مصاباً باضطرابات كبدية أو كلوية؛ فقد تحتاج إلى تعديل جرعتك من تيمول.<br />- إن كنت قد أصبت مسبقًا بعدوى الالتهاب الكبدي ب أو قد تكون مصابًا بها حاليًا. يرجع ذلك لأن تيمول قد يسبب إعادة تنشيط الالتهاب الكبدي ب، وهو ما قد يكون قات في بعض الحالات. سيقوم الأطباء بفحص مرضاهم بعناية لرصد علامات هذه العدوى قبل بدء العلاج.</p><p>&nbsp;</p><p>يجب تجنب استخدام تيمول للأطفال تحت عمر 3 سنوات بسبب نقص التجارب على الاستخدام في هذه الفئة من المرضى.</p><p>يمكن أن يسبب تيمول عقماً دائماً. ينبغي للمرضى الذكور استعمال وسيلة منع حمل فعالة وتجنب الإنجاب لمدة 6 أشهر بعد التوقف عن العلاج. يُنصح المريض بطلب المشورة الطبية بشأن المحافظة على المني قبل بدء العلاج.</p><p>&nbsp;</p><p><strong>استخدام أدوية أخرى</strong><br />يُرجى إخبار الطبيب أو الصيدلي إذا كنت تتناول حاليًا - أو تناولت مؤخرًا - أي أدوية أخرى، بما في ذلك الأدوية التي تحصل عليها دون وصفة طبية.</p><p>&nbsp;</p><p><strong>الحمل والرضاعة الطبيعية</strong><br />يجب على المريضة إخبار الطبيب إذا كانت حاملاً أو تظن أنها حامل أو إذا كانت تخطط للحمل. يُحظر علاج المرأة الحامل بالعقار تيمول إلا إذا صرَّح الطبيب بذلك بوضوح.</p><p>&nbsp;</p><p>يجب على المرضى الذكور والإناث الذين يتعاطون تيمول استخدام وسائل منع حمل فعالة (انظر أيضاً القسم &quot;اتخاذ العناية الخاصة مع تيمول&quot;). يجب على المرأة المرضعة التوقف عن الرضاعة الطبيعية أثناء تعاطي تيمول.</p><p>&nbsp;</p><p><strong>قيادة المركبات واستخدام الآلات</strong><br />قد يسبب تعاطي تيمول الشعور بالتعب أو النوم. إذا حدث هذا؛ فيجب على المريض تجنب قيادة مركبات أو استخدام أية أدوات أو آلات.<br />معلومات مهمة عن بعض المكونات في العقار تيمول<br />تحتوي كبسولات تيمول الصلبة على مادة اللاكتوز. إذا كان الطبيب قد أخبرك أنك لا تتحمل بعض أنواع السكر، فاتصل بالطبيب قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>3. طريقة تعاطي تيمول</strong><br /><u>مقدار الجرعة ومدة العلاج</u><br />سوف يحدد لك الطبيب الجرعة المناسبة لك من تيمول. يعتمد هذا على حجم الجسم (الطول والوزن)، وهل أنت مصاب بورم راجع وهل أخذت علاجاً كيميائياً سابقاً أم لا.<br />قد تُعطى أدوية أخرى (مضادات القيء) تتناولها قبل و/أو بعد تناول كبسولات تيمول لمنع الغثيان والقيء أو السيطرة عليهما.<br /><u>مرضى الورم الأرومي الدبقي متعدد الأشكال حديث التشخيص:</u><br />إذا كانت حالتك مشخصة حديثاً؛ فسيكون العلاج على مرحلتين:<br />- العلاج بهذا العقار مع العلاج الإشعاعي (مرحلة المعالجة بالأدوية المصاحبة) أولاً<br />- ثم يتبعها العلاج بالعقار تيمول وحده (مرحلة المعالجة أحادية الدواء).<br />أثناء مرحلة المعالجة بالأدوية المصاحبة؛ سيبدأ الطبيب بإعطائك جرعة من تيمول قدرها 75 مجم/م 2 (الجرعة العادية). سوف تأخذ هذه الجرعة كل يوم لمدة 42 يوماً (وقد تصل إلى 49 يوماً) بالتزامن مع العلاج الإشعاعي. قد يؤخِّر الطبيب أو يوقف جرعة تيمول، حسب نتائج اختبارات عد الدم الخاصة بك ودرجة تحملك للدواء أثناء مرحلة المعالجة بالأدوية المصاحبة. بعد إتمام العلاج الإشعاعي، سوف تقطع العلاج لمدة 4 أسابيع. سيعطي هذا الإجراء الفرصة لجسمك حتى يتعافى. بعد ذلك سوف تبدأ في مرحلة المعالجة أحادية الدواء.</p><p>أثناء مرحلة المعالجة أحادية الدواء، ستختلف جرعة تيمول وطريقة تعاطيها. سوف يحدد لك الطبيب الجرعة بالضبط. قد تصل الفترات العلاجية إلى 6 فترات (دورات). مدة كل دورة 28 يوماً. ستأخذ جرعتك الجديدة من العقار تيمول وحده مرة واحدة خلال الأيام الخمسة الأولى (&quot;أيام أخذ الجرعة&quot;) من كل دورة. ستكون الجرعة الأولى 150 مجم/م 2. ثم تقضي 23 يوماً بدون تعاطي تيمول. فتكمل بهذا دورة علاجية واحدة مدتها 28 يوماً.</p><p>&nbsp;</p><p>بعد اليوم 28 ، تبدأ الدورة العلاجية التالية. فتبدأ من جديد أخذ تيمول مرة واحدة في اليوم لمدة 5 أيام تتبعها 23 يوماً بدون تعاطي تيمول. قد يُعدِّل الطبيب جرعة تيمول أو يؤخرها أو يوقفها، حسب نتائج اختبارات عد الدم الخاصة بك ودرجة تحملك للدواء أثناء كل دورة علاجية.<br /><u>مرضى الأورام الراجعة أو المتفاقمة )الورم الدبقي الخبيث، مثل الورم الأرومي الدبقي متعدد الأشكال أو الورم النجمي الكشمي( الذين يتعاطون العقار تيمول فقط:</u><br />مدة الدورة العلاجية بالعقار تيمول 28 يوماً. سوف تتعاطى تيمول وحده مرة واحدة يومياً خلال الأيام الخمسة الأولى. تعتمد هذه الجرعة اليومية على تعاطيك العلاج الكيميائي سابقاً من عدمه.<br />إذا لم تكن تعاطيت علاجاً كيميائياً سابقاً، فستكون الجرعة الأولى لك من تيمول 200 مجم/م 2 مرة واحدة في اليوم خلال الأيام الخمسة الأولى. إذا كنت تعاطيت علاجاً كيميائياً سابقاً، فستكون الجرعة الأولى لك من تيمول 150 مجم/م 2 مرة واحدة في اليوم خلال الأيام الخمسة الأولى. ثم تقضي 23 يوماً بدون تعاطي<br />تيمول. فتكمل بهذا دورة علاجية واحدة مدتها 28 يوماً.</p><p>&nbsp;</p><p>بعد اليوم 28 ، تبدأ الدورة العلاجية التالية. فتبدأ من جديد تعاطي تيمول مرة واحدة في اليوم لمدة 5 أيام تتبعها 23 يوماً بدون تعاطي تيمول.</p><p>&nbsp;</p><p>قبل كل دورة علاجية جديدة؛ سيُجرى لك اختبار دم لتقرير هل تحتاج إلى تعديل جرعتك من تيمول أم لا. وحسب نتائج اختبار الدم الخاصة بك؛ يمكن أن يعدل الطبيب جرعتك في الدورة العلاجية التالية.</p><p>&nbsp;</p><p><strong>طريقة تعاطي تيمول</strong><br />تأخذ جرعة تيمول التي وصفها لك الطبيب مرة واحدة في اليوم، ويكون ذكل في وقت واحد محدد كل يوم.<br />تناول الكبسولات على معدة خاوية;مثلاً قبل تناول وجبة الإفطار بساعة واحدة على الأقل. ابلع الكبسولة (الكبسولات) كاملة مع كوب من الماء.<br />لا تفتح الكبسولات ولا تمضغها. في حالة تلف كبسولة؛ تجنب ملامسة المسحوق الموجود داخلها لجلدك أو عينيك أو أنفك. وإذا حدث ذلك؛ فاغسل المنطقة المصابة بكاملها بالماء.<br />حسب الجرعة الموصوفة، يمكن أن تحتاج إلى تعاطي أكثر من كبسولة واحدة من تركيزات (محتوى المادة مقدراً بالمليجرامات) مختلفة مع بعضها. يختلف غطاء الكبسولة لكل تركيز (انظر الجدول أدناه).</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>التركيز&nbsp;</td><td>لون غطاء الكبسولة</td></tr><tr><td>تيمول 5 مجم - كبسولات صلبة&nbsp;</td><td>أخضر</td></tr><tr><td>تيمول 20 مجم - كبسولات صلبة&nbsp;</td><td>برتقالي</td></tr><tr><td>تيمول 100 مجم - كبسولات صلبة&nbsp;</td><td>أرجواني</td></tr><tr><td>تيمول 140 مجم - كبسولات صلبة&nbsp;</td><td>أزرق</td></tr><tr><td>تيمول 180 مجم - كبسولات صلبة&nbsp;</td><td>بني داكن</td></tr><tr><td>تيمول 250 مجم - كبسولات صلبة&nbsp;</td><td>أبيض</td></tr></tbody></table><p>يجب التأكد من الفهم التام لما يلي وتذكره:<br />&bull; عدد الكبسولات التي يجب عليك تعاطيها في كل يوم من أيام أخذ الجرعة. اطلب من الطبيب أو الصيدلي تدوينه لك (بما في ذلك لون الكبسولات).<br />&bull; أيام أخذ الجرعة الخاصة بك.<br />راجع الجرعة مع الطبيب عند بداية كل دورة علاجية جديدة، لأن الجرعة قد تختلف عن الدورة العلاجية السابقة.<br />يجب تعاطي جرعة تيمول حسب إرشادات الطبيب بالضبط دائمًا. من المهم جداً استشارة الطبيب أو الصيدلي في حالة عدم التأكد من طريقة تعاطي الدواء. قد تؤدي الأخطاء في تعاطي هذا الدواء إلى عواقب صحية خطيرة.</p><p><strong>في حالة تناول جرعة زائدة من تيمول عن الجرعة الموصوفة</strong><br />في حالة تناول جرعة زائدة عن الجرعة الموصوفة من كبسولات تيمول، اتصل بالطبيب أو الصيدلي على الفور.</p><p><strong>في حالة نسيان جرعة تيموزلومايد</strong><br />خذ الجرعة المنسية في أسرع وقت ممكن في اليوم نفسه. إذا انقضى يوم كامل دون أخذ الجرعة؛ فاستشر الطبيب. لا تأخذ جرعة مزدوجة لتعويض الجرعة المنسية إلا إذا أمرك الطبيب بذلك.<br />إذا كان لديك أي أسئلة أخرى بشأن استخدام هذا الدواء، فينبغي استشارة الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p><strong>4. الآثار الجانبية ممكنة الحدوث</strong><br />مثل كل الأدوية، يمكن أن يسبب تيمول آثارًا جانبية وإن كانت لا تحدث في جميع الأشخاص الذين يتعاطونه.<br />اتصل بالطبيب فورًا إذا لاحظت أيًا من الأعراض التالية:<br />- رد فعل أرجي (فرط حساسية) شديد (شرى، أزيز أو صعوبة أخرى في التنفس)،<br />- نزيف غير قابل للسيطرة،</p><p>- نوبات صرع (اختلاجات)،<br />- حمى،<br />- صداع شديد لا يزول.<br />يمكن أن يسبب العلاج بالعقار تيمول نقصاً في أنواع معينة من خلايا الدم. وقد يؤدي هذا إلى زيادة إصابتك بكدمات أو نزيف وفقر دم (نقص خلايا الدم الحمراء) وحمى ونقص مقاومة الجسم للعدوى. يكون نقص عدد خلايا الدم قصير الأجل عادة. في بعض الحالات، قد يستمر لمدة طويلة ويؤدي إلى شكل خطير جداً من فقر الدم (فقر الدم اللاتنسجي). سيقوم الطبيب بمراقبة حالة دمك بانتظام للتحري عن أية تغيرات، وسوف يقرر مدى احتياجك إلى أي علاج خاص. في بعض الحالات، سوف يخفض لك الطبيب جرعة تيمول أو يوقف علاجك بهذا العقار.<br /><u>الآثار الجانبية الواردة من الدراسات السريرية:</u><br />يمكن حدوث الآثار الجانبية بمدى تكرار معين حسب الموضح أدناه:<br />&bull; آثار شائعة جدًا: تؤثر في أكثر من مريض واحد من كل 10 مرضى<br />&bull; آثار شائعة: تؤثر في مريض واحد حتى 10 مرضى من كل 100 مريض<br />&bull; آثار غير شائعة: تؤثر في مريض واحد حتى 10 أشخاص من كل 1000 مريض<br />&bull; آثار نادرة: تؤثر في مريض واحد حتى 10 مرضى من كل 10000 مريض<br />&bull; آثار نادرة جدًا: تؤثر في أقل من مريض واحد من كل 10000 مريض<br />&bull; آثار جانبية غير معروفة: لا يمكن تقدير مدى التكرار من البيانات المتوفرة.</p><p><u>العلاج بالعقار تيمول مع العلاج الإشعاعي لحالات الورم الأرومي الدبقي حديث التشخيص</u><br />قد يُصاب المرضى الذين يتعاطون تيمول مع العلاج الإشعاعي بآثار جانبية مختلفة عن التي تصيب المرضى الذين يتعاطون تيمول وحده. قد تحدث الآثار الجانبية التالية؛ وقد تحتاج إلى عناية طبية.</p><p><strong>شائعة جداً:</strong> فقدان الشهية، صداع، إمساك (صعوبة التبرز)، غثيان (رغبة في التقيؤ)، قيء، طفح جلدي، سقوط الشعر، تعب. شائعة: عدوى فموية، عدوى الجروح، نقص عدد خلايا الدم (قلة العدلات، قلة<br />الصفيحات، قلة اللمفاويات، قلة الكريات البِيض)، زيادة سكر الدم، نقص الوزن، تغير الحالة الذهنية أو التيقظ، قلق/اكتئاب، نعاس، صعوبة الكلام، اختلال التوازن، دوار، ارتباك، نسيان، صعوبة التركيز، العجز عن النوم أو الاستمرار في النوم، إحساس بوخز، كدمات، ارتجاف، اضطراب الرؤية أو تغيم الرؤية، ازدواج<br />الرؤية، ضعف السمع، قصر النفس، سعال، جلطة دموية في الرجلين، احتباس السوائل في الجسم، تورم الرجلين، إسهال، ألم في المعدة أو البطن، حرقة القلب، اضطراب المعدة، صعوبة البلع، جفاف الفم، تهيج الجلد أو احمراره، جفاف الجلد، حكة، ضعف العضلات، ألم في المفاصل، آلام وأوجاع في العضلات، كثرة<br />&nbsp;لتبول، صعوبة التحكم في البول، رد فعل أرجي، حمى، إصابة إشعاعية، تورم الفم، ألم في الفم، مذاق غير سوي، نتائج غير سوية في اختبارات وظائف الكبد.</p><p><strong>شائعة: </strong>أعراض مشابهة للأنفلونزا، بقع حمراء تحت الجلد، تورم الوجه أو ضعف العضلات، انخفاض مستوى البوتاسيوم في الدم، زيادة الوزن، تقلبات مزاجية، هلوسة واختلال الذاكرة، شلل جزئي، اختلال تناسق الجسم، صعوبة في البلع، اختلال الحواس، فقدان جزئي للرؤية، جفاف العينين أو ألم في العينين، صمم، عدوى الأذن الوسطى، طنين في الأذن، ألم في الأذن، خفقان )إحساس الإنسان بنبض قلبه(، جلطة دموية في الرئة، ارتفاع ضغط الدم، التهاب رئوي، التهاب الجيوب الأنفية، التهاب الشُّعَب الهوائية، برد أو إنفلونزا، تورم المعدة، صعوبة التحكم في التبرز، بواسير، تقشر الجلد، زيادة حساسية الجلد لضوء الشمس، تغير لون الجلد، زيادة العرق، تلف العضلات، ألم في الظهر، صعوبة في التبول، نزيف مهبلي، عجز جنسي، فقدان دورات حيض أو غزارة الحيض )عند الإناث(، تهيج مهبلي، ألم في الثديين، نوبات بيغ ساخنة، رعاد، تغير لون اللسان، تغير في حاسة الشم، عطش، خلل في الأسنان. العلاج الأحادي بالعقار تيمول للورم الدبقي الراجع أو المتفاقم قد تحدث الآثار الجانبية التالية؛ وقد تحتاج إلى عناية طبية.&nbsp;</p><p><strong>شائعة جداً: </strong>نقص عدد خلايا الدم (قلة العدلات أو قلة اللمفاويات، قلة الصفيحات)، فقدان الشهية، صداع، قيء، ضعف، غثيان (لرغبة في التقيؤ)، إمساك (صعوبة في التبرز).</p><p><strong>شائعة: </strong>نقص الوزن، تعب، دوار، إحساس بوخز، قصر النفس، إسهال، ألم في البطن، اضطراب المعدة، طفح جلدي، حكة، سقوط الشعر، حمى، رعاد، توعك، ألم، تغير في التذوق. ارتفاع في انزيمات الكبد, نعاس.</p><p><strong>غير شائعة:</strong> نقص عدد خلايا الدم (قلة الكريات الشاملة، فقر دم، قلة الكريات البِيض). عدوى الفيروس المضخم للخلايا, التهاب الكبد الفيروسي ب, مرض السكري الكاذب.</p><p><strong>نادرة: </strong>سعال، عدوى بما فيها الالتهاب الرئوي.</p><p><strong>نادرة جداً: </strong>احمرار الجلد، ارتيكاريا (شرى)، طفح جلدي، ردود فعل أرجية.</p><p><u>تشمل الآثار الجانبية الأخرى ما يلي:</u><br />لوحظ حدوث حالات نادرة جداً من الطفح الجلدي الشديد المصحوب بتورم الجلد، بما في ذلك راحتي اليدين وأخمصي القدمين، أو احمرار مؤلم في الجلد و/أو تنفطات على الجسم أو في الفم. ينبغي إخبار الطبيب على الفور حال حدوث هذه الأعراض.<br />لوحظ حدوث حالات نادرة جداً من الآثار الجانبية الرئوية مع تعاطي تيمول. عادة يظهر على المرضى أعراض قصر النفَس والسعال. يجب إخبار الطبيب حال ملاحظة أيٍ من هذه الأعراض.<br />في حالات نادرة جداً، قد يكون المرضى الذين يتعاطون تيمول عرضة بدرجة صغيرة للإصابة بسرطانات ثانوية بما فيها ابيضاض الدم.<br />إذا زادت خطورة أي من الآثار الجانبية، أو إذا لاحظت حدوث أي آثار جانبية غير المذكورة في هذه النشرة، فيرجى إخبار الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>5. طريقة تخزين تيمول</strong><br />يُحفظ بعيدًا عن متناول الأطفال ونظرهم.<br />لا يُستخدم تيمول بعد انتهاء تاريخ الصلاحية المطبوع على الملصق التعريفي والعلبة الكرتونية. يشير تاريخ الصلاحية إلى آخر يوم في الشهر المطبوع.</p><p><u>الكبسولات المعبأة في عبوة مصنوعة من البولي إثيلين عالي الكثافة</u><br />تُخزن في درجة حرارة أقل من 30 درجة مئوية.<br />تُخزَّن الكبسولات في العبوة الأصلية لحمايتها من الرطوبة.<br />احفظ العبوة مغلفة بإحكام.</p><p><u>الكبسولات المعبأة في أكياس</u><br />تُخزن في درجة حرارة أقل من 30 درجة مئوية.<br />ينبغي عدم التخلص من الأدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لا تحتاج إليها. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>6. معلومات إضافية<br />أ. ماهي محتويات تيمول</strong><br />- المادة الفعالة هي تيموزولومايد. تحتوي كل كبسولة على: 5 مجم تيموزولومايد.<br />- المادة الفعالة هي تيموزولومايد. تحتوي كل كبسولة على: 20 مجم تيموزولومايد.<br />- المادة الفعالة هي تيموزولومايد. تحتوي كل كبسولة على: 100 مجم تيموزولومايد.<br />- المادة الفعالة هي تيموزولومايد. تحتوي كل كبسولة على: 140 مجم تيموزولومايد.<br />- المادة الفعالة هي تيموزولومايد. تحتوي كل كبسولة على: 180 مجم تيموزولومايد.<br />- المادة الفعالة هي تيموزولومايد. تحتوي كل كبسولة على: 250 مجم تيموزولومايد.</p><p>- المكونات الأخرى هي:</p><p><u>محتويات الكبسولة</u></p><p>&nbsp;</p><p><u>لاكتوز لامائي</u><br />ثاني أكسيد السيليكون الغرواني<br />جليكولات نشا الصوديوم (النوع أ)<br />حمض طرطريك<br />حمض الستياريك</p><p><strong>غلاف الكبسولة، الحجم 0:</strong><br />5 مجم: جيلاتين، ثاني أكسيد التيتانيوم (إي 171 ). أكسيد حديد أصفر (إي 172 )، صبغة النيلة (صبغة<br />زرقاء رقم 2) حسب معيار الأغذية والعقاقير ومستحضرات التجميل (ي 132)<br />20 مجم: جيلاتين، ثاني أكسيد التيتانيوم (إي 171 ). أكسيد حديد أحمر (إي 172 )، أكسيد حديد أصفر (إي 172)<br />100 مجم: جيلاتين، ثاني أكسيد التيتانيوم (إي 171 )، أكسيد حديد أصفر(اي ٢٧ )، صبغة النيلة (صبغة ١زرقاء رقم 2) حسب معيار الأغذية والعقاقير ومستحضرات التجميل (إي 132)<br />140 مجم: جيلاتين، ثاني أكسيد التيتانيوم (إي 171 )، صبغة النيلة (صبغة زرقاء رقم 2) حسب معيار الأغذية والعقاقير ومستحضرات التجميل (إي 132)<br />180 مجم: جيلاتين، ثاني أكسيد التيتانيوم (إي 171 ). أكسيد حديد أصفر (إي 172 )، أكسيد حديد أحمر(إي 172)، أكسيد حديد أسود (إي 172)<br />250 مجم: جيلاتين، ثاني أكسيد التيتانيوم (إي 171)<br />حبر الطباعة<br />حبر اسود، شيلاك، جليكول بروبيلين، ماء منقى، محلول نشادر الصوديوم، هيدروكسيد البوتاسيوم، أكسيد حديد أسود (إي 172)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>ب. ماهو الشكل الصيلاني تيمول ووصفه وحجم عبوته</strong><br />5 مجم: كبسولات جيلاتينية صلبة حجم 0 (غطاء الكبسولة معتم أخضر اللون/جسم الكبسولة معتم أبيض اللون) مطبوع على جسم الكبسولة الرقم 5.<br />20 مجم: كبسولات جيلاتينية صلبة حجم 0 (غطاء الكبسولة معتم برتقالي اللون/جسم الكبسولة معتم أبيض اللون) مطبوع على جسم الكبسولة الرقم 20 .<br />100 مجم: كبسولات جيلاتينية صلبة حجم 0 (غطاء الكبسولة معتم أرجواني اللون/جسم الكبسولة معتم أبيض اللون) مطبوع على جسم الكبسولة الرقم 100 .<br />140 مجم: كبسولات جيلاتينية صلبة حجم 0 (غطاء الكبسولة معتم أزرق اللون/جسم الكبسولة معتم أبيض اللون) مطبوع على جسم الكبسولة الرقم 140 .<br />180 مجم: كبسولات جيلاتينية صلبة حجم 0 (غطاء الكبسولة معتم بني داكن اللون/جسم الكبسولة معتم أبيض اللون) مطبوع على جسم الكبسولة الرقم 180 .<br />250 مجم: كبسولات جيلاتينية صلبة حجم 0 (غطاء الكبسولة معتم أبيض اللون/جسم الكبسولة معتم أبيض اللون) مطبوع على جسم الكبسولة الرقم 250 .<br />&nbsp;</p><p><u>الكبسولات المعبأة في عبوة مصنوعة من البولي إثيلين عالي الكثافة</u><br />عبوات بيضاء اللون مصنوعة من مادة البولي إثيلين عالي الكثافة مزودة بغطاء تجميعي يُفتح ويُغلق بالضغط عليه، مصنوعة من مادة البولي بروبيلين، مع سدادة ملفوفة من نسيج البوليستر، وتحتوي العبوة على 5 كبسولات.</p><p><u>الكبسولات المعبأة في أكياس</u><br />الأكياس مصنوعة من الورق وبطانة الكيس من البولي إيثيلين منخفض الكثافة (الطبقة الخارجية)، والألومينيوم والبوليمر المشترك من الإيثيلين وحمض الأكريليك (الطبقة الداخلية).<br />يحتوي كل كيس على كبسولة واحدة صلبة ويوزع في علبة كرتونية. تحتوي العلبة الكرتونية على 5 كبسولات صلبة أو 20 كبسولة صلبة، كل كبسولة معبأة في كيس مغلق بإحكام.<br />قد لا يتم تسويق العبوات بكل الأحجام.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>ت. الشركة صاحبة تفويض التسويق والشركة المصنعة<br />الشركة المصنعة:</strong><br />إيرجن فارما المحدودة<br />ويستسايد بزنس بارك. طريق اولد كيمليادين. واترفورد، ايرلندا.<br /><strong>معبأ بواسطة:</strong> ميلماونت هيلثكير المحدودة نافان ,ايرلندا(معبء اساسي) و ميلماونت هيلثكير المحدودة, سيتي نورث (معبيء ثانوي)</p><p><strong>الشركة صاحبة تفويض التسويق:</strong><br />أسبن فارما تريدينج المحدودة<br />3016 ليك درايف، سيتي ويست بزنس كامبوس، دوبلن 24 ، أيرلندا<br />لأي معلومات عن هذا الدواء، فضلاً الاتصال بالوكيل المحلي لمالك حقوق التسويق: الشركة السعودية<br />العالمية للتجارة المحدودة. هاتف: 00966114707500</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ث. تم الموافقة على هذه النشرة بتاريخ { 01 / 2016 } ، { 1}.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Temol 5 mg hard capsules
Temol 20 mg hard capsules
Temol 100 mg hard capsules
Temol 140 mg hard capsules
Temol 180 mg hard capsules
Temol 250 mg hard capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each hard capsule contains 5 mg temozolomide.
Each hard capsule contains 20 mg temozolomide
Each hard capsule contains 100 mg temozolomide
Each hard capsule contains 140 mg temozolomide
Each hard capsule contains 180 mg temozolomide
Each hard capsule contains 250 mg temozolomide
Excipient with known effect:
Each 5 mg hard capsule contains 399.3mg mg of anhydrous lactose.
Each 20 mg hard capsule contains 384.3 mg of anhydrous lactose.
Each 100 mg hard capsule contains 61.7 mg of anhydrous lactose.
Each 140 mg hard capsule contains 86.4 mg of anhydrous lactose.
Each 180 mg hard capsule contains 111.1 mg of anhydrous lactose.
Each 250 mg hard capsule contains 154.3 mg of anhydrous lactose
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Capsule, hard.
-The hard gelatin capsules are size 0 and have a green opaque cap/white opaque body with 5 printed in black ink on the body.
-The hard gelatin capsules are size 0 and have an orange opaque cap /white opaque body with 20 printed in black ink on the body.
-The hard gelatin capsules are size 0 and have a purple opaque cap /white opaque body with 100 printed in black ink on the body.
-The hard gelatin capsules are size 0 and have a blue opaque cap /white opaque body with 140 printed in black ink on the body.
-The hard gelatin capsules are size 0 and have a chocolatebrown opaque cap/white opaque body with 180 printed in black ink on the body.
-The hard gelatin capsules size 0 and white opaque cap /white opaque body with 250 printed in black ink on the body.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Temol hard capsules is indicated for the treatment of:<br />&bull; adult patients with newly-diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment.<br />&bull; children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Temol hard capsules should only be prescribed by physicians experienced in the oncological treatment of brain tumours.</p><p>Anti-emetic therapy may be administered (see section 4.4).</p><p>Posology</p><p><u>Adult patients with newly-diagnosed glioblastoma multiforme</u><br />Temol hard capsules is administered in combination with focal radiotherapy (concomitant phase) followed by up to 6 cycles of temozolomide (TMZ) monotherapy (monotherapy phase).</p><p>Concomitant phase<br />TMZ is administered orally at a dose of 75 mg/m<sup>2</sup> daily for 42 days concomitant with focal radiotherapy (60 Gy administered in 30 fractions). No dose reductions are recommended, but delay or discontinuation of TMZ administration should be decided weekly according to haematological and non-haematological toxicity criteria. TMZ administration can be continued throughout the 42 day concomitant period (up to 49 days) if all of the following conditions are met:<br />11 absolute neutrophil count (ANC) &ge; 1.5 x 10<sup>9</sup>/l<br />11 thrombocyte count &ge;100 x 10<sup>9</sup>I l<br />II common toxicity criteria (CTC) non-haematological toxicity &le;Grade 1 (except for alopecia, nausea and vomiting).</p><p>During treatment a complete blood count should be obtained weekly. TMZ administration should be temporarily interrupted or permanently discontinued during the concomitant phase according to the haematological and nonhaematological toxicity criteria as noted in Table 1.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3"><p>Table 1. TMZ dosing interruption or discontinuation during concomitant radiotherapy and TMZ</p><p>&nbsp;</p></td></tr><tr><td><p>Toxicity</p></td><td><p>TMZ interruptiona</p></td><td><p>TMZ discontinuation</p></td></tr><tr><td><p>Absolute neutrophil count</p></td><td><p>&ge; 0.5 and &lt; 1.5 x 10<sup>9</sup>/ 1</p></td><td><p>&lt; 0.5 X 10<sup>9</sup>/1</p></td></tr><tr><td><p>Thrombocyte count</p></td><td><p>&ge; 10 and&lt; 100 x 10<sup>9</sup>/1</p></td><td><p>&lt; 10 X 10<sup>9</sup>/1</p></td></tr><tr><td><p>CTC non-haematological toxicity</p><p>(except for alopecia, nausea, vomiting)</p></td><td><p>CTC Grade 2</p><p>&nbsp;</p></td><td><p>CTC Grade 3 or 4</p><p>&nbsp;</p></td></tr></tbody></table><p>a: Treatment with concomitant TMZ can be continued when all of the following conditions are met: absolute neutrophil count &ge; 1.5 x 10<sup>9</sup>/l ; thrombocyte count &ge; 100 x 10<sup>9</sup>/ l; CTC non-haematological toxicity &le;Grade 1 (except for alopecia, nausea, vomiting).</p><p>Monotherapy phase<br />Four weeks after completing the TMZ + RT concomitant phase, TMZ is administered for up to 6 cycles of monotherapy treatment. Dose in Cycle 1 (monotherapy) is 150 mg/m<sup>2</sup> once daily for 5 days followed by 23 days without treatment. At the start of Cycle 2, the dose is escalated to 200 mg/m<sup>2</sup> if the CTC non-haematological toxicity for Cycle 1 is Grade &le; 2 (except for alopecia, nausea and vomiting), absolute neutrophil count (ANC) is &ge; 1.5 x 10<sup>9</sup>/1, and the thrombocyte count is &ge; 100 x 10<sup>9</sup>/1. If the dose was not escalated at Cycle 2, escalation should not be done in subsequent cycles. Once escalated, the dose remains at 200 mg/m<sup>2</sup> per day for the first 5 days of each subsequent cycle except if toxicity occurs. Dose reductions and discontinuations during the monotherapy phase should be applied according to Tables 2 and 3.</p><p>During treatment a complete blood count should be obtained on Day 22 (21 days after the first dose of TMZ). The dose should be reduced or administration discontinued according to Table 3.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3"><p><em>Table 2. TMZ dose levels for monotherapy treatment</em></p></td></tr><tr><td><p>Dose level</p></td><td><p>TMZdose (mg/m<sup>2</sup>/day)</p></td><td><p>Remarks</p></td></tr><tr><td><p>-1</p></td><td><p>100</p></td><td><p>Reduction for prior toxicity</p></td></tr><tr><td><p>0</p></td><td><p>150</p></td><td><p>Dose during Cycle 1</p></td></tr><tr><td><p>1</p></td><td><p>200</p></td><td><p>Dose during Cycles 2-6 in absence of toxicity</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3"><p><em>Table 3. TMZ dose reduction or discontinuation during monotherapy treatment </em></p><p>&nbsp;</p></td></tr><tr><td><p>Toxicity</p></td><td><p>Reduce TMZ by 1 dose level<sup>a</sup></p></td><td><p>Discontinue TMZ</p></td></tr><tr><td><p>Absolute neutrophil count</p></td><td><p>&lt; 1.0 x 10<sup>9</sup>&nbsp;/l</p></td><td><p>See footnote b</p></td></tr><tr><td><p>Thrombocyte count</p></td><td><p>&lt; 50 x 109 /l</p></td><td><p>See footnote b</p></td></tr><tr><td><p>CTC non-haematological Toxicity (except for alopecia, nausea, vomiting)</p></td><td><p>CTC Grade 3</p></td><td><p>CTC Grade 4b</p></td></tr><tr><td colspan="3"><p>a: TMZ dose levels are listed in Table 2.</p><p>b: TMZ is to be discontinued if:</p><p>&bull; dose level -1 (100 mg/m2) still results in unacceptable toxicity</p><p>&bull; the same Grade 3 non-haematological toxicity (except for alopecia, nausea, vomiting) recurs after dose reduction.</p></td></tr></tbody></table><p><em><u>Adult and paediatric patients 3 years of age or older with recurrent or progressive malignant glioma:</u><br />A treatment cycle comprises 28 days. In patients previously untreated with chemotherapy, TMZ is administered orally at a dose of 200 mg/m<sup>2</sup> once daily for the first 5 days followed by a 23 day treatment interruption (total of 28 days). In patients previously treated with chemotherapy, the initial dose is 150 mg/m<sup>2 </sup>once daily, to be increased in the second cycle to 200 mg/m<sup>2 </sup>once daily, for 5 days if there is no haematological toxicity (see section 4.4)</em><br />&nbsp;</p><p><em><u>Special populations</u></em><br />&nbsp;</p><p><em>Paediatric population</em><br />&nbsp;</p><p><em>In patients 3 years of age or older, TMZ is only to be used in recurrent or progressive malignant glioma. Experience in these children is very limited (see sections 4.4 and 5.1). The safety and efficacy of TMZ in children under the age of 3 years have not been established. No data are available.</em><br />&nbsp;</p><p><em>Patients with hepatic or renal impairment<br />The pharmacokinetics of TMZ were comparable in patients with normal hepatic function and in those with mild or moderate hepatic impairment. No data are available on the administration of TMZ in patients with severe hepatic impairment (Child&#39;s Class C) or with renal impairment. Based on the pharmacokinetic properties of TMZ, it is unlikely that dose reductions are required in patients with severe hepatic impairment or any degree of renal impairment. However, caution should be exercised when TMZ is administered in these patients.</em><br />&nbsp;</p><p><em>Elderly patients<br />Based on a population pharmacokinetic analysis in patients 19-78 years of age, clearance of TMZ is not affected by age. However, elderly patients (&gt; 70 years of age) appear to be at increased risk of neutropenia and thrombocytopenia (see section 4.4).</em><br />&nbsp;</p><p><em><u>Method of administration</u><br />Temol hard capsules should be administered in the fasting state.<br />The capsules must be swallowed whole with a glass of water and must not be opened or chewed.<br />If vomiting occurs after the dose is administered, a second dose should not be administered that day.</em></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
Hypersensitivity to dacarbazine (DTIC). 
Severe myelosuppression (see section 4.4).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Opportunistic infections and reactivation of infections</u></p><p>Opportunistic infections (such as Pneumocystis jirovecii pneumonia) and reactivation of infections (such as HBV, CMV) have been observed during the treatment with TMZ (see section 4.8).</p><p><u>Pneumocystis jirovecii pneumonia</u><br />Patients who received concomitant TMZ and RT in a pilot trial for the prolonged 42-day schedule were shown to be at particular risk for developing Pneumocystis jirovecii pneumonia (PCP). Thus, prophylaxis against PCP is required for all patients receiving concomitant TMZ and RT for the 42-day regimen (with a maximum of 49 days) regardless of lymphocyte count. If lymphopenia occurs, they are to continue the prophylaxis until recovery of lymphopenia to grade &le;1.</p><p>There may be a higher occurrence of PCP when TMZ is administered during a longer dosing regimen. However, all patients receiving TMZ, particularly patients receiving steroids, should be observed closely for the development of PCP, regardless of the regimen. Cases of fatal respiratory failure have been reported in patients using TMZ, in particular in combination with dexamethasone or other steroids.</p><p><u>HBV</u><br />Hepatitis due to hepatitis B virus (HBV) reactivation, in some cases resulting in death, has been reported. Experts in liver disease should be consulted before treatment is initiated in patients with positive hepatitis B serology (including those with active disease). During treatment patients should be monitored and managed appropriately.</p><p>Hepatotoxicity<br />Hepatic injury, including fatal hepatic failure, has been reported in patients treated with TMZ (see section 4.8). Baseline liver function tests should be performed prior to treatment initiation. If abnormal, physicians should assess the benefit/risk prior to initiating temozolomide including the potential for fatal hepatic failure. For patients on a 42 day treatment cycle liver function tests should be repeated midway during this cycle. For all patients, liver function tests should be checked after each treatment cycle. For patients with significant liver function abnormalities, physicians should assess the benefit/risk of continuing treatment. Liver toxicity may occur several weeks or more after the last treatment with temozolomide.</p><p>Malignancies<br />Cases of myelodysplastic syndrome and secondary malignancies, including myeloid leukaemia, have also been reported very rarely (see section 4.8).</p><p><u>Anti-emetic therapy</u><br />Nausea and vomiting are very commonly associated with TMZ. Anti-emetic therapy may be administered prior to or following administration of TMZ.</p><p><u>Adult patients with newly-diagnosed glioblastoma multiforme</u><br />Anti-emetic prophylaxis is recommended prior to the initial dose of concomitant phase and it is strongly recommended during the monotherapy phase.</p><p><u>Patients with recurrent or progressive malignant glioma</u><br />Patients who have experienced severe (Grade 3 or 4) vomiting in previous treatment cycles may require anti-emetic therapy.</p><p><u>Laboratory parameters</u><br />Patients treated with TMZ may experience myelosuppression, including prolonged pancytopenia, which may result in aplastic anemia, which in some cases has resulted in a fatal outcome. In some cases, exposure to concomitant medicinal products associated with aplastic anemia, including carbamazepine, phenytoin, and sulfamethoxazole/trimethoprim, complicates assessment. Prior to dosing, the following laboratory parameters must be met: ANC &ge;1.5 x 10<sup>9</sup>I l and platelet count &ge; 100 x 10<sup>9</sup>/1. A complete blood count should be obtained on Day 22 (21 days after the first dose) or within 48 hours of that day, and weekly until ANC &gt; 1.5 x 10<sup>9</sup>/l and platelet count&gt; 100 x 10<sup>9</sup>/1. If ANC falls to &lt; 1.0 x 10<sup>9</sup>/ l or the platelet count is&lt; 50 x 10<sup>9</sup>/1 during any cycle, the next cycle should be reduced one dose level (see section 4.2). Dose levels include 100 mg/m<sup>2</sup>, 150 mg/m<sup>2</sup>, and 200 mg/m<sup>2</sup>. The lowest recommended dose is 100 mg/m<sup>2</sup>.</p><p><u>Paediatric population</u><br />There is no clinical experience with use of TMZ in children under the age of 3 years. Experience in older children and adolescents is very limited (see sections 4.2 and 5.1).</p><p>Elderly patients(&gt; 70 years of age)</p><p>Elderly patients appear to be at increased risk of neutropenia and thrombocytopenia, compared with younger patients. Therefore, special care should be taken when TMZ is administered in elderly patients.</p><p><u>Male patients</u><br />Men being treated with TMZ should be advised not to father a child up to 6 months after receiving the last dose and to seek advice on cryoconservation of sperm prior to treatment (see section 4.6).</p><p><u>Lactose</u><br />This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In a separate phase I study, administration of TMZ with ranitidine did not result in alterations in the extent of absorption of temozolomide or the exposure to its active metabolite monomethyl triazenoimidazole carboxamide (MTIC).</p><p>Administration of TMZ with food resulted in a 33 % decrease in Cmax and a 9 % decrease in area under the curve (AUC). As it cannot be excluded that the change in C<sub>max</sub> is clinically significant, Temol should be administered without food.</p><p>Based on an analysis of population pharmacokinetics in phase II trials, co-administration of dexamethasone, prochlorperazine, phenytoin, carbamazepine, ondansetron, H <sub>2</sub> receptor antagonists, or phenobarbital did not alter the clearance of TMZ. Co-administration with valproic acid was associated with a small but statistically significant decrease in clearance of TMZ.<br />No studies have been conducted to determine the effect of TMZ on the metabolism or elimination of other medicinal products. However, since TMZ does not undergo hepatic metabolism and exhibits low protein binding, it is unlikely that it would affect the pharmacokinetics of other medicinal products (see section 5.2).</p><p>Use of TMZ in combination with other myelosuppressive agents may increase the likelihood of myelosuppression.</p><p><u>Paediatric population</u><br />Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u><br />There are no data in pregnant women. In preclinical studies in rats and rabbits receiving 150 mg/m2 TMZ, teratogenicity and/or foetal toxicity were demonstrated (see section 5.3). Temol hard capsules should not be administered to pregnant women. If use during pregnancy must be considered, the patient should be apprised of the potential risk to the foetus.</p><p><u>Breast-feeding</u><br />It is not known whether TMZ is excreted in human milk; thus, breast-feeding should be discontinued while receiving treatment with TMZ.</p><p>Women of childbearing potential</p><p>Women of childbearing potential should be advised to use effective contraception to avoid pregnancy while they are receiving TMZ</p><p><u>Male fertility</u><br />TMZ can have genotoxic effects. Therefore, men being treated with it should be advised not to father a child up to 6 months after receiving the last dose and to seek advice on cryoconservation of sperm prior to treatment, because of the possibility of irreversible infertility due to therapy with TMZ.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>TMZ has minor influence on the ability to drive and use machines due to fatigue and somnolence (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Clinical trial experience</u><br />In patients treated with TMZ, whether used in combination with RT or as monotherapy following RT for newlydiagnosed glioblastoma multiforme, or as monotherapy in patients with recurrent or progressive glioma, the reported very common adverse reactions were similar: nausea, vomiting, constipation, anorexia, headache and fatigue. Convulsions were reported very commonly in the newly-diagnosed glioblastoma multiforme patients receiving monotherapy, and rash was reported very commonly in newly-diagnosed glioblastoma multiforme patients receiving TMZ concurrent with RT and also as monotherapy, and commonly in recurrent glioma. Most haematologic adverse reactions were reported commonly or very commonly in both indications (Tables 4 and 5); the frequency of grade 3-4 laboratory findings is presented after each table.</p><p>In the tables undesirable effects are classified according to System Organ Class and frequency. Frequency groupings are defined according to the following convention: Very common (&ge;1/10); Common (&ge; 1/100 to &lt; 1/10); Uncommon (&ge; 1/1,000 to&lt; 1/100); Rare (&ge;1/10,000 to &lt;1/1,000) and Very rare (&lt;1/10,000). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p><u>Newly-diagnosed glioblastoma multiforme</u><br />Table 4 provides treatment-emergent adverse events in patients with newly-diagnosed glioblastoma multiforme during the concomitant and monotherapy phases of treatment.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3"><p>Table 4. Treatment-emergent events during concomitant and monotherapy treatment phases in patients with newly-diagnosed glioblastoma multiforme</p></td></tr><tr><td><p>System Organ Class</p></td><td><p>TMZ +concomitant RT n=288*</p></td><td><p>TMZ monotherapy n=224</p></td></tr><tr><td colspan="3"><p>Infections and infestations</p></td></tr><tr><td><p>Common:</p></td><td><p>Iufection, Herpes simplex, wound infection, pharyngitis, candidiasis oral</p></td><td><p>Infection, candidiasis oral</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>&nbsp;</p></td><td><p>Herpes simplex, herpes zoster, influenza-like symptoms</p></td></tr><tr><td colspan="3"><p>Blood and lymphatic system disorders</p></td></tr><tr><td><p>Common:</p></td><td><p>Neutropenia, thrombocytopenia, lymphopenia, leukopenia</p></td><td><p>Febrile neutropenia, thrombocytopenia, anaemia, leukopenia</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Febrile neutropenia, anaemia</p></td><td><p>Lymphopenia, petechiae</p></td></tr><tr><td colspan="3"><p>Endocrine disorders</p><p>&nbsp;</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Cushingoid</p></td><td><p>Cushingoid</p></td></tr><tr><td colspan="3"><p>Metabolism and nutrition disorders</p></td></tr><tr><td><p>Very common:</p></td><td><p>Anorexia</p></td><td><p>Anorexia</p></td></tr><tr><td><p>Common:</p></td><td><p>Hyperglycaemia, weight decreased</p></td><td><p>Weight decreased</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Hypokalemia, alkaline phosphatase increased, weight increased</p></td><td><p>Hyperglycaemia, weight increased</p></td></tr><tr><td colspan="3"><p>Psychiatric disorders</p></td></tr><tr><td><p>Common:</p></td><td><p>Anxiety, emotional lability,</p><p>, ,</p><p>insomnia</p></td><td><p>Anxiety, depression, emotional lability, insomnia</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Agitation, apathy, behaviour disorder, depression, hallucination</p></td><td><p>Hallucination, anmesia</p></td></tr><tr><td colspan="3"><p>Nervous system disorders</p></td></tr><tr><td><p>Very common:</p></td><td><p>Headache</p></td><td><p>Convulsions, headache</p></td></tr><tr><td><p>Common:</p></td><td><p>Convulsions, consciousness decreased, somnolence, aphasia, balance impaired, dizziness, confusion, memory impairment, concentration impaired, neuropathy, paresthesia, speech disorder, tremor</p></td><td><p>Hemiparesis, aphasia, balance impaired, somnolence, confusion, dizziness, memory</p><p>impairment, concentration impaired, dysphasia, neurological disorder (NOS), neuropathy, peripheral neuropathy, paresthesia, speech disorder, tremor</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Status epilepticus, extrapyramidal disorder, hemiparesis, ataxia, cognition impaired, dysphasia, gait abnormal, hyperesthesia, hypoesthesia, neurological disorder (NOS), peripheral neuropathy</p></td><td><p>Hemiplegia, ataxia, coordination abnormal, gait abnormal, hyperesthesia, sensory disturbance</p></td></tr><tr><td colspan="3"><p>Eye disorders</p></td></tr><tr><td colspan="3"><p>&nbsp;</p></td></tr><tr><td><p>Common:</p></td><td><p>Vision blurred</p></td><td><p>Visual field defect, vision blurred, diplopia</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Hemianopia, visual acuity reduced, vision disorder, visual field defect, eye pain</p></td><td><p>Visual acuity reduced, eye pain, eyes dry</p></td></tr><tr><td colspan="3"><p>Ear and labyrinth disorders</p></td></tr><tr><td><p>Common:</p></td><td><p>Hearing impairment</p></td><td><p>Hearing impairment, tinnitus</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Otitis media, tinnitus, hyperacusis, earache</p><p>&nbsp;</p></td><td><p>Deafness, vertigo, earache</p></td></tr><tr><td colspan="3"><p>Cardiac disorders</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Palpitation</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3"><p>Vascular disorders</p></td></tr><tr><td><p>Common:</p></td><td><p>Haemorrhage, oedema, oedema leg</p></td><td><p>Haemorrhage, deep venous thrombosis, oedema leg</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Cerebral haemorrhage, hypertension</p></td><td><p>Embolism pulmonary, oedema, oedema peripheral</p></td></tr><tr><td colspan="3"><p>Respiratory, thoracic and mediastinal disorders</p></td></tr><tr><td><p>Common:</p></td><td><p>Dyspnoea, coughing</p></td><td><p>Dyspnoea, coughing</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Pneumonia, upper respiratory infection, nasal congestion</p></td><td><p>Pneumonia, sinusitis, upper respiratory infection, bronchitis</p></td></tr><tr><td colspan="3"><p>Gastrointestinal disorders</p></td></tr><tr><td><p>Very common:</p></td><td><p>Constipation, nausea, vomiting</p></td><td><p>Constipation, nausea, vomiting</p></td></tr><tr><td><p>Common:</p></td><td><p>Stomatitis, diarrhea, abdominal pain, dyspepsia, dysphagia</p></td><td><p>Stomatitis, diarrhea, dyspepsia, dysphagia, mouth dry</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>&nbsp;</p></td><td><p>Abdominal distension, fecal incontinence, gastrointestinal disorder (NOS), gastroenteritis, haemorrhoids</p></td></tr><tr><td colspan="3"><p>Skin and subcutaneous tissue disorders</p></td></tr><tr><td><p>Very common:</p></td><td><p>Rash, alopecia</p></td><td><p>Rash, alopecia</p></td></tr><tr><td><p>Common:</p></td><td><p>Dermatitis, dry skin, erythema, pruritus</p></td><td><p>Dry skin, pruritus</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Skin exfoliation, photosensitivity reaction, pigmentation abnormal</p></td><td><p>Erythema, pigmentation abnormal, sweating increased</p></td></tr><tr><td colspan="3"><p>Musculoskeletal and connective tissue disorders</p></td></tr><tr><td><p>Common:</p></td><td><p>Muscle weakness, arthralgia</p></td><td><p>Muscle weakness, arthralgia, musculoskeletal pain, myalgia</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Myopathy, back pain, musculoskeletal pain, myalgia</p></td><td><p>Myopathy, back pain</p></td></tr><tr><td colspan="3"><p>Renal and urinary disorders</p></td></tr><tr><td><p>Common:</p></td><td><p>Micturition frequency, urinary</p><p>incontinence</p></td><td><p>Urinary incontinence</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>&nbsp;</p></td><td><p>Dysuria</p></td></tr><tr><td colspan="3"><p>Reproductive system and breast disorders</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Impotence</p></td><td><p>Vaginal haemorrhage, menorrhagia, amenorrhea, vaginitis, breast pain</p></td></tr><tr><td colspan="3"><p>General disorders and administration site conditions</p></td></tr><tr><td><p>Very common:</p></td><td><p>Fatigue</p></td><td><p>Fatigue</p></td></tr><tr><td><p>Common:</p></td><td><p>Allergic reaction, fever, radiation injury, face oedema, pain, taste perversion</p></td><td><p>Allergic reaction, fever, radiation injury, pain, taste perversion</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Asthenia, flushing, hot flushes, condition aggravated, rigors, tongue discolouration, parosmia, thirst</p></td><td><p>Asthenia, face oedema, pain, condition aggravated, rigors, tooth disorder</p></td></tr><tr><td><p>Investigations</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Common:</p></td><td><p>ALT increased</p></td><td><p>ALT increased</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Hepatic enzymes increased, Gamma GT increased, AST increased</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>*A patient who was randomised to the RT arm only, received TMZ + RT,</p><p>Laboratory results<br />Myelosuppression (neutropenia and thrombocytopenia), which is known dose-limiting toxicity for most cytotoxic agents, including TMZ, was observed, When laboratory abnormalities and adverse events were combined across concomitant and monotherapy treatment phases, Grade 3 or Grade 4 neutrophil abnormalities including neutropenic events were observed in 8 % of the patients, Grade 3 or Grade 4 thrombocyte abnormalities, including thrombocytopenic events were observed in 14% of the patients who received TMZ,</p><p><u>Recurrent or progressive malignant glioma</u><br />In clinical trials, the most frequently occurring treatment-related undesirable effects were gastrointestinal disorders, specifically nausea (43 %) and vomiting (36 %), These reactions were usually Grade 1 or 2 (0 - 5 episodes of vomiting in 24 hours) and were either self-limiting or readily controlled with standard anti-emetic therapy, The incidence of severe nausea and vomiting was 4 %,<br />Table 5 includes adverse reactions reported during clinical trials for recurrent or progressive malignant glioma and following the marketing of Temol ,</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2"><p><em>Table 5, Adverse reactions in patients with recurrent or progressive malignant glioma</em></p></td></tr><tr><td colspan="2"><p>Infections and infestations</p></td></tr><tr><td><p>Rare:</p></td><td><p>Opportunistic infections, including PCP</p></td></tr><tr><td colspan="2"><p>Blood and lymphatic system disorders</p></td></tr><tr><td><p>Very common:</p></td><td><p>Neutropenia or lymphopenia thrombocytopenia (grade 3-4) (grade 3-4),</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Pancytopenia, anaemia (grade 3-4), leukopenia</p></td></tr><tr><td colspan="2"><p>Metabolism and nutrition disorders</p></td></tr><tr><td><p>Very common:</p></td><td><p>Anorexia</p></td></tr><tr><td><p>Common:</p></td><td><p>Weight decrease</p></td></tr><tr><td colspan="2"><p>Nervous system disorders</p></td></tr><tr><td><p>Very common:</p></td><td><p>Headache</p></td></tr><tr><td><p>Common:</p></td><td><p>Somnolence, dizziness, paresthesia</p></td></tr><tr><td colspan="2"><p>Respiratory, thoracic and mediastinal disorders</p></td></tr><tr><td><p>Common:</p></td><td><p>Dyspnoea</p></td></tr><tr><td colspan="2"><p>Gastrointestinal disorders</p></td></tr><tr><td><p>Very common:</p></td><td><p>Vomiting, nausea, constipation</p></td></tr><tr><td><p>Common:</p></td><td><p>Diarrhoea, abdominal pain, dyspepsia</p></td></tr><tr><td colspan="2"><p>Skin and subcutaneous tissue disorders</p></td></tr><tr><td><p>Common:</p></td><td><p>Rash, pruritus, alopecia</p></td></tr><tr><td><p>Very rare:</p></td><td><p>Erythema multiforme, erythroderma, urticaria, exanthema</p></td></tr><tr><td colspan="2"><p>General disorders and administration site conditions</p></td></tr><tr><td><p>Very common:</p></td><td><p>Fatigue</p></td></tr><tr><td><p>Common:</p></td><td><p>Fever, asthenia, rigors, malaise, pain, taste perversion</p></td></tr><tr><td><p>Very rare:</p></td><td><p>Allergic reactions, angioedema including anaphylaxis,</p></td></tr></tbody></table><p>&nbsp;</p><p>Laboratory results</p><p>Grade 3 or 4 thrombocytopenia and neutropenia occurred in 19 % and 17 % respectively, of patients treated for malignant glioma, This led to hospitalisation and/or discontinuation of TMZ in 8 % and 4 %, respectively, Myelosuppression was predictable (usually within the first few cycles, with the nadir between Day 21 and Day 28), and recovery was rapid, usually within 1-2 weeks, No evidence of cumulative myelosuppression was observed, The presence of thrombocytopenia may increase the risk of bleeding, and the presence of neutropenia or leukopenia may increase the risk of infection,</p><p>Gender</p><p>In a population pharmacokinetics analysis of clinical trial experience there were 101 female and 169 male subjects for whom nadir neutrophil counts were available and 110 female and 174 male subjects for whom nadir platelet counts were available, There were higher rates of Grade 4 neutropenia (ANC &lt; 0,5 x 10<sup>9/</sup>1), 12 % vs 5 %, and thrombocytopenia(&lt; 20 x 10<sup>9</sup>/1), 9% vs 3 %, in women vs men in the first cycle of therapy, In a 400 subject recurrent glioma data set, Grade 4 neutropenia occurred in 8 % of female vs 4 % of male subjects and Grade 4 thrombocytopenia in 8 %of female vs 3 %of male subjects in the first cycle of therapy, In a study of 288 subjects with newly-diagnosed glioblastoma multiforme, Grade 4 neutropenia occurred in 3 % of female vs 0 % of male subjects and Grade 4 thrombocytopenia in 1 % of female vs 0% of male subjects in the first cycle of therapy,</p><p><u>Paediatric population</u><br />Oral TMZ has been studied in paediatric patients (age 3-18 years) with recurrent brainstem glioma or recurrent high grade astrocytoma, in a regimen administered daily for 5 days every 28 days, Although the data is limited, tolerance in children is expected to be the same as in adults, The safety of TMZ in children under the age of 3 years has not been established,</p><p><u>Post- Marketing Experience</u><br />The following additional serious adverse reactions have been identified during post-marketing exposure:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2"><p><em>Table 6 Summary of events reported with temozolomide in the post-marketing setting*</em></p></td></tr><tr><td colspan="2"><p>Blood and lymphatic system disorders</p></td></tr><tr><td><p>Very rare:</p></td><td><p>prolonged pancytopenia, aplastic anaemia.</p></td></tr><tr><td colspan="2"><p>Neoplasm benign, malignant and unspecified</p></td></tr><tr><td><p>Very rare:</p></td><td><p>myelodysplastic syndrome (MDS), secondary malignancies, including myeloid leukaemia</p></td></tr><tr><td colspan="2"><p>Respiratory, thoracic and mediastinal disorders</p></td></tr><tr><td><p>Very rare:</p></td><td><p>interstitial pneumonitis/pneumonitis, pulmonary fibrosis, respiratory failure</p></td></tr><tr><td colspan="2"><p>Hepatobiliary disorders</p></td></tr><tr><td><p>common:</p></td><td><p>liver enzymes elevations, hyperbilirubinemia, cholestasis,</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>hepatitis hepatic injury, hepatic failure</p></td></tr><tr><td colspan="2"><p>Skin and subcutaneous tissue disorders</p></td></tr><tr><td><p>Very rare:</p></td><td><p>toxic epidermal necrolysis, Stevens-Johnson syndrome</p></td></tr><tr><td colspan="2"><p>Infections and infestations</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>cytomegalovirus infection, infection reactivation such as &nbsp;cytomegalovirus, hepatitis B virus</p></td></tr></tbody></table><p>Events classified according to System Organ Class and post-marketing product usage</p><p>Including cases with fatal outcome</p><p><u>Reporting of suspected adverse reactions</u><br />Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>- The National Pharmacovigilance and Drug Safety Centre (NPC):<br />- Fax: 00966112057662<br />- Call NPC at 00966112038222, Exts: 2317-2356-2353-2354-2334-2340.<br />- Toll free phone: 8002490000<br />- E-mail: npc.drug@sfda.gov.sa<br />- Website: www.sfda.gov.sa/npc</td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Doses of 500, 750, 1,000, and 1,250 mg/m<sup>2</sup> (total dose per cycle over 5 days) have been evaluated clinically in patients. Dose-limiting toxicity was haematological and was reported with any dose but is expected to be more severe at higher doses. An overdose of 10,000 mg (total dose in a single cycle, over 5 days) was taken by one patient and the adverse reactions reported were pancytopenia, pyrexia, multi-organ failure and death. There are reports of patients who have taken the recommended dose for more than 5 days of treatment (up to 64 days) with adverse events reported including bone marrow suppression, with or without infection, in some cases severe and prolonged and resulting in death. In the event of an overdose, haematological evaluation is needed. Supportive measures should be provided as necessary.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agents- Other alkylating agents, ATC code: L0lA X03</p><p><u>Mechanism of action</u><br />Temozolomide is a triazene, which undergoes rapid chemical conversion at physiologic pH to the active monomethyl triazenoimidazole carboxamide (MTIC). The cytotoxicity of MTIC is thought to be due primarily to alkylation at the O<sup>6</sup> position of guanine with additional alkylation also occurring at the N<sup>7</sup><br />position. Cytotoxic lesions that develop subsequently are thought to involve aberrant repair of the methyl adduct.</p><p>Clinical efficacy and safety</p><p><u>Newly-diagnosed glioblastoma multiforme</u></p><p>A total of 573 patients were randomised to receive either TMZ + RT (n=287) or RT alone (n=286). Patients in the TMZ + RT arm received concomitant TMZ (75 mg/m<sup>2</sup>) once daily, starting the first day of RT until the last day of RT, for 42 days (with a maximum of 49 days). This was followed by monotherapy TMZ (150- 200 mg/m<sup>2</sup>) on Days 1 - 5 of every 28-day cycle for up to 6 cycles, starting 4 weeks after the end of RT. Patients in the control arm received RT only.</p><p>Pneumocystis jirovecii pneumonia (PCP) prophylaxis was required during RT and combined TMZ therapy.</p><p>TMZ was administered as salvage therapy in the follow-up phase in 161 patients of the 282 (57%) in the RT alone arm, and 62 patients of the 277 (22 %) in the TMZ +RT arm.</p><p>The hazard ratio (HR) for overall survival was 1.59 (95% CI for HR=1.33 -1.91) with a log-rank p &lt; 0.0001 in favour of the TMZ arm. The estimated probability of surviving 2 years or more (26 % vs 10 %) is higher for the RT + TMZ arm. The addition of concomitant TMZ toRT, followed by TMZ monotherapy in the treatment of patients with newlydiagnosed glioblastoma multiforme demonstrated a statistically significant improvement in overall survival (OS) compared with RT alone (Figure 1).</p><p><img alt="" width="871" height="514" src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAkACQAAD/4RD6RXhpZgAATU0AKgAAAAgABAE7AAIAAAAQAAAISodpAAQAAAABAAAIWpydAAEAAAAgAAAQ0uocAAcAAAgMAAAAPgAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAEFobWFkIEFsWmFocmFuaQAABZADAAIAAAAUAAAQqJAEAAIAAAAUAAAQvJKRAAIAAAADMDIAAJKSAAIAAAADMDIAAOocAAcAAAgMAAAInAAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAADIwMjE6MDE6MDMgMTM6Mjc6MDQAMjAyMTowMTowMyAxMzoyNzowNAAAAEEAaABtAGEAZAAgAEEAbABaAGEAaAByAGEAbgBpAAAA/+ELImh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8APD94cGFja2V0IGJlZ2luPSfvu78nIGlkPSdXNU0wTXBDZWhpSHpyZVN6TlRjemtjOWQnPz4NCjx4OnhtcG1ldGEgeG1sbnM6eD0iYWRvYmU6bnM6bWV0YS8iPjxyZGY6UkRGIHhtbG5zOnJkZj0iaHR0cDovL3d3dy53My5vcmcvMTk5OS8wMi8yMi1yZGYtc3ludGF4LW5zIyI+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczpkYz0iaHR0cDovL3B1cmwub3JnL2RjL2VsZW1lbnRzLzEuMS8iLz48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOnhtcD0iaHR0cDovL25zLmFkb2JlLmNvbS94YXAvMS4wLyI+PHhtcDpDcmVhdGVEYXRlPjIwMjEtMDEtMDNUMTM6Mjc6MDQuMDE5PC94bXA6Q3JlYXRlRGF0ZT48L3JkZjpEZXNjcmlwdGlvbj48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOmRjPSJodHRwOi8vcHVybC5vcmcvZGMvZWxlbWVudHMvMS4xLyI+PGRjOmNyZWF0b3I+PHJkZjpTZXEgeG1sbnM6cmRmPSJodHRwOi8vd3d3LnczLm9yZy8xOTk5LzAyLzIyLXJkZi1zeW50YXgtbnMjIj48cmRmOmxpPkFobWFkIEFsWmFocmFuaTwvcmRmOmxpPjwvcmRmOlNlcT4NCgkJCTwvZGM6Y3JlYXRvcj48L3JkZjpEZXNjcmlwdGlvbj48L3JkZjpSREY+PC94OnhtcG1ldGE+DQogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgIDw/eHBhY2tldCBlbmQ9J3cnPz7/2wBDAAcFBQYFBAcGBQYIBwcIChELCgkJChUPEAwRGBUaGRgVGBcbHichGx0lHRcYIi4iJSgpKywrGiAvMy8qMicqKyr/2wBDAQcICAoJChQLCxQqHBgcKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKir/wAARCAICA2cDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6RooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKK4u8murn4svpX266htJtCZtkMxUI5l271HQMB0OKwNZ8J3OneKtA0yDxh4paHUpJlmZ9TJZQibhtwMDn1BoWtvP8A4P8AkNq1/wCulz1OiuQb4fbrOOD/AIS7xUNjs/mDU/nbIAwTt5A28D3PrXO+D/C1zrUV/Pd+LvE4NnqU1sipqR2skbDG4EHJPemtXYT0Vz1GiuI+JUdzdL4d0611TUNMW+1ZIJptPuDDLsMbnAYe4HXNZOoaReeANS0a6sPFmu6q17qMVpLp+rXi3AmRzglAQCpXO7I9OaS1fzt+X+YPT7r/AJ/5HptFc7r/AI0sNBv0sBZ6hqd8yeabXTbYzSInTcwyABn3pJ/HeiweGIte8yV7F5lgYqmGiYttIdSRjB6/1oA6OiuJk+KuiwSLFd2OrWssksaQx3Np5TTq7hBIm4jK5Ye+O1R/EzxSujWllpcEl1DfahKjQzQNtCqkse8FgQRkNjgHPOaaV7eYr2ud1RXO674zs9DvhYpYanql5sEj2+mWpmaJDnDNyAAcetYPib4gqPCen6poEN/ILm+jhkEdtl49rjfGwPRj90epPXvSGegUVzVlq1pc+MiGk1S3uG0lLl7W5YLBEhc8lM5Eo6HtgVUt/iZotxfRxi21KOymk8qLVJLQraSMTgASe54yRinbp/XYDsKK5fWPHun6PrU2ktYane30USTCCxtvNaRWzyMHtjnOOo61at/F9le+GU1rTbS+vomkERt7e33TI27aQUzxtPX25pLXYHob1FMllSGF5ZDtRFLMfQAZrj/DKyeNtDXXtTvL6GO7kdrO3tLuS3WCIMVXPlsN7HGTuyOcAUAdnRXA23jmXQW8Q2GtQ3eqSaC6OZrZEMj27ruV2BZRlejEexx1rpm8QMP7KxpGoN/aZwNvlH7P8u795+84GMn5d3THUgE32B6bmxRWDN4vsYLyGOSC6FpNcfZU1Davkednbszu3dRjdt254zmorHxrZanqE9pY6fqcrW12LSd/s20RMRkMwYhgvvjuO3NG/wDX9dw2OjornbXxrp93qVpbrbXaQX0rw2d86p5Nw6ZyqkMWH3WxuUA44zXLabZx+d8RrXzLjy0lDKftMm9T5O/h927Ge2fbpxSbsm/K/wCX+Y0rtLzsel0Vzvw+JPw50Ank/YYv/QRXI27jxPrmoxa/4z1DRL23vJIYNMs7tbQrGPutgjMmQN2feqkrScSU7x5j1CiuVj1DUPBvhm9u/FN4dVgtph9nngQec8TEKocfKu4E9QeRWvrGvWuiiw+1RzP9vu0tIvLUHDvnBOSOOO2aBmnRXKXXxAsYNbudJttL1bUL21mWKWOzthJtBUEOTuAC84ycc59M1pW/irTrjwk3iL97FZJE8jrIoEibSQykA/eyCMZ60ulw62NmiuQHiOzi1y+vCmstNDpEd5JYEoY1jJJ+VN3+t655xx1rYvfE1hY+G4daPmzW1wIzCkKgvKZCAqgEgZOR3p2/r8A/r+vvNeiuU1T4g2OnX89pa6VrGrSWx23J02yMqwNjO1myBnB7Zqhr/iaPVdJ8L6loN7MlteazBG5RmjLLlgyMPTI5B44pLW1vL8Q2/rsd1RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRVa/1Gz0u1NzqFxHbwr1eQ4HTP8gT+FAFmiqumalaaxpsN/ps3n2s4zHIFI3DOOhAParVABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHFN/yXOP/sAn/wBHVJ4p/wCSh+Df+u11/wCia7GimtLeX/B/zG9W/P8AysFcf8Of+PDXP+w3d/8AoQrsKKS0d/66f5Ceq/rzOC+KWlWett4X03VIfPtLnWUSWPcV3DypOMqQR+BrU0D4aeEPC+oC+0TRIoLoD5ZnkeVk7fKXY7eCemK6mihabf1sD1/r1OAutcsvBPjzWrzxGJbez1VIHtrxYWkTKKVMZKgkHuB71g6gbj/hD77WJbGdINQ8RQ3Vtaum2R496AHaehbaT75r12snxFof9v2MFt9o+z+Tdw3O7Zuz5bhtuMjrjGaFo18vuun+gPVP+uljyz4ja7b+Ml0y68N2l5fQ6FdLd38i2rqYlDpmMBgCW7kDstZ3xE8U6d4t1/w3e6H581ihkUXTwNGkjeZFlV3AE4xycY5r3qinF8rT7O4pK6PNfGHiaay8WTafquvXugWKwxtZizs/Ne9Y53fPtbBB4xx61z2lzeT8Lrq6lF2UtPEa3E/2kFp0QSIxaQAZ3Y5PFe10Uo6f15p/oN6/15WPOLsL4h8caqNKlDrqHhYC3k5UNvdtp55HUVnXniiz1XwBH4OsbO6HiBreK0bT2tXBgZdoLs2NoUYznPpXrFFGm3T/AILf6hre/X/gJfocfosOz4o61v8AmkTTbRN/ry+f5VS8H6zZaJoOuXmq3HkW669cpv2s2C0gAGACeprvaKa3/rvcVv6+ViK5gS7s5reTlJo2RvoRiuI8F6nZ+D/DcPhzxLdQ6bd6e7xRm4cIt0m4lXjJ+/kEcDJB4xXeUUthnFeGtEOpa34k1+/t5I7fWtlvBDOpVjAibdxU8jcckA84x61J4DN1Lp/2S+VxLom/Td7D/WFW+97/ACCM59zXY0UeXl/X6/eD1/r+vL7jx/Qo/DjBfCvie31iXXbW4bbZNdXZinw5KTKFby1XocnAHNdF4D1WyuvE3jIWV3b3TtqAlRIpVYuojUZHPTPGema76ij/AC/y/wAge/8AXn/meQx6pb39x4P1KW62SjVXWaxhXZDYHZJ+6KKPv5/vfMSTjAOKuabrmk/bfiPIdTtAjMGDeeuCPJCZHP8Ae+X68V6lRSaumu9/xt/kPqn2t+v+ZzHw3uIbn4baGbaaOUJZxxsUYNtYDBBx3B7Vz174s8PFXsfijpcFtfwyOivJp7yRTLn5XiYBiOCM89a9IoqpPmk2TFWVjyCTTLy6+HfildEs70aO80Uml2k6t5gRCrSFFb5gpIJA9qu6/wCM9L8USeGU0X7RMsetWxnlaBkSJufkJYDLc9BnpXqVFCdmvK34f8MPpb1/E43wgijxv4zcD5jeQgn2EQ/xrn7+0uU8ZTeCFgkOm6perqhl/hWEfPLH+Mij/vqvUqKS0a8v0/4KDo/M420RX+MOqIwBU6PCCD3HmNWBoFtdz+LrfwhcwyfYfDdw94srdJEP/Huv4b2/75r1GihaW/rrdfcD1v8A10t+J5Lq3iueTXtSste8Rapos0Nw0dppmnWO554uzrJtOS31AFZ2gk/8IJ4YRvMEieKVV1mP7xTubhv9r1r2uiiPu2fp+DTCWv4/imv1CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACq2pf8gq7/64v/6Cas1T1W2u7zTZbewuYbaWQFTJNAZVAIwflDLz+NTNNxaRUXZpmB8MP+SZ6L/1wP8A6G1dXXLaL4Y1jRPCKaJa69CjQKFtrpLDDIMkncrOwbOfbHvW/ptvd2unxxaje/brhR89x5Qj3/8AARwK0k05NmcU1FJlqimtIiY3sq56ZOKY11bouXnjUepcCpKJaKr/ANoWX/P3B/39X/GmvqlhGuZL62UerTKP607MV0WqKpf21pf/AEErP/v+v+NMk1/R4l3S6tYoM4y1yg/rT5Zdg5l3NCisv/hJtB/6Denf+Bcf+NI3inQE661p/wCFyh/kafs59hc8e5q0Vj/8Jb4f/wCg1Y/9/wBf8aa/jDw6mM6zZnP92UH+VHs59mLnj3NqisP/AITTw5/0GLX/AL7pj+OPDUeN2r25z/dyf5Cn7Kp/K/uD2kO5v0Vz3/CeeGf+gvD/AN8t/hR/wnnhw/c1Eye8dvK4H5Kafsan8r+4PaQ7o6Giue/4Tvw9/wA/k3/gHN/8RSjxvojf6qS6lHcpZTED/wAdo9jU/lf3B7SHdHQUVz//AAmuk+l9/wCAMv8A8TR/wment/q7XUpB/eSwlx/Kl7Kp2D2kO50FFc//AMJjZf8APjqv/gBJ/hSf8JhAf9Xo+tyL/eTT3xR7KfYPaQ7nQ0Vz3/CXx/8AQD13/wAFz0f8Jax5Tw7rrL2P2QLn8CwNP2U+we0j3Ohornv+Esk/6FvXf/AZP/i6UeJrtuU8M6vt7bkjB/LfR7Kf9WD2kToKK5//AISW9/6FnVfyj/8Ai6P+Eg1U8r4XvsdszRA/lupeyl/TQc8f6TOgorn/AO39W/6Fa+/7/wAX/wAVSf254gPK+E5sds30IP5Zo9lLy+9f5hzr+kzoaK57+2/EP/Qpzf8AgfD/AI0f2v4m/wChXi/HU1/+Ip+yl5fev8w9ovP7mdDRXPf2t4n/AOhXh/8ABmv/AMRS/b/FP/QDsf8AwPP/AMRS9nLuvvQc68/uZ0FFc/8Ab/FX/QEsR/2/H/4ij7T4t/6B2lf+BT//ABFHs33X3oOdef3HQUVz/wBo8XHgafpIPYm6kIH/AI7SbvGX/PHQv+/s3/xNHs33X3hzrszoaK57d4zPHl6Evv5kxx+GBn86NvjL/ntoX/fqb/4qn7PzQc/kzoaK57y/GTcNcaIg/vLDKSPzal+zeLf+gjpX/gK//wAXS9mv5kHO+zOgorn/ALL4sbg6npiD+8to5I/N6PsHin/oOWP/AIAH/wCLo5F/Mvx/yDmfZnQUVz507xS/B1+0jH95NPyf1ek/snxN/wBDRD/4LF/+Lp8kf5l+P+Qcz/lf4f5nQ0Vz39j+JW4bxSqj/pnpsYP6k/yo/sTxD/0Nk3/gBD/hRyR/mX4/5BzP+V/h/mdDRXPDQtdb/W+K7kj/AGLOFT+eKX+wNW/6Gm+/78Rf/E0uSP8AMvx/yDmf8v5f5nQUVz//AAjupt/rfFGokdtkcS/+y0f8I1e/9DNqv5x//EUckf5vzDml2/I6CiuePhe5f/W+JdZOOmyVF/klH/CJyf8AQya7/wCBKf8AxFPlh/MHNLsdDRXPf8Ijn/WeINdf0/03bj/vkCj/AIRCP/oOa7/4MXo5YfzfgHNLsdDRXPjwdbH/AFuqaxKexfUJOPyNH/CHWX/P9qv/AIHyf40uWHf8AvPt+J0FFc//AMIXph5km1CQ+r30uf8A0Kj/AIQrSfW+/wDA6X/4qi1Pu/u/4IXn2/H/AIB0FFc9/wAINoTcy29xI3957ybP/oVH/CCeHv8Anzm/8DJv/i6dqfd/d/wQvPsvv/4B0NFc9/wgfhr+LS0c92eV2J/Etmj/AIQPwz/0CIf++m/xotT7v7v+CF59l9//AADeaaJWw0iAjsWFJ9oh/wCesf8A30Kxl8E+G0UKNHtsD1Un+dL/AMIX4c/6A9r/AN8UrU+7+7/ghefZff8A8A1Tf2ikhrqAEdQZBSf2hZf8/cH/AH9X/Gs8eEfDyqANGsuPWEGj/hEvD/8A0BbH/vwv+FH7vu/6+Ye/5Fs6zpisQ2o2gIOCDOvH60f21pf/AEErP/v+v+NQDwxoIAA0TTuPW1Q/0o/4RnQf+gJp3/gJH/hT/d+Ye/5CnxLoQJB1rTgR1H2tP8aT/hJtB/6Denf+Bcf+NTDRNKUADTLMAcAC3Tj9KX+xdL/6Btn/AN+F/wAKP3fmHv8AkVf+Et8P/wDQasf+/wCv+NJ/wlvh7/oNWP8A3/WtAadZAYFnb4/65L/hR/Z9l/z6Qf8Afpf8KX7vsw9/yMv/AITTw5/0GLX/AL7oPjXw2AT/AGxa/g1bH2eH/nlH/wB8igQQjpEn/fIovT7P7/8AgBafdfd/wTC/4Tzwz/0F4f8Avlv8KP8AhPPDPbVoyfRUck/hiuhop3p9n9//AAAtPuvu/wCCc9/wnfh7/n8m/wDAOb/4ij/hOtAPCXU7t2VbObJ/8croaKL0+z+//gBafdfd/wAE5/8A4TXSfS+/8AZf/iaP+E00o/cjv3bsq2MuT/47XQUUr0+z+/8A4AWn3/D/AIJz/wDwmNl/z46r/wCAEn+FB8Y2h/1em6vI3ZV0+TJ/Sugoo5odvx/4AWn3/A57/hL4/wDoB67/AOC56P8AhLlPCaBrrn0+wlf1YgV0NFPmh/L+IWl3Oe/4SyT/AKFvXf8AwGT/AOLoHimd+IvDWtE/7cKKPz310NFHND+UOWXc5/8A4SW9/wChZ1X8o/8A4uj/AISPUW4i8MakT/ttEo/9CroKKXPH+X8w5Zdzn/7f1b/oVr7/AL/xf/FUHXdbb/VeFbo+u+6hX/2augoo54/yr8f8w5X/ADfl/kc9/bfiH/oU5v8AwPh/xo/tnxI33PCu318zUYx+WAa6Ginzx/lX4/5hyv8Amf4f5HPf2t4m/wChXh/8Ga//ABFKNT8UP08PWsWP7+og5/JK6Cijnj/Kvx/zDlf8z/D/ACOf+3+Kf+gHY/8Agef/AIij7X4sfldK02Mej3jE/oldBRS51/Kvx/zDlfd/gc/9p8W/9A7Sv/Ap/wD4ikMvjF+VtdFjHo88pP6LXQ0Ue0X8qDkfdnl6/E3WP+FoL4Fewsf7RzzMC/k48nzuud33ePu9fbmvUK+f/wDm8/8Az/0D6+gKmUr9BpW6hRRRUlBRRRQAUUUUAFFFFABRRRQBj+JdOsL7SZZNRgimEETshkGdp29R+Vcb8PNA0jU/D5u7qytrpvOYBpE3YGOld5rMEdxo12koyDA//oJrk/hZCsXhN4ohhVnYfoKtVJpWTJcYt3aN4+FNAC4GiWZ9/JWuT1j4OaLqt9JML3UbONgP3VrcmMD6YFeiBOASMHvTQDkFRtHOc0e0n3YuSPY+ZPjD8OJfA+k2+p6Jrmp+UzFWSe7dz0z614zaeJ9Vt76O4N/dzeUwbZJOzISPUE8ivuDxn4LsfHGjDT9TkkWJHLDYASeMd68G8Vfs9zQeKrCPQEd9MJ/fvt+YDP5dKOefcfJHsXPDnizxvrnhu61JNM0WH7IimJH04Eyg/jWDH8etTs2t4LnQLKK8W4/0g/ZVUFcdAO3Nc/f+I/HHgPWXjjub4WNrIUiWdQFKg4HQeld8R4F+J3hMT3ElnYeI/J86Zt2N8h4OaXNLuOyPb9D1DR9a0+2mt4LUmSMOUAQkGtxbW2jGYraFc9QEAr4f0y/8ReAPF00mkTNPPbK3miNiUKcH8sV9LWfxm0Oy0axbxHMsVzNCkm1T6gHvSuwsj0wQQ+ZzCgz/ALIqVESPOxVXPXAxWF4c8XaR4othNpF7FcLjOFbJFbufekMdRSLzS0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAfP/8Azef/AJ/6B9fQFfP/APzef/n/AKB9fQFABRRRQAUUUUAFFFFABRRXPSeJbm61K+tNB01b8acwS6kkuPKG/GSifK25gOoO0cjmgDoaKoaLrFpr+jwalp7FoJhkBhhlIOCpHYg5BqLXddh0OC33xtPcXc629rboQDLI3bJ4AABJPYD8KHo7AWtU/wCQTd/9cX/9BNcp8MP+RZm/6+G/kKtXniS5t5zpPiHT47G4vreU2klvcmeKUqmSm4ohVsc4IwR0NU/hkxTwxN8uT9obj8qAO3HSg9KRTlRiloAjz6UMMAlQC3vT9uOlIVzQBy3jXwZaeLfD82nFY4pZBkSeWCQa8x8PfAH/AIR3SNTMtz9vnnt9kCf6va2Qc7ga928vjg0x1O4gngigD461D4eeIfA8z6v4pMcNrJMEYJKJC6Ht+Qr26Ox8MfED4bm50K2jkdLcxRmWMIVZFwetdp478IQ+NPDMulS+UrNgpJIudp9a+UvGdh4h+FniBtBstauWtRGrn7MzIvzDmgDR+D3ik+A/iHLZauh23Ci2cCQlYznOQPwr69SQSRrMhyrKGAI6jFfHHiSy8OWvgLRPEWizyvrMsoa6E8m/naT6V7x8KviXBrPg2G48RXtvFcJhB246dPwoA9UjGBj8afiqdlf297bedZyiVCeCDU4kznbyAcGgCXOKTNNycdOaN2CP84oAfRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAQXN7a2ZiF3cwwGaQRRCWQL5jnoq56n2FSyyxwQvLM6xxxqWd3OAoHUk9hXC/FO9t9Nh8N3t7J5dvb61DJK+0naoDEnA5P4VX174reDL3w7qNrbazvmmtZI41+yzDcxUgDJTHWk37ra3/4CKS95J/1qdMfHfhFWIbxTooI6g6jF/8AFVqafqun6vbfaNJvra+gzjzbaZZFz6ZUkV89fDPxD8NtK8PXcHjeHTn1A3rsputMNw3l4XHzCNuMg8ZrvPA40rUviTcav4DsDZ+HW0/yrmWO2NvBcz7/AJdiEDlRnJAq+XW39bX/AOB6kX0/rv8A0z1OoPt9oLR7o3UP2eMsHm8wbF2nByegwQQayfGmqTaR4SvLi0OLlwsEB9JJGCKfwLZ/Cub8Y2VlpcPhTT9T2jw7DceXeeZ/qyRGfLMntu5OeM9akZ3NjqNlqdv9o028t7yHOPMt5VkXPpkHFUJfFvhyG4eCbX9LjmRijRvexhlYHBBGcg+1chp+qaBZ/Em3tvCH2Q2txp8xuo9NVTE7oQyY2fKXA3DjnkZrG0UJpejRX3ib4cq9sXee81S6jhaZGaQksYmG/aMjnsB0prW39dbfoHc9Wu9TsdP8r7fe29r5zbIvOlVPMb0XJ5PsKlnuYLZVa5mjiVnCKZGCgsTgAZ7k9q4LxNPDb+KL+fUpI/sV7oRgsS4yskhYkxr6scrwOTx1xSadqCxto8XiCWTGi20UckaxvK8t80f3QqAliiZJwD97Paktf69f8vxQP+vw/wA/wPQqo6jrelaOEOranZ2If7purhI9303EZpy6nbT6O2pWkq3Fv5RlV0P3gBn+lcV4H8K6Vr3h2HxH4ksLXVtT1YG4llu4hKI1J+VEDAhQBgcUa3fkGh30Usc8KywSLJG4yro2Qw9QRUd1fWliIje3UNuJpBFF50gTe56KM9SfQc1j+G/CsPhe61BdNuGXTbqRZYbDb8tq2Pn2nPRjg47Vi/FD/U+GP+xgtf5tT3aXdr8Q6P5ncO6xozyMFVRlmJwAPWmW9zBeW6XFpNHPDINySROGVh6gjg1JXD6TOfDXxLufDqtjTtUgN9Zx9oZcnzEX2OC2O1Jb2B7XO4orlfEHh/xdqOqmfQfG39jWhQAWv9kxXGGHU72OefSotF8OeM7HWILjWPHn9qWaE+baf2PDD5nBA+dTkYODx6ULUGdfUJvLYXwsjcQi6MZlEG8bygOC23rjJxmotUS/l0ydNImhgvGXEUs6F0Q56lQRnjPGa8x8MaLPonx8uor3VLnVbqbQRNPdXGAWYzAYVRwq8DCjpTjrK3r+TYPRX/rc9ZrJn8V+HbW4e3ute0uGaNirxyXkaspHYgnINarHapOCcDOAK8i0sfYtOm1PxD8OPtVvJcT3N5qF3HCZo1aRjnynG8gLj06E0uo+h6pe6nYabai51G+trSBiAJZ5lRTnpyTip4Zo7iFZYJEljcZV0YEMPUEda881ObQJ/iNG/itrJtLbS0fSzfbfs5JY7yN3y7sbevOMVe8AajYz654ksNDZDpVtcRSWqxDEa70+fZ22llJGOOcjrTWv9ediTtJ7iG2hMtzKkMa9XkYKB+JomuIbeMSXE0cSFgoZ2CgknAGT3J4rnTJ/bnjd7WQ7rPSUVzH2eZuhP0H61keOdOvmurG/vL8tbpqdultaRLtVQWGWc/xN+gpLW3mN9fI72qL65pMepjTZNUslvm6WpuEEp/4BnP6VdZdyFQxXIxkdRXkXjfw/4e8MeGpNLg8N3V9d3EbSNr81oZPs7luZZZ0XcCDzgClfUdrnrF3eW1havc31xDbQRjLyzOEVfqTwKbY6hZ6nai5027gu4GOBLbyiRT+IOK57UPDml65pmlajq7y63Bp1sZUgQLJFdsUHzlMfO3HyjOPmrnfh9LYTeOtal03Tn8OxSWsQGjT25t5XIJ/fmPG0Dnb8pPviqt7zRN/dUj0uiud1vxxo/h/WrXS9QeXz7nByiZWME4BY5459M1tX63b6fOumyRR3bIRC8ylkVuxIHUe1LpcfWw8XUBuzaieP7QE8ww7xvC5xux1xnjNS15t4Q0y50r4va1Df6jNqV0+mQyTXEoC7mLnhVHCqMcDtXoN/5/8AZtz9j/4+PKbyv9/Bx+tJu0eYFrK39bELa5pKaoNNfU7Nb9ulqbhBKf8AgGc/pV6vGtGPw+X4bk6sdNbXTA/2ozhTf/aud2M/vN2/piuz0O41vxP8NNFnsNSWxu7qBPtN28XmPtAIYoM43EjqenpVW38hdV/Wx1sN1BctKLeeOUwuY5AjhtjYztOOh5HHvSwXENzH5ltLHMm4rujYMMg4IyO4IIrhPhFbCz0fXrYSyTCHW7mPzJW3O+Noyx7k9zWnZzHSPibdaYhxaatafbo0/uTIwSTH+8Cp+oJ70dUu6/S4+/k/1sdZRRRSAKKKKACiiigAooooAKKKKAPn/wD5vP8A8/8AQPr6Ar5//wCbz/8AP/QPr6AoAKKKKACiiigAooooAK4X4aRtZp4ltbvK3UWszPKG4JVgCrfQjmu6rLv/AA5pep3Rubu3fzWUJI0U7xeao6K4RgHHs2RR/l/l/kHQ5v4TxSr4TuriQFYbrUZ5rcY48stgEe2Qa1fF/hu51xdOvNKuY7bUtKuftNsZgTG5xgo+OcEdxyKt6n4T0TV1tVv7BXWzGIFR2jEY9AFIGOBVvUNJtdTt0gujcCNDkLBdSQ54xhtjDcPY5FD6W6W/AO/nf8TyP4mTeJ/EOoWFro0Ft9t0ZZLm7+xztLHA5ACAyFF+YruO3GQD711fwiNwfBKNfLi58w+YffArpNQgstB8M3MdhaJBAkMmIoEwMkHJ47n1rm/hZcLN4PklAcK07fKQcjgUAd8OlFIpyoIpaACiiigAprfep1FADCcVga54Q0PxGr/2vp8dxKy7d7jkCuixmkwKAPmn4rfBm30fSbJfCVlNLLLcYZUXKoMGvHtW8J+IPC7M+paZcRQqQA8gKrzX3q0SN99Q3OeRmq19pVhqUPlX1rDOmc4dAf50AfGGgfGfxP4ft/s1lcEw8AJnhQPSvc/D/wC0D4Zn0awXVp5BeNGPPLAYDfnXpDeCfDgwV0iz4/6Yr/hXzH+0B4MfRvE0WoWlqkGmzJjdGoADZPGB7UAfU+la1p2u263OmXKXCbcqUOQa0MBRkZGeuK/Pqx1/V9OVo7LULiEdAFnYD+dex/B34vWPh6O4i8Wajcys5AjyGkwSfWgD6mzQDVSx1C31Kxhu7OQSQTDcrg9qmRiXAJOee1AE1FHNFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHI+PLK6vLjw0bS2mnEOtQyymKMt5aANlmx0Hua3PEcUk/hfVIoUaSSSzlVEQZLEocADua0qKTV4uI07SUjzT4KaNeWHgW/s9b02e2aW/lJgvIChdCqDO1hyDzV3w7Z6n4L8azaCltdXXhrUAZ9PmSNpFsHH3oWIztQ9VzgdvWu+oq3K8ub5E20t8zl/iJavceDLiaJN72UsV3tHcRuGb/x0Gp/E97eposF1pulxa1ZSMpvLTy97ywEcmME4J6HBzmugdFkRkcBlYYII4Iqtpmnx6VpsVjbvI8MI2x+YQSq54XOOgHA74A61PS39f1sPrc43QLGbVfEKazZaHJoNjYWUltY2t3biFmldss5iX7q8Ae+ag1LXde8QaDc+GrjwtqNvqt1Cbea5MQFkmeGdZCxyMcgcntXodFGj06AtNTNuGk0Tw2fskEt5La24SKJFJaVgMKOPU457VzEuh3Gg3XhzUJVmvFtHuH1FreJpXaWZOZAigsRu44BIBHYV3NFO7vcEklY57wbptxZ+FzDqETRNcTzzeQ/WNJJGYKfQ4PIrmdK1bWPh9ZHQtR8N6tq9jbOwsL3SoRcF4iSVV1yCpUHGfavR6KXoHqc34auvEWoTXup69bHTrSQBbLTSFaRFGcu5H8TcfLnjFYXiya78T6L4YvbLR9TgK67BLLb3NqVlhRWYFnUZ2r3yeMEV6DSMwVSzEAAZJPanezT7W/AO/mULPVvtmpXVn/Z99B9nOPPnh2xS84+Rs81ybIdb+NkUttzBoVgVmkHTzZM4T/vk5/Cu2huIL6082yuUlicELNC4YZBwcHkZBH6VU0XRLXQbFre0MkhkkaWaeZt0kzsclmPGT+lJaO/b/hgeqa7mN4g+GfhHxTqp1LXtJ+1XZQIZPtMqfKOgwrgfpUWi/CrwZ4e1iDVNH0b7PeW5Jil+1TPtyCDwzkHgnqK6+ihabA9dwrhY9PvR8fJtQNpOLI6AIRc+U3ll/Ozt3YxuxzjrXdUU1o7/wBbWDpYzjqzNrT6YlhehhHuF20H+j5xnG7PX2rkL/xF4g1LRbrw9d+FdQGr3UL27XMUQ+wjdld/mFjhcHODk9q9AoqbX0Y721RwusCfQLXTNO1Dw0fEmhwWaREW9oLieOZMAEoxwVI7gcGtHwbpl1FPqutahaNYzarOrR2rEboYUQKitjgHqcds11NFVd3bZNtEjltOU6Z8QtSgm4XUoknhY/xFeCv15NS+N7W4u9N09bWCSdk1K3dhGhYqobknHYetbGo6XBqSwmVpI5YJBJFNEQHQ+xIPXoQauUl08v0G935lDWNQk06zV4LS4upZHESCCHzNhPRmAI+UdzmuNn8YeIpNMm0a/wDBeqSa1LE8Xm20S/YWY5Abzi3yrjnB57V6DRSsmrMd7ao4a3/t7wH4d0K0g019a0+1tfKvls033KOBkNGCwDLnIxjPSk0Yah4o8eW3iWXSL7R7CxspLeJL9RHNO7sM5jBJVRjv1yK7qiqvd8z/AKuTbSy/qxl6h4b0jVdRtr/ULGOe6tTmKRiQRg5GcHBGexzWpRRSGcdp9ldp8YdXvXtpltZNLgjScxkRswc5UN0JHpXQpqjTa1daYljeRtBCsgu5YcW8hP8ACrZ5I7itCijpYOrf9dDy641LVLlbmzn+H8q+Kp4pLf8AtS3tEW1wcgSC4JLAYwdp57V3/h3SE0Dw3p+lRsGFpAsRYD7xA5P4nJrSoo6A9Wcb8ObG7sbfxAL21mtzNrdzLGJoym9CRhhnqD606WM6j8Ybd4xmPSNLYyNnpJM4Cr/3yhP5V2FUdM0i30trp4DJJLeTtPPLK2WdjwPwAAUDsAKFuvJfpYHs/N/rcvUUUUAFFFFABRRRQAUUUUAFFFFAHz//AM3n/wCf+gfX0BXz/wD83n/5/wCgfX0BQAUUUUAFFFFABRRRQAUUVxtjquq+KX1e70fUDY22n3D21rGsKOLl0A3NIWBO3JwApU+9K4HZUVjeE/EEfijwzaarGnlNMpEkec7HU4YfmPyxVHxx4im8PWeneTJHapfXqW0t7Km5LVSCdxHTPGBngZyfSqas7Atrm5qgB0q6BGf3L8f8BNcp8MMf8I3MBxi4bj8qi1q+1bRr230+21SXW4761neUTxxCS3VUyJAYlUbCflwRyTwe1J8KjI/g8yzL+8M7MR74FIDvB0opB0paACiiigAooooAKKKKACkxS0UARyJuXjrWD4r8I6d4v0tbHV48wK28L6HGK6KigD5f8V/s3nStJvNSsL8SCFGk8sgk4GTivCBazfa4oTGUdnCjK45JxX6ITokqsjjepUhlxXjPxe+EEviS3guvDkVvDPFlzuO0nAoA848O/GLWvhzJJ4d1e2F1DZjyhsxx+tfSfg3xTZ+LvDtvq1k+FmHMZbJUjivkbwxp3h9PEF9pvxD+0W93KTEJivETcc5Jrptc0XxV8HY11fw7rIuNFfAhJcbju9QBigD6z3UA5rz34Q+Nbnxt4Ji1G/KG5WVo3+bk7cc13inIDA/KeSG7CgCeio1GByefapB0oAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDA1fU7u18ZeH7GGbZbXgufPTaDv2ICvJGRg+lZR+KWhC+8s2+p/YPN8n+1/sbfY9+duPM+vGcY96ueIbG4u/Gnh14YZWhjS7WWZEJWLdGAMnoMnpmuMWTXV8BnwAPCmpG/8AJNn9u2L9j2E483zc+nO3Gc0L+vvA7bX/AB1p2gakmnmy1LUrryxLLHp1qZzBGTgO+DwOD6n2q/4a8R2XirRI9V0sSi2kd0TzlCsdrFc4yeDj61y01zqHgnxPfzjQdS1q21SKARTafGJGjkjTZscEjapxnd05NZ/g/wANyeKfBNrPPqutaDIt7eM0Ol3nkjLTtkN8p3bSMD8aEHb+uh1eoeNrKw8SDQl0/Ury9/dFltLfzFRHJG9jn5VGOSfUYzzVC7+KGj2l5Ih0/WJbGGQxTarFYs1pEwbacyZ6A8ZANP0HS7nT/iBqxZbqW3GmWcMd3cgt5zJvBy+MM3Qn615p4g0zV9X0fUrTU/DninUvEGXZp2kYWKgPkGIBtrYXGEAJz70dUO1/w/I9S1zx/p2h6udMNhqeoXv2dLlIdPtfOaRGJGRg9sZOcDkdap3njMajbeGL7QLh4rbUdUFtcJLEA+0K+5GBB2kMvb061JpFpdD4jyXj2s8du+h28YleIqu8SMSuT/EAeR1rk5/C13qelWen3VjfxQSeK7iWbyo3Rlgbf8+QOFOcbunPWnbVL+vit+RN7pv+vhv+Z6Vo+u22uG5ewima2hk8tLplAjnI6mM5ywB4zgAnpmrt5O9rYzTxQPcvGhZYYyA0hA6AkgZPuawPBkd/plpP4f1KKYjS2EdrdtGQlxbn/VndjG5R8rD2B710U3+ok/3T/KpnoroqO+pxmmfEKa8sdF1K80VrPTNYm+zxz/ad7xykkKGQL91sYznOeo710niHUrrR/D95qNjYi/ltYzL9nMvl71HJw21ucZ4xzXm3hQTeIvAPhXRrayvIzb3kdzcXEkDLEsccjPlXI2sWOAACSOc4xXb6N4NGj6pNeP4g17UlmRkNtqF75sKhjnIXaMEYwPYmqkt0vP8A4Alur/1uV4/GN22l6JfnTIDDqVu9zP5d4WNvGqb8geX8/GB/D8xA560aV4obxBejSdW0ZIItQ037bAGmEyywsQpWRSo2t8wyvzDnrWJ4W0zxBpOla1Etowm0eKez0cSLxMCxkVhnqP8AVr/wE1W0HzrTxXp2rS6Trchk0SRL27uLSQyNPvRmUg/MMYbCgYPRAaTs79v+A2v0DVLz/wCCv+CSeCtfm0HwL4Rt47BJ7fUbt7NpPP2NCxkcghdp3DAPcdq23+IEdmdXTV7W3spNPvo7KMteDy5mddysXZVCDacnrjB69+V0m1v0+HfhWSTStSSTSNYE13btZyCZU3SfMqYy4+dT8oPf0NMv7TxBLrOt6vpmg3zPaavb6lAkyBPtUawiNkUZzuwxPT2+9xVPWTv3/wDkf82HXT+vi/4B3fhLxhb+KTfwxi3W40+URy/ZboXELhhlWSQAbgeewIIIrRvfEGm2Vz9lefzrvGfstshllx6lFyQPc4HvUPh7WrrXbd7ubSLzSrfAWOK/jEczNzuJUE4XpjOCefamN4Ws4Lya90eWbSrqdt8z2pGyVs5y8bAqT15wG560nuJbGjYXNzdQmS6sWsgT8kckis+P9oLkD8CatVVsBfpCU1N7eWRT8ssCsgce6knb/wB9Gmatqf8AZVl9o+xXl78wXyrOLzH574yOKTGjnfFOo63d+JrHw14a1GHS7ia2ku7i8kgEzRxqyqAqHgkknr2FVtK8R6rojeINO8VXcWoz6PaLex3cUHk+fEVY/MoOAwKkcetJ4le80bxdpniu10a/1O3Ni9nc29nHvniDMrq2zPPOQR2qpYaVf+L7rxNqt7pt1pMGp6eun2kN6gSbaA2XZQfl+ZuntS15XbfX9bfoVpzK+2n6X/UqSal440jw7B4w1LXrS6snWKe40lLBVWKFyudkgO4sAe/HXrWvq174i8QeL7nRPDGtQ6LBp9tFNcXJtFuJJHk3FVCtwBgZz15rnrvUtc17wVD4KXwnrFnfvFDaXF3NCBaxopUM4kz83A6Afyra1Ce88F+OL7VY9B1PVrDVLWCMtpkPnSRSRbhgpkcFSOauVr6bXdv6/rUhX5dd+v3r/gmp4W1/UptN1W31qP7bqej3TW8v2OPb9oG0MjKpOASG6ZxVew8Qa9cfEKHTdSto7C0ksnnS1DLI/wB7ALsOh4PAOPrU3gSyvs6zrOqWUlhLq9758dtKB5kcaoFXdjoeM47U6ezuT8WrW8FvMbVdLaMzhDsDbydu7pn2pdVft+n+YdHb+tf8jq6KKKQwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA+f/APm8/wDz/wBA+voCvn//AJvP/wA/9A+voCgAooooAKKKKACiiigANcH8NQNJ8O61Z3f7uXT9SuPOL9SMBgx+orvKy77w1pWpXbXN5alpJFCShZXRZlHQSKpAkA9GBpd/NWGc/wDCa0mtfh7ayXCsrXUslwqt2VmOPzHP41c8b3iGHTdDlgikTW7r7I7zIGSNdpYnB4LcYXPfnnGK1NU8N6TrSwLqVmJVt/8AVAOyBP8AvkirF/pNhqlj9j1C1juLcEEJIM7SOhB6gj1HNVKz/roJXWv9XPN20e6+G2tQ2Wl3DXuha1vg+zzgNNayCNiCr9WTA6HoK3/hnk+G35xi4bPHsKh8U+CHNmtzod7cQTQQyhpLq6muH2sBwrSMxUcHgY60fCmJovCPkzzmaRZjubPXgUX0F1O7HSikU5FLSGFFFFABRRRQAUUUUAFFFFABRRRQAx1YnjoetJ5WM+nvzUlFAHyd+0rprW3jW1u4YFSKa3+Z1XGTuPX3rrPDnjK0+KPgD/hFLW2VdVjgJVJEyvyDruIxXrHjfwJpfjjSza6ooEgGUkHVTXzHYXmp/Bb4h3iR2b3bRKUQ7cjDCgCPQvB3j/w34mjhsra6VUm/1aSssbHP5V7Pq3xgv/CV7bxeKbK3ij8wRziGdZGj/wCAjmtb4V/FaDx9b3EV1C1peWnzOJWABBOBxUXxD+D2leKbPUb6wiRdWuFO2THBagDqvBfjvSPHOnPd6LMXMTYdWGCv4V1Acbsc9M9K+N9KuvEPwW8WGwaUNDJLG1zsRhle/wChNfVPhvxVp/iTSI9RspQIZDwruMmgDoFcN0NOqFDvIyu0jkA+lTUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBy+u+ArHW9WbUo9T1fSrqRFSd9MvDD9oVegcYOcdO1bulaXaaLpcGnabF5VtAu1FySfUkk9STkk1boo2Vg31CiiigAooooAKhvI55rKaO0lSGd0KpJJGZFQ+pUEZ+mRU1FJq6sGxieD9An8MeGbbR7i+S++zZWOZYPKypOcEbm5yTzx9K26KKptt3YkrBRRRSGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB8/wD/ADef/n/oH19AV8//APN5/wDn/oH19AUAFFFFABRRRQAUUUUAFFFU4tX02fUZNPg1C1kvYhmS2SdTIg91ByKALlFFVNQ1XT9JhWXVb+1so3bar3Myxhj6AsRzQBHrc8dtot3LMcKsL/8AoJrk/hdOs3hNpo3+Rp2OfbArYv8AxT4cvbGe3t9c0q5kkidVhS7jdnJU4AAOSayfheuPC7KiqI/tDALt6DAoA7hTlRilpBwKWgAooooAKKKKACiiigAooooAKKKKACiiigBhiHUcGqF5oem3MrT3FlFNM2Msy5JrSpkpCp82evGKAPkP4j+A/Ffh/wAY3+o6Va3AtJWMnm2wO1RkkA49K6v4E/FDV9T8SnSvE2sebbi3KwJIQPnyMV9DX9jHqVjJa3Sb45RtcA44r5r8dfArWbHVLu/8LEpaxEvEsbbX+metAH0LrWh6fr1jLFcWUNw0iFN7r2I9a+aPFXwq8aeC7S91qyvFi020lMkUcMxLBc4Hy4rG0X4qeNPDeu2enavcuIYZVSRJV+YrkZ5PtX1Nf3tlrvgua5j2zxy2xYRghuo70Acn8EPGc/ijwkv9q6gtxfREBlYjcOPSvUC57Yr4v+GPitvh94xm1LVra5S3kVkKlGC9fTGO1fVPhXx5o/izS47yzuYk3HBjZgCD2oA6lWzS0xMAcetOzQAtFAooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD5/8A+bz/APP/AED6+gK+f/8Am8//AD/0D6+gKACiiigAooooAKKKKAOe8faxPoPgLV9RsyVuIbciJh/CzEKG/AnP4VyfiWxGi/A+zu7LCXumxW95FOOG83cpds9SW3Nn1ya77XNIg17Qb3SrvIiu4WiYgcrkcEe4PNcddeH9d1vwfZ+ENSshBFEYYrzURKhjmhjIP7tQd+5toGGVQMnk0lfX5fqPTRvbW/4f8E7iwuftum211t2+fEsm30yAcfrVbUdA0vWLiOXVrGC+8lSscdzGJETPUhSMZOBz7U2K61CPVBZpo4TT0G1bsXK9AOPk6+1aEzOkDvFGZXVSVQEDcccDJ4pytuiY3tZnBzaBo8ni27k0vSbGzh0aycO9tbJHvnkToSoGdqc4/wBsVa+GA/4pmX/ru39KtWqR+H/CMo1ueKG/vUluLks4+aVhlgD325Cj2Aqp8L3V/DEjoQytOxBHfpT20Hu7nbDpRRRSAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAEAA6DFNc9MLmn0189VJzigDyT4gfBPSvF2qS6u91LBIqE7UOM4H09q8c8NfFfUfhzfXmheR9stIbhkZ5hk7c9K+uyhPUAjHINed+N/hH4Z8Q2N7cf2eI79kLCWMHJP0zQBlDSvDPxk8HoLaMWQLBt0ZAbpXi3j3wtP8KfE9nHoN3cSRblmbklTtIPNc0tz4q+G2uBUe4sDuyNwwHGe2a+u82vif4dtdWoiuZLjT2XcVDbnMeCM+uaAMX4RfEmT4gaRcG5gEN3AcsE4UrnANei53NuDHAGMDvXxf4c8WeJ/hJ4gltJrVrdLjarRygrhd3XpX1dpHjrQ9Veyht76GS4uofMVI3ByM4P60AdOpJXpj60tMVsLzzS7xx79KAHUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHz/AP8AN5/+f+gfX0BXz/8A83n/AOf+gfX0BQAUUUUAFFFFABRRRQAUUUUAFFFFAHPeMPDlhr+mE36uTbxSGPY+3qBnP5CsX4VwrbeFmgiUiOOYgZbPYV03iW6Fn4dvZ/LMpSCQhR1PymuW+Ek/2zwOlwo8tppC+xuq5A4NAHeqcrS0g+6KWgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACom5Yk8VLTdnX3oA8I/aD8Gat4jksJNEsxMYo8ORj1NR/s8a9qi6bLod5ZO8Fu7fvi+QpBPGPrXu9xEXhcBtuVxn0r49ufFPij4SePb6ytrkSQSTtIYjny2DEnOPxoA+nfEvgjRPFC51SzSSXadj4G7OOBmvlN9N1X4Y/FSyXUpvJjjn3RNu3ARZ549M9q+uvCurf294YsNUYp5txAryCPpuI5FYvjX4X+HfG6htVtlS72lVnQDcB9aANTwr4x0jxXYtLo139o8sKJcrtwfxrcO3zFxnOep6CvkO/1XxF8FPEl/pGlFXh3xuZSD869QD+Fe+/Cn4hy+OfCn2/V/KguGuWiEanGQACDQB6LmlzTN2Acf/roVu5G360APopM8ZHNAOaAFooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD5/8A+bz/APP/AED6+gK+f/8Am8//AD/0D6+gKACiiigAooooAKKKKACiszUfEOmaVcrb3k7+ey7/AC4YJJmVP77BFJVf9o4HvV+2uYby1juLWVJoJVDxyRtuV1PQgjqKAJKKytS8TaRpNytre3i/amAZbWFGmmIzjIjQFsc9cVpQyrPCkqBgrqGAdCjAH1UgEH2PNAFbVwDpF2CAQYHBz/umuS+Fy7PDDqoAAuGxj0wK6HxXbzXXhm9htZPLkaF8N6fKa5v4RRPb+CY4ZpPMkRyGb1OBQB3g6cUUg+7S0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAIfunFeU/GjwXZ654Lu9QtbBX1GAhhL0YKOTx9BXqzfdNVbqJbi1mgdQ6yIUdT3BGKAPDv2ZNSv7nSdQs7m4L28J/do38JyK94PHIG4ivlGy8SXHwd+KGrLd2Uv2C4kJiiVsDbuJHtX0H4P+IOh+MdJiu7K6jikk4eGSQKyt6c9aALPi7wVpXjLTXtNUto2yOJQPmWvl34ieB7/AMAeLoLfwl/aE8Ecayl0UgBuc8DivsOPbIoZCcdPrTJrC1nbdPbxSHplkBoA+YoPjd47s9NY32kKkUcWfMmZlzjt0619BeDdcOv+F7TUZWj82VAW2vkA46VQ8c+BrPxV4ZuNOSOK2kbmKVUA2nHU46/SvmiLVdV+GnjaDRJ9blmsYJFaU7GUYJyeCaAPsXkjHRhT1wRkd6wtA8UaX4lsI7nRbpJ1deRu+ZB7jrW3FwuPSgB9FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAfP/8Azef/AJ/6B9fQFfP/APzef/n/AKB9fQFABRRRQAUUUUAFFFFAHA/Dmd9R8QeMtQuzm4Oqm1wf4Y4xhB9OTXOaR4quvDPw18XzWgVjpmrz21jx8qb3GOPQFycV3P8AYGp6P4h1LUfDptJItWKPcW93IyCGVRjzV2q27IxlTjJH3hWfB4CmGgT+GryW2n0i8geS6uQGFy92z7jIByoUcYHJ4HWl0+SX5f5P7/UrTm+d/wA/8/wKOn/2h8PPC/8Aadzoa6gHQXGq3y3mbt2P3mKFMFR2G/gdutd9p9/b6pptvf2T+Zb3MayxPjGVIyK5m50fxRqPh2TQL+bTRBLD9nl1KN3MskZGCfJK4ViM87yM847V0mmadb6RpVrp9kpW3tYlijBOSFUYHNW7O/4Ga0S/E57x5410XwjpqJrd4lu17HKsCsfv7QM/+hD86zPhVcxXfhA3UDZiklLoR3ziug8WeHdM17THOqWyzm3ikMRYfdyOf5CsP4WRxweE2hjj2RxzsigewFSUdyhJUEjBpaQcDmloAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooARhlSP51EVOMlvbB6VNRQB5j8VvhQPiHawPBcLa3cDHax+6RjvXzffeGrr4Z/EvTrfXJVaGK4WXzF6MoPUZr7cfPGK8y+JnwhsvH9xFdNOYbmGMopH1zQB2fhTxFp/iTw5b6jpVwJrdsoHz3HBFbe7NfJHjTwr4x+EujW62Wru+nyucqpHynPt9a7z4afHPTIfCcUHi+7la8jlMSbE3ZXjBNAHurDJ4AIU9D2NeP/FX4Jv481oavYXohvNgEqv8AdIA+XGBXrlndxX9ilzAVdJF3Lg9alzuzxg45FAHyB8PtaufhP8VJbDWHjigmb7PdSyZG1Ac5H4gV9baRqMGq6XDe2b+ZBMu5G9RXin7Rfg5ZvDEWtaVaL59vKZL2XuY8cfqau/Ar4mW2qeFzp2qz29q9jiOPzJADIMZzg0Ae15pwqvE6zKJI9rIwyrBs5qdTlQaAFooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPn/8A5vP/AM/9A+voCvn/AP5vP/z/ANA+voCgAooooAKKKKACiiigAooooAKKKKAM3xBJLFoV48EZkcQvhQcfwmuX+FTu/hBpJV2s0xJU9jgV12qj/iV3RAGRBJgnt8prk/hkD/wjDnjJmbLDpnA5oA7cfd5paQfdFLQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAIwzj2poT1Ap9FAGZq+jWGtW32bVbaO5iyGIdQcY+tfOfxi+EeqS+JG1PwrpSJpqW65EWFywJzxX04+O9QTRmSF0IBjZSKAPFfgP8RZtXt18K3dpIs9nAxNw7Zzg+nXvXtrgOq7iQOvBxmvk69vtZ+D/AMUtR1NbMz2kshQTsPlcHFer+FPj54e13yLa7HkXUr7RGSMA5oA9Tv7KDUrKW2u40mhnTa8TjIYV8veNvgX4qtvE93eeGYVaxZtyGJxHsH519Towc71G7cOHHpTZUEsRiKgxuOSegFAHyV8JfGOs23xOtNO17WJltIfMjkSWUlQVGMdcdRX1bY67puoSGKyvIZXAyVSQHArxTxP+ztZXesSapot0ymV2d4G/i5ycYFeeanZ+IvhF4iXVbLSnt7eZRGnmghW5zj60AfXu/wCbFO3CvPfh18S4fGNq8d3GlpeQlQbY/ebIzkV6ADgZORnsaAH0UgGP8aWgAoopGdVKhmALHCgnqaAFooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPn/wD5vP8A8/8AQPr6Ar5//wCbz/8AP/QPr6AoAKKKKACiiigAooooAKpxavps+oyafBqFrJexDMlsk6mRB7qDkVlePtYn0HwFq+o2ZK3ENuREw/hZiFDfgTn8K5PxLYjRfgfZ3dlhL3TYre8inHDebuUu2epLbmz65NK61b6W/Edr2S6/1+p6Pd3ltp9q91f3MNrbxjLzTOERe3JPAqDTda0rWVkbSNTs78RkBza3Cy7M9M7ScVzHiu313X9I0mfR9N0vUbQgXN1Y6i5AmyvyqBjacZJ+Y4yBxxVnwDqWlX2nXcWnaFFoF7azeXf6fHCkZjkxwflADAjo3eqtq0+hN1ZNdSfxtqdtaeFL9y6SyKnl+UsoVvmIU/lnP4VH4S0ax8K6ENNGrQ3QDFt5IT8MbjVL4h6LpkXhHUr+Owt1vCY2M4jG/JkUE5+hNbv/AAiXh/8A6Atj/wB+F/wrflp+zT13f6GXNPna9P1NAahZAf8AH3B/39X/ABo/tCy/5+4P+/q/41n/APCJeH/+gLY/9+F/wo/4RLw//wBAWx/78L/hWf7vuy/f8jQ/tCy/5+4P+/q/40f2hZf8/cH/AH9X/Gs//hEvD/8A0BbH/vwv+FH/AAiXh/8A6Atj/wB+F/wo/d92Hv8AkaH9oWX/AD9wf9/V/wAaP7Qsv+fuD/v6v+NZ/wDwiXh//oC2P/fhf8KP+ES8P/8AQFsf+/C/4Ufu+7D3/I0P7Qsv+fuD/v6v+NH9oWX/AD9wf9/V/wAaz/8AhEvD/wD0BbH/AL8L/hR/wiXh/wD6Atj/AN+F/wAKP3fdh7/kaH9oWX/P3B/39X/Gj+0LL/n7g/7+r/jWf/wiXh//AKAtj/34X/Cj/hEvD/8A0BbH/vwv+FH7vuw9/wAjQ/tCy/5+4P8Av6v+NH9oWX/P3B/39X/Gs/8A4RLw/wD9AWx/78L/AIUf8Il4f/6Atj/34X/Cj933Ye/5Gh/aFl/z9wf9/V/xo/tCy/5+4P8Av6v+NZ//AAiXh/8A6Atj/wB+F/wo/wCES8P/APQFsf8Avwv+FH7vuw9/yND+0LL/AJ+4P+/q/wCNH9oWX/P3B/39X/Gs/wD4RLw//wBAWx/78L/hR/wiXh//AKAtj/34X/Cj933Ye/5Gh/aFl/z9wf8Af1f8aP7Qsv8An7g/7+r/AI1n/wDCJeH/APoC2P8A34X/AAo/4RLw/wD9AWx/78L/AIUfu+7D3/I0P7Qsv+fuD/v6v+NH9oWX/P3B/wB/V/xrP/4RLw//ANAWx/78L/hR/wAIl4f/AOgLY/8Afhf8KP3fdh7/AJGh/aFl/wA/cH/f1f8AGj+0LL/n7g/7+r/jWf8A8Il4f/6Atj/34X/Cj/hEvD//AEBbH/vwv+FH7vuw9/yND+0LL/n7g/7+r/jR/aFl/wA/cH/f1f8AGs//AIRLw/8A9AWx/wC/C/4Uf8Il4f8A+gLY/wDfhf8ACj933Ye/5F839ket3B/38X/Gk+22X/P5Bj08wf41R/4RLw//ANAWx/78L/hR/wAIl4f/AOgLY/8Afhf8KP3fdh7/AJFPxNoPh3xXpb2OqvayRt33rkH868Yn/ZpsRqP2nTvHcFmitujjFiGKc+vnDNe5/wDCJeH/APoC2P8A34X/AAo/4RLw/wD9AWx/78L/AIUfu+7D3/IwPBWgXvheIw6l4yh1eAIFRGgWLafXO9q6z7ZZFQPtkHBz/rB/jXP65o2h6XHYtFoWnv8Aab6G2bdAOFdsEj3rT/4RLw//ANAWx/78L/hVcsEr6/18xc0r20Ln2uyL7mvLc46fvFGP1rA8XeGfD/jPS0sdWuIGjjfep8wcHGPUVp/8Il4f/wCgLY/9+F/wo/4RLw//ANAWx/78L/hU/u+7H7/kePD4Ci08Tf2xpHxBjsXDhkjFkG247Z84Z6eleq+Hre60uErq/iiDVWPRvKWLH/jxq5/wiXh//oC2P/fhf8KP+ES8P/8AQFsf+/C/4Ufu+7D3/IvrfWS/8vkH/f0f40v9oWX/AD9wf9/V/wAa5fUtJ0az8UaJpsWh6aYdQ8/zWa3G5diBht7dTzkGtj/hEvD/AP0BbH/vwv8AhVOMEk23qSpSba7Gh/aFl/z9wf8Af1f8az9YtNF12zFvqFxCQjb43ScK8bdmUg8Gj/hEvD//AEBbH/vwv+FVNS0bwjo9m11qWnadbwr/ABNCvJ9AMZJ9hRHlv7rdwlzW1SsZv9san4W/4/LqPXdLX/lvG6/aYR/tDPzj3611GlaxYa3Zi50y5SePvtPKn0I6g/WuH/sBfFPGl6FaaLpjf8vc9svnyj/YX+Ee59iK6/QfDOmeHLcx6bBtdhh5n5d/qf6Ditayp8v97+tyKbnf+6a1FFFch0BRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHz/wD83n/5/wCgfX0BXz//AM3n/wCf+gfX0BQAUUUUAFFFFABRRUdxcRWlrLcXMixwwoXkdjgKoGSTRsG5U1zSINe0G90q7yIruFomIHK5HBHuDzXG3fh/Xdb8HWfhHUrIQRRGGK71ESoY5oYyD+7UHfubaB8yqBk8mtdPGjrYWur3um/Z9Fu5FSG6M26RQ5wjyR7cKpOOQxPIyBXVUWt/XYL/ANepzdprPiCJ4IrjwfLHbncmba/gkaLa2FJViowVweCSOmKvaTpJtdS1HVLhI0utQZN6ochERdqgnuepJ98dsnWrmNN8b2uq+Pbzw1Z2zsLS0+0NdlsK537SqjHIBz82eoIoWrt1/pidkr9A+I//ACT/AFL/ALZf+jUrp65j4j/8k/1L/tl/6NSunrZ/wo+r/QhfxH6L9QooorE0CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiikJwOaAOf8X/6nR/8AsL2v/oddDXnHxh8R3vh7QLO7sYoZJIJWu0EqkgvCu9QcEcE9f5ivHz+0v48guoI7vR9CiSYjDG2nHHrzLWsvgj8zOPxs+p6K5vQPG+j63DaRRahavezQq7RRSDhtuTgZzXRBiT1GMVkaDqKYGO0Fh37U5TkUAczrv/JQPCn/AG+f+ihXT15P8aPF1/4Nm0vWtMit5bixDmNbhWZD5hSNsgEHoTjkc16RoeoS6nodpezqiyTRhmCAgAkdsmtqnww9P1ZnD4pev6I0KhuLK2u2ia6t4pjC2+MyIG2N6jPQ1m+I9R1DTdFuLrS4I5541JVHUtk/QEGvEfDHx+8VXPja20bxbp+kaZbySbXfyJY2UeuWkIH5VjexofQ1FcynxB8Nu4C6xZ46HMy5J9ua3oLpbmJZbdleNgCpB60AWKKTcM4oBzQAtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUmfmxQB4B/zef8A5/6B9fQFfPQlY/tkM+BkMw/KwIr6FoAKKKKACiiq99afbtPntfPntvOQp51u+yRM91bsfegCxXMfEmO4l+G+tLaZ8z7MScf3QQW/8dBrpY08uJU3M21QNzHJPufeldFkRkkUMrDDKRkEelKSumhxdmmeeeMngb4EAQgFJLK1WEKepJTAFd3pqTR6VaJckmZYUEhJ/i2jP61j2/gzT4Ps8TT3c1haSiW2sJXUwwsORjC7mAPIDMQOw4rQutH+1anFef2jfw+Xj9xDPtibHquOatu7b7slKyS7Gd4q1ZrT7NYCLUFiu93n3VlYz3BijGMqPKRirNnAJxgZPUDPEaNrOmxfHW4+yWt/DbHRIbaGL+y7hCmJOMoYwUX/AGiAvvXrNY8Xhmzi8ZT+JllnN7PaLZtGWHlhA24EDGc59/wpR0kn6/k0EtVb0/NFD4j/APJP9S/7Zf8Ao1K6euY+I/8AyT/Uv+2X/o1K6etX/Cj6v9CF/Efov1CiiisTQKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKa/QcZ5p1I3Tj1oA8m+PKb/AA9ZqGxvW4Ue37vrVbRfhh4c8WeCdMvNQheS5FsQm047/Srfx2GND07H964/9FV1Xw1+f4c6Pu5/c5z+JraX8OPzM4/HL5Hy7P4a8SfDHx1/a0FnJFa204zK/K+UzdPyr6g8JfEPQvGCKdMl+cDOzNM+JeiweI/AWpWM84gHlmQMOpKcgfpXyR8OfHFz4E8TC5SBLgsQrRuT1z7ViaH3MDyG7elOTp+NU7K5N1Z291jaZYg5X3Iq0CenTjJ9aAPBP2oLh4NJ01ECkTyiNs9hkNx+Kj9a9k8If8ijp3/XBf5V4n+1ExbS9GPb7Tjnr0Ne2eEf+RQ03/riv8qbbe4kkjTkX958ufm6nPArkPE3wy8M+LL4XurWLPNjAaNgu79K7baD1FBUHtSGfMnxk+GUGlQ6ZB4W0ySOONWaW4yCQN3c16d8LvENlbfDSG4vtQV4rRzFJK5yVIwMZr0DUdPt9T06eyuot0MyFGUjqCMEVwOtfCDS5/C0uhaPNJplpcnMyQY+bByOvvQB1ek+LtE1q9Nrpl+k0q/MQDmugX3Oa+P5Jv8AhRfxEdbNjqX7vDCY8Dn2719SeGfEcPiXw3a6taqyR3C9G7HvQBu0VGHIxj5h3p26gB1FN3U6gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigANJ/F+FKaT+L8KAPndf+TxH/wCujf8ApCa+ia+dl/5PEf8A66N/6QmvomgAooooAKKKKACiiigAooooAKKKKAOY+I//ACT/AFL/ALZf+jUrp65j4j/8k/1L/tl/6NSunrZ/wo+r/QzX8R+i/UKKKKxNAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8j+P8Acw2ug6Y9xIsatJOgLHGSY+BXXfDZQ3w30cf9MOv4mvOf2pP+RR0T/r+b/wBAr0n4Zf8AJN9H/wCuP9TVOTcVHsSo2bZ0MsSyLtdA0eMMpXOa8g+KnwSi8VSRah4diitr1PvqMIGFe00w9Se9SUfG0Pijx38M/EEukrLcTxQOPMQgyhxjoG5x+Fej+H/2kTLqsVj4i0j7IJNqqyuSRn1GK9wuPD2kzzmefTYJpG6syA18v/H3wPfaf4wOt6bZeVYTRoqiFPuMo5PFAHU/tM3KXmh6HPA2+KS4DKQPY17h4R/5FDTf+uK/yr5F8Y+PLLxH8P8Aw1oaJL9r03aLiaRs7yAR/Wvrbwc27wjp2D/yyXGfpQB0AOelFNT7p+tOoAYQTznp7UMvynnr7U+g9KAPMvH3wd0XxuzXEm+2u3OROCTn2xXlHw38T6r8OfHOoeFtUnSSzt43lbfJkKFGeD64PSvqAfMQOhWuM1P4V+GdW1ebUbu0Z55htcqQMjp6UAcMf2kNAfXI7S3il+zOwVpShyGJ9PSvZ7O7hvLZJrd1dGGQVOa8H+KnwbsLPw5EfB+lSNebySVYdsYriPhn478Q+FPG0Wh+JZZ0gecJJHI33D6D2oA+ts806qNpeQ3KI6XMUjYzhGB4NWyQRmgB9FNU5706gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAA0n8X4UppP4vwoA+d1/5PEf/AK6N/wCkJr6Jr52X/k8R/wDro3/pCa+iaACiiigAooooAKKKKACuVj8Q6nrmr6pbeGvsSwaTIIJZLqNn+0TYy0a7WXYBwNx3cnpxXVVwHwviOmr4p0+8wtzb6zNJJnqUcBlb6EUu/p+q/wAx9Pn/AJnU+Gdfh8TeH7fU7eNofM3LJCxyYpFJVlP0IPPeq+vTeKjJ5fhe00sBRlptSlfDn0VUGfxJH071g/CG2kj8IXV242w3+o3FzAMEfuy2Afx2k11+q6fJqdmbeLUbvT8nJlsygcj0yytj8MH3pyEupwur69e698K9ZfVbD7Fe2lytrMiHKMySplkPpz+lej15Nctqtr4G8V6JqdwL2DS7mCO2u9gVpAzoxVscFhkZPqa9ZreX8KL9fyiZR/iS/rqwooorA1CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDwv8Aak/5FHRP+v5v/QK9J+GX/JN9H/64/wBTXm37Un/Io6J/1/N/6BXpPwy/5Jvo/wD1x/qaAOrpCPTn60tFAEcke5DgAkjp61n6pp0eoaPc2jqhaSJkVSMhSRitSo1+6T0OaAPhTxz4J1bwZrMh1S2fyfOKxS7fkkYehr6F+DfxZtfEGmDTNWkt7W6hKxwRFuX4rB/ai50nSYznLXGTx0O01w8Hwb8YaDY2evaC0c0zAMuHHGaAPr1ZMr8w20u7nFfNvgL453uh3k2i+PtxlEgVJVXPJOCOPSvoS11KzvoI5rO5jmik/iRg2PqR0oA0KRhkYpR0ooAaAcc9aNuTyBinUUAR7CFxgHnvXknxU+DH/Ca6kmsaVe+RqES7QjYCHnOScZzXr9RuCWOT8uORQB8W+BfHl78OPHMraozXcMZeKWMMSPTIr6H8J/HPwt4pvPssUr2shOFW4wu76c1Y174L+ENZinkeydLiQkmQOeCe9eZXv7OWq6drMd14Z1JfLABUuACp/E0AfSCSKclRwP1pwcHPtXhupf8ACW+DPDU0/jLxAEtkbMLwQh2LY4BwelXvhf8AFXTL/RI4Nb1dZLlpWCl1CcbuKAPZN/y5wcYo3jj3rGj8QaVcaj9hhvoJrkjKxxzA8duhrRSVGyjOoZOqK2TQBZyKAwLECmK28nHK44NOXgDAoAdRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAAaT+L8KU0n8X4UAfO6/wDJ4j/9dG/9ITX0TXzsv/J4j/8AXRv/AEhNfRNABRRRQAUUUUAFFFFABWVqPhnSdVuzc3lsxmZBHI0Uzxean92QIwDryeGyOTWrRQBSvNG0++01dPubZTaJtCwoSiqF6AbcYA9KpSeEtHk1V9SWG4hu5FVXkt7yaHeFGBuCOA3HqK2qKAOS8e2sFl8ONQgtIUhiXyyFQYGTKpJ+pPeutrmPiP8A8k/1L/tl/wCjUrp62l/CXq/0M1/Efov1CiiisTQKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPC/2pP8AkUdE/wCv5v8A0CvSfhl/yTfR/wDrj/U15t+1J/yKOif9fzf+gV6T8Mv+Sb6P/wBcf6mgDq6KKKACmKMrz60+mp0/GgD5+/ajO3TtG7/6T0P0NezeEVU+ENOyBjyV4/CvGP2pf+Qbo3/Xz/Q17R4P/wCRQ07/AK4r/KgDyn4w/BhdfiTUPDKRxXcJeWdSv+s4zx+teZfDD4iX/wAOb29j8S2V7PZyR/LHnCo2RzzxX1zIm6QHk47dq4j4p+H5dZ+HWqWOmWcT3EsJWMIvJNAFrwF8StK+IGnyz6WrQvAwWSGQ5Iz06V16Sb2wPxr4w8A+OdS+FGuT2F9ZbRNKv2gPkMo6dPpX174e1m08Q6PbalYndFKuQR9KANaiiigApMdc0tFADSoJ5pNoDZ9sU+koAzda0LTdd09rPVrWO5gbqJFzj3rwzxp+zpcanr4vPC93a6fAAMIYz1H0r6EbJxg45pnD85IGcUAfI+ofCf4jeE/ECXei+bfzbRi4tztGfTk5rN1XVvil4V1B7jVXv4Zp+rFi2PyNfZWMnkdKjkggm+aWNJceqg4oA+f/AAh+0ZY2Gm21h4isbo3RcLJNuAABP3iDz717V4e8Z6F4n3DRNRjujGNzBM8D8a8u+InwDs/EFxe61pV5LDeldy22xRG2B0z15rynw9p3jr4U6lJqkeiSSpKoG0hto5oA+wjKARznJxQJCWwRt9M968U0X47XNxaW1te+H7xr6T5SI4iRu/OuhX4tJaa9aadrGkzWDXX+raZCuf196APTc+tAbLYqKGeOaMSRNvVuQRT8A96AEaURxvJIcKgJJ9AK5fSfiNoWt+KrjQ9MuFmngjDu4PGc4x9a1vEDXQ0G6Gnx+ZKYmCr6nHSvljwl4f8AFmgfFy31G40mYy7vtNxBGpPynIx+dAH1wZcHB4OM4PcUvm4wex6e1Yc/iS0s9Niu9XYWbsP9U/BHsantvEWl3di15DdxmLHzHPSgDVMhDYxu+lG87gO2Mk1z1r4z0O6uxBDqEYcf7Q5FNsvG+hXuqf2fBfRm4zjZuHNAHShiQCOaN3zYrFtfE2mXeuTaVbXCtcRqCVB6VsISQuRz3NAElFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUABpP4vwpTSfxfhQB87r/yeI//AF0b/wBITX0TXzsv/J4j/wDXRv8A0hNfRNABRRRQAUUUUAFFFFABRRXLyeMJpzqM+jaX/aGn6XI8V1OLjY7ugyyxJtIcjocsvPTNAHUUVW07ULbVdNt7+wkEttcxiSJwMZUjIrntb8Vaza3c0Hhrwrca4LY7Z5vtUdvGrYyVUtkuRxnA9s54oejswWquh/xH/wCSf6l/2y/9GpXT151rPiyz8XfCvVru0hmtpbeZILm2uFw8MglTKmvRa2krUo+r/JGS/iP0X6hRRRWJqFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFIaWkNAHiX7TkQl8JaRuyNt27DHqEr0P4Zf8k30f/rj/U15/wDtL8+FNKA5JuZP/QK9A+GX/JONI/64/wBTQB1dFFFABTU6fjTqYpAXJ9aAPn39qb/kG6L/ANfI/ka9p8I/8ihpv/XFf5V4v+1MP+Jbo3/XyP5GvaPCP/Ioab7Qr/KgDcpMDHQUoooA+Yf2oNNs7XVNKuraBY55o38xgMbvmAr1n4Jyo3w1sFgkRwM7gGBK8CrPxF+GWmeP4YpNRedZLZSIgjYHPNfP3gXWr74dfFqPRdS1GWz0yOZw6Ox2ODkLwPegD663E5FOXpVKy1OzvYQ9vcRyY67W6VcUjBOeKAHUUZFFABRRRQAUYoooAKMAdBRRQA0oD1pktrDOu2eJJF9HUEfrUtJQBVTS9PjcOllbqwOQwiUEfpXjv7R2jtc+GLW5sraaS6ikGx4FJZQSM9K9sI9qiuIllUCVFdf7pFAHyJ4O+OHiTwjaxabPCbqOFsMs3EhHpzzmvcPBnxksvFesCxubVtOBhMge5zGHxjoWAzXRX3w38K6jfG7uNDszO3zNKIhuLepNeXfFT4N6hNYQXvhRr69vIm8tIBIMIhOTjpgUAe5291BcErFcRyuvPyMDgHp0rkS3/F4JA2cLpyYYDvvNeZ/Cvwd8QNP8S/8AFQpeWenyQMjszjcDtwvIPrVL4kW2oeEvEl3/AGb4g1OS9/s5XiLSli539OnSgD2DxtbaNawDXdTjM01ohMMBkwJT1xt79K8K1fTtZsfh/ea5P59vJql6PLtQxARfM+X6cGue0LxP4i8aahZadquuIl3bTKYEuNxaRs5ANe4x+Hr/AMU+G7nQvEur2pnJU25t8qY2U55z9BQBxS32v+H59BHirTbc2V5iKF4NodTgnnAyfxqPXNG17w9p0Et3FCkVi/7m4QgSSMx3KDjlvSursPhb4o1HWNOXxZrUVzY6W4KLEGBkwCM89+a6fxJ4Mu/E3ifSWuLlRpFiN5hIP7x1IK5/WgDzPwX4xk8L+ZPJp/2rfLvu7x2y0fmNwMYz1Ne/2Nyt5bxXMZJWRdynGMivKtb+Fmqy61dxaXdW8Wk3zxvNGUO8bW3cHpXq1hbJYWkVtESUjG0Z7CgC5RRkUmRnFAC0UhYDqaXNABRSEgdaMgd6AFopNw9aMjNAC0UgIIyDS5oAKKKKACkbPGKWkPvQA0AlRk1Rn1nTrWVkudRtYmBHySTKpH5mrx5IHtXzfq6eGrz41azF4zvPJtFiTy92eu0+xoA+gl1ixlt5J47+3MSHmQSqVH45pn/CQaS2M6rY5z0Fyn+NeUeAtC8O62+saXod3LdaSwwTu4U7hkdPpXMwfDjR3+Mk+hN56WqRNIuGHbH+NAH0RBdxTqJIZVdW4BQ7h+YqXcQcE5PrisrSdLs/DekC3tXK20ILMZDk4rznW/jDY2fxD07Tra/hOnSAea+Dgdf/AK1AHrTOBwzduT0FUjr2lx583UrNMHbhrhRz+dFjeWmuaYs1nMk1rKpwy968O+MHw+0nSLK1vLUzmS4vED/OMDc4/wAaAPc01exlRpIb62dE++wmUhR+dTi6hZPPWWMxbciTeNuPr0ryfxH4JsfDXwv1eXSvOe4urTaAGHB3A8flXOW3jKSP9nV8v/pK/wCikZ+cM27H8qAPdF1exe2NxHeW7QKxDyCVcA/XNMj17SpZ1ji1K1d3OFVZlOf1rxD4HadDr/w1vbDWXdoTM7Oc/N97NUvCvgSLV/irLLo32mDSdJk2ly3DOD0/I0AfRYJ2j69aepyOuaiQMsYVTwoABPepV+7QAtFFFAAaT+L8KU0n8X4UAfO6/wDJ4j/9dG/9ITX0TXzsv/J4j/8AXRv/AEhNfRNABRRRQAUUUUAFFFFADZQxicJwxU4+tee/CrFv8LZ0vPlmhnuhd7m5DhjuyfXFeiVz114Msbm4vWiury0t9RYtfWltIqx3LEYJPyllJHXYy575pNXTXdWGnt5O5k/B6K4i+FulC6DAsJGjDHkIZGK/pXU399HpsISGISXMxPkW0eAZW6n6DJyW7dabPo8UsFpDbT3FjDaFfLjtJPLUqOApGOV46Vzup/DlNU1ufVH8VeJbWeYbcWl8sKogOQgCp0H/ANc81UnzSuTFWRR8QaAugfC7V0d1lu7y4W6u5VGA8rzITj2HAHsK9ArzzxH4Yi8OfDvWdup6nqks5hLT6nc+dIAJVwoOBgck4969DrWX8KPq/wAkZx/iP0X5sKKKKxNQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqObO0bQp553HFSUEZFAHmHxd01by68ICdFe0bXre3dGPUOTkfTCmvR7G0gsLOO1s4xFDGMKo6AVxPxQTB8HE8k+KbLP/AI/XegYz70ALRRRQAUzbhTn1p9GPWgDyj41/DnV/H1rp8ejNCDbTeZJ5r7flwRx716HoVjNpuhWlncYMsUYVtvI4FaZGe9Jt4wDQAq5xzS0AYooAjI4O3rnvXl3xD+C2neMppr+3f7PqDBQr+mK9T2k455oIPXP6UAfGni7SvFfwk1COC31WQwzcrIr5JHofyr6J+FfxCtvGHh6BJbhW1CJcTLn8q1vHPw70fx7ZJbaujBojuikRtpB98da+YfEvhnX/AINeI4rnSLqaSJyW8wRnaAD0PagD7G4VzwSwHWpV+6Oc15H8IvixB4s0WUa9PBaXcBJLyyqgcE4GAa9Ss9StL6LfZXMNygOC8ThgD+FAFuimeZz047ml3jBxQA6ik3emD+NGaAFooooAKKKKACiiigAwKTFLijFACYrg5Y/O+L8sbhZEbTUBV1Bx85rvcVw5GPjFIP8AqHJz/wADNAGMPgp4e/4S1ddV2Eyyh/L2gAmvOPEfw28Y2/xLk1PwqhtoBIpUrIxByeeua+lQn0z64o8vGMHB9aAPJdc1fxd4WtI73xBqltBbb8GRZASfbkVWi/aG8O+dexvuZYEyhI/1hx9a7Px18ONN8dxxR6rJMI4znZHKVB/AVwGsfszeH5LFho881tck8SO7OPyzQB2eifE/StS8Hw6/dg20FxMYEQ9SQQO/1re1TxZpWhmyivLjYbyTy4cY5OM/0rxMfs7a+NPjsB4mIton8xI/LOA2c56+1cv8SfAXjDwz/Z9w+pz6u8b7o9kTfuzg89TQB9Xq6yKGGSrjINIWyCrEBR3Br5Ht/wBoTxlp0CWwjRTEu0iSEE/qK2PDP7RPii41yCPUbAX8DNt8uCEKeeM8CgD6hLgepOaAML8nHrmvN/id8R7vwf4GtNTtLQtc3j7PmGPKOM5PHtXmcX7TmoLZTrNpe6YriJuAFOOvTnmgD6V3bR2H1oLAnBXNfN/hj9pDWJbeVNR0OXUpgcr9njPA/AGuovfjpcnwZear/YFzYujGONJlIycZzyKAPZ143L69KbuGcAsSvXArxTQ/2gZ9UurKF/C14I5XVGuMNsQE4LE7ccVR+Jvx1v8AQPFSab4dSKSKIK8jgBw4PbPbpQB76v3R29qXNeReB/jaPFeuW+nTaJNaG5AKTux2uenHHSvWd4ONvI7nPSgCcdKKYHBxt5o8wbse/agB9BpMikYjIoAB8wyOuK8gtfh+up/FbW7zWdPEtjPCiRyEHrtINeu8qF+tNYgNwvzdOKAOA8CeDJPBWtahY2UWNNmPmJIeuSen6VTi8PamPjfJq7wEWRgZQ/1I/wAK9LOBhCST2FBX5eenr3oAZPFHNDJHKgaJ12sCeoPBFeaaj8FPD954ttNQiso47OMDzLfcfm6++a9NA6AcEdic04457+/pQBT0zTrTStNSy0y3WC3iGEjBPy1w/wAXvD9/ruk6fHp0Rcx3MbsB6Bgf6V6GeG+bpnjFJkc5GfY80Ac74g0y41Dwa1n5f70xAEfjXjsvwx1s+P5bRYWOgu6zeX/DkAf/AF6+hu3z8knH1pSMcj09KAPA9H0Xxd4S8I6vFo2k75ri7kEac8IXOD+Rra8G+IPFejwWmmzeFNrMQJ5wG+c/3q9fC/xHgmlSPHTnHAPoKAGxMWVGc+WzDJSp16c1HuU5wOR3Ipxk2rlhx7UAPopgkDdPXvS7qAHGk/i/CjOelH8X4UAfO6/8niP/ANdG/wDSE19E187L/wAniP8A9dG/9ITX0TQAUUUUAFFFFABRRRQAUUUUAFFFFAHMfEf/AJJ/qX/bL/0aldPXMfEf/kn+pf8AbL/0aldPWz/hR9X+hmv4j9F+oUUUViaBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBwnxS/5k7/sarH/2eu7rhPil/wAyd/2NVj/7PXd0AFFFFABRRRQAUUUUAFFFFABRRRQAlYXizwvZeLtGfTNRRvJdgxKHB4rdIB60jDPWgDwL4h/AazPhu1j8HWbSXUUjF+Bk8DrXOfCDS/F/hrx8dGvY7uKxWQedEDhGPHP5V9PlQTnFM8iPeXEabj1bHNAHA6l8YvDWjXZttXvFtZFJADZGcfhUVl8cPBl9eJbQanG0kjYHJ/wrS8ZfC7QfG00Murx5e3BCbUAwD1ry3xT+zhFDO9/4avWi8qMMkL4XBHJoA+gYZI5YEliKsrjIZe9Sg18r+FvjhrWi+JLfSNfcCwhcRyMh3FR619G+GfFWm+LNJXUdGdpIMlcuMZI4oA3R0pah8w84/SlZ23ADjn8DQBLRTFYkE+nal3dD69qAHUU3dSg5oAWiiigArh3/AOSyP/2Dk/8AQzXcVw5OfjFMcfd01P8A0M0AdwO9FRl+ODznFIXIIz1HUCgCQnnmj8aj8w7eBz2DcUeZ83Gf6UALxyeWqOSNJVCsFIXqGGcVJwWPHIpBywYc54I9KAOan+HfhO6kee40Cwlkc5Z5Isk1Pp3grwzo90LjTdFs7SVfuyRx4roiAetG0ZzjmgDJ1jQtP121FrrNjDfRbt2yVcrn6Vjt8OPBskf/ACL2nFc/xQ8V1hjU546nJpQoH0oAwtI8I6BoUjSaLo9vZuRy0CBc1Y1LRdO1u1+zarZQ3cAO7yJVzg1q4AORwaTaM5xzQBn2+k6bb6cbC3tI47TG0wKuFwe2KxG+HXg6SRy3h7TywHJ8nr7V1mM8EcGjYoGMUAfMni34d/EEeMrqfwwLm10u2kxYxwNgQp6Lzxzmtay1L4weG9Cf7VBBKkKM7y3SlnI68nNfQmxQfwrN17Q7bxDo02nXo/dSdcGgDyDwJ8ebC40cp4slji1XzWCxx8Ar2x+tdVL8bvCViqfbbn7KXXISTgn9Krad8BPCml6hFfRxs0sZ3AYzz+da/i74UeHfG1zbz6nBskt08tSqYyuc4oAy/wDhf3gf/oJx/mf8KP8Ahfvgg/d1KM47ZP8AhVP/AIZx8G/883/L/wCvSr+zr4PhcSJG25Tkcf8A16ALz/HbwXD8st+qEjI3E/4UsPxx8IXkvl2V758pGRGh5wPwpNW+BvhfWJITcRH92uOF/wDr1J4a+CnhrwvrK6nZRlp0BCllzgGgDesPHGn3+mTahFHIIokzg9TWX/wtbRdpKxy9MgEd67hbaBE2rEiqeo2jmg2NqettD/3wKAOQu/iPpdnZ291IGYT5yoHIxWXc/G7wlZTBLy7EDbN2x85x+VehvZ2zYzbxnb0+QcVwviz4P+HPF+rC+1CILKFC5RccelAFWP44eE7izaeG68yNf9aw6J9eK0Lf4qeGrvQP7VsrxJYt+wRJ9484zTNI+Enh3R/Dt/o9rEGt79g0pZeemKi8LfBzw54T1IX1gGMq52qwyoz7ZoAWX4v+HrZZJLkvFDGuTIw4qjB8dvBkzpDFqKySscKqk/MfTpXZeIvC+m+JNDuNOvbeNY5htO1AM1xelfAXwnpOqQXkCFpIZBIileMj8aALN38ZvDVmytqLSWp/h3nG6pY/jBoU8JuIYp5IscMOhFa3i74faL4yit4tRhVfsxym1AP89K19H8O6fpGkw6fb28ZhhUKuUHSgDLv/ABtY2Oiw6oVkaCT+AdaraV8R9N1i9FtawyxuQDlxxiusa0ifAaJCo6AqMCgWdurArBGCO4QCgDkNW+JGk6TqklpPFM8itjK9Kd/wsfSP7Fk1Fw6W8Z5yOa602duzlmt42Y9SUBqve6RaX9hLZzQRrHKMEBRQBy/hn4reGPFGrR6bpV2r3Dj5UzzxXb/xfhXBeHPhHoHhjxENZ05NtyCSOOOf/wBdd0T3HU0AfPS/8niP/wBdG/8ASE19E187+XL/AMNhsoC+YWYgZ45sc/yr6IoAKKKKACiiigAooooAiu7qGxs5rq7kWKCBDJI7dFUDJNcuPG8kWnWus6hpf2TQ7t0WK6a4zKgc4R5I9uFU5HIZiMjIHOJviTaXN78N9bgsgzTNakhVGSwBBIH1ANc54zmiufgHGLMed9qtLSK3ReSzFkAA9TSXX5fjcdrtLvf9P8z0rr0qG6llgt2eC3e5kGAI0ZVJ59WIGB1/x6U3T4pINLtYpzuljhRXPqwUA1YqmrOxMXdXPNNZ8WnxT4D8TI2nPYtp1zFbOkkoclhImenAwcjgmvS68Wtv+RX+If8A2GR/6OFe01q/4MX/AFtEzX8WS/rdhRRRWJqFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHCfFL/mTv+xqsf8A2eu7rhPil/zJ3/Y1WP8A7PXd0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAGKaQT04p1FADCpK4zUUsQeIoQShBU8888VYooA8U8V/s5aJrDyXOk3EtleSy73ldi649NtO034HS+HvCc9rZa1eTX6oxiMMzxJk5/hzivaTSUAfK95rHxa+FOlpJfyxtazsQsk2J2z19SRW54O/aSA2w+M7VkfH/H0i4U/8AAr3vVtD0/XIRDqtnFdRLyFkXNcdr3wb8H64FMumx2m3p5SgUAdRoPiKw8RaRFqdjJiGQ/KW4zWskqOxCMrBfQ5rxj4o+GNb0DwFY2XgOS5ijtmO5bc4JyRXnfg3Ufi2v2i3tY7t8qSWuDk/hg0AfVglRzhWU/Q08YFfF0XxI+IXg/V51vrq6lmbOY7kkqPcYr0fwH+0Fi0uT42ZVOR5QiBGPXOaAPoujI9a4XQviv4V161M8OqRQANt2ynk/lXYQ3EN1CstvKjxHnch60AWq4YqB8YpueP7NTP/fZrtckYJPFcVh2+ME4RFZf7NRif+BmgCh4l+KMWk+L7HQLK2aSa4uEjZyvyqCcdcVB498dazp/iO18NeE7ZZtTnXzHL4wBjPer3jzSrC3k0m7gs0E8uqwbpQvueK5PxfqsXhT44WWtaofLsJrfy2lA4UhMD+dAF7SvijqZ8P67DrUKw6zpAPyhMhsEDPH1qLSfinfweFNYuNZMY1CzkWO3CqMOWUkcd+1VPAKW3i74geJdYMXm6XIDDHkcTAMDmuW1PRTrmra9eaFAw0zSUYIMf6yTbkN9RgigD3PwZfajqPh23uNbMYuph5mEI4U8jgV0IJL/LwM814f8AD7U528c6fbaZqs1/bSWaG7R2yI32cr+B4r3AcPgcjr9KAJKDRRQAlHalooAQUuKKKACiiigBGGevSm9R8vIp9FADRn0pFXB9afRQAmP85oIxS0UAMweRjg0dOh4+lPooAbk46Zp1FFACHpxSEckLwfpTqKAGLn6++KUfn+FOooAbjOPamgNwWI9OlSUUAMOexx68U4ew4paKACiiigAxSHpnvS0UANIJ60gPJ9AcdKfRQB8+Bf8AjMvHI/H/AKh9fQdfP/8Azef/AJ/6B9fQFABRRRQAUUUUAFFFFAB1rHtvCei2l6lzBZkNG5kijaZ2ihY9WSItsQ8nlQDya2KKAM4aBpi6ydVFt/pp6y+Y3pjpnH6VcurZLy1eCVpVRxgmGVomH0ZSGH4GpaKOlg8zzvxh4O0XQvBuq3elw3MM0rxvLm+ndZWMigs6s5DHk8kH1r0SuY+I/wDyT/Uv+2X/AKNSunraX8KPq/yRmv4j9F+oUUUViaBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBwnxS/wCZO/7Gqx/9nru64T4pf8yd/wBjVY/+z13dABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFJilooAYy89M/jRtJxk49qcaKAIXiDgq4DLkYBFCwRox2RqM+igVPijFAGRfeGtL1KZZL+wgmZRwxUZFcf48+D+j+LNFFpahbCRWDB4kGTg9K9HpkhHHY9qAPlf4mfCWTwP8O7Wawm80wXTSzys21tu3AAA681P8GvjHpXhbQ72DxZeXU0rTr5KpHvAXbz39a+iPEvhrT/FelvpusxtJbv12Ptrhh+z/AOAwQotLk4GQPPP+FACyfH3wZbyRRztfRNJ93zLfAweh69Kgg8deG5vigdRGsWsdvJpqKWaUAZ3k4qHxt8BNI8Sm2bT5jZtAgQhiWyAAB/KuN0P4D6La+ObjRddlmvo/sazRmGQx7CWx+NAHtQ8U+E9Xmhtk1mxnkEoaKNZlJ3DpxWlq+habrkAi1W1juEU5Ut1r5l8cfCXV/AniSy1DwgXuufMVSpbYQeAfWvV/C2m/ELWtCg1DUtftbSV8q0Bs8kY6d6APR9M0fT9JtTb6bbJBD6KKS20Sxs7eW3t7dESY7nUD7/1rw/xrqnxX8KaikVhcwX9vjcsiWvU+mM1T8Pa/8X9dW5knMNvDbws4c24BLAZAxmgD3bSvDWl6PcyTabZxwvJy7CtVchVJ+XntXyjqvxQ+K2lKr3saxhWPzi14YfSuy8HftDA2Qh8W2csM4XAmCEK5+mOKAPoDcPelBz0rE8P+JdM8S232vSrkTIoAYDsTWwgIYknj09KAH0UUUAFFFB6UAcTN8YfAtvPJDNrm2SNijD7JOcEHB/grWg8deGrnw5Pr1vqsUum22POlRGJjyQACmNwPI4xXnXg7xT4n0LwneNpvgx9W0+C8uXN1HqKIx/eEkCPaW49q6v4eW11qN5qfi+7is7VdaWLyrazlEoVUBG53AALkkg49KFqvkD0fzF/4XP4B/wCg9/5Jz/8AxFdVout6f4h0mLU9HuPtFnNnZJsZM4JB4YA9Qe1c1N/yXG2/7AL/APo8V1OrXMllot7dQJvlht3kRR/EQpIFDaUOZ+f4Nr9B2blyry/FGTrfjzwz4cufs2savDBP3iVWkZfqEBI/GtLSNc0zXrP7Vo99DeQ5wWibO0+hHUH2NYnw70y2tPB1jeqiPeahELm6uSMvK7/MSW6nrXK/Ea4l8Ha6NW8N7bS8v9Nu/tHloCGaJN6SFSCCQeMkd6H7rsxL3tUeqVT0vVbLWbL7Xps3nQb2TfsZfmUkEYIB6g156+o+OdCfQta1nXLO9s9Ture2uNLislRYBLwGWXO5iDjrxyeKZoGpX2i/Dq01Wzl221rqsxvotgbfAZmVj0yCuQ3HpTtr+H5f5ivpdf1v/keo0Vzsmq3d549ttLsJ9tnbWZurzaqnzC52xrkjI6M3GOgroqXS4wooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPn//AJvP/wA/9A+voCvn/wD5vP8A8/8AQPr6AoAKKKKACiiigAooooAKKKKACiiigDmPiP8A8k/1L/tl/wCjUrp65j4j/wDJP9S/7Zf+jUrp62f8KPq/0M1/Efov1CiiisTQKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOE+KX/Mnf8AY1WP/s9d3XJ+PdE1DWv+Ea/sy38/7Dr9reXHzquyFN25uSM4yOBk+1dZQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUYoooAMUUUUAFBGRRRQA0RqOg59aQoeRkn+lPooAjEeGJ9RXFFVX4xOAP+Ycn/AKGa7muHf/ksj/8AYOT/ANDNAHbFFZssM4pDEMjBIA7CnjvRQAxow33uSDkE9qRYkQkoNueuO9PNFAFK/wBNtNSieK+gSaPA4YZryr4zeEbCL4c3kukaRDHMIySY05r2HAORWR4n0ybWPC9/YWxTzp4ike48ZoA8F/Z08UaD4e8P6rHrepwWkrzoUSU84AOa950LxTofiGaZNE1KC9aIBpBESSoPTNfL837OHjoyO0IsAGcnP2vBxn0xXovwG8G6r4J8Z+IdO1plab7JA2VbcOS3egD3WiiigAooooA53wP4fuvDXh1rC/khkla6mmzCxK7XcsOoHODUPh7wzeeG/Eup/YZIP7Avj9ojtix3285+/tGMbD168HtXUUUbfkG/5nPyaBdN8R4fEAkh+yJpjWZTcfM3mQNnGMYwPX8K6AgMpBGQeCDRRR0t/XcOtziE8N+K/DfmW/g3UdNm01nLx2erJJ/o2TkqjpyRnoD0qC/8B6tq+kaxPrWp295rd9YvaW2EMdtaKw5Cjk8nq2M+1d9RR0HfW5zPiHw3eatoejWVtJAslje2txKZGIBWJgWAwDzxxnH4VX0rTLTwt4Gm0/xVe2UVvNLOJHaXajLIzMFywHOD0rrqr3un2epW/kajaQXcO4N5c8QdcjocEYzQ9U13/wCB/kJaW8v+D/mcf8KtNng8Mtql9LJNcaiylJJR83kRjZED/wABGf8AgVdxSABVCqAABgAdqWm3diWgUUUUhhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB8/wD/ADef/n/oH19AV8//APN5/wDn/oH19AUAFFFFABRRRQAUUUUAFFFYp1nULlnm0nS47uyjdkaR7ry5JCpwfLTYQwyCMsy5x6c0AbVFQWd7Bf2MV5bPuglQOrEY49x2PtWQNev5Yf7QtNLSbSdpfzvtJE7oP41i2YII5GXBI7dBQBW+I/8AyT/Uv+2X/o1K6euU+IE0dz8N76eBxJFIsLo6nhgZEIIrq62l/CXq/wBDKP8AEfov1CiiisTUKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4c/8lml/wCwZH/6Ga7isP8A4Rv/AIrNtf8AtX3rVbfyPL6YbOd2f0xQBtiloAxRQAUUUUAFIQMdKWigBuPamJbQpcPOsSCZ1CtIF+ZgOgJqWigArzb4i/DrVvF3iKC/024sooo7VYSLh3Dbg7nsp4+YV6TRQB4V/wAKR8Sf8/ul/wDf2T/43R/wpHxJ/wA/ul/9/ZP/AI3XutFAHhX/AApHxJ/z+6X/AN/ZP/jdH/CkfEn/AD+6X/39k/8Ajde60UAeFf8ACkfEn/P7pf8A39k/+N0f8KR8Sf8AP7pf/f2T/wCN17rRQB4V/wAKR8Sf8/ul/wDf2T/43R/wpHxJ/wA/ul/9/ZP/AI3XutFAHhX/AApHxJ/z+6X/AN/ZP/jdH/CkfEn/AD+6X/39k/8Ajde60UAeFf8ACkfEn/P7pf8A39k/+N0f8KR8Sf8AP7pf/f2T/wCN17rRQB4V/wAKR8Sf8/ul/wDf2T/43Xs+h2MmmeHdOsJ2VpbW1ihcoSVLKgBxntxV6igAooooAKKKKACiiigAooooAKKKKACiiigAooooA+f/APm8/wDz/wBA+voCvn//AJvP/wA/9A+voCgAooooAKKKKACiiigAPINc/wCGLmCw8JRw3kyRPpiGG7MjY2MnVj6ZHzA9wQa6CqVzo2mXl9FeXmnWk91D/qp5YFZ4/wDdYjI/CgDktI1q3htovC832iLUtShuLmHdHgRrI8jqrdCG2npjjHWt3StVtLbwXBczlYUtbdYpou8cirtMeP72RjHfitdrO1a8W7a2hNyilFmMY3qvoG649qgfRtLk1NNSk020e+QYW6aBTKo9nxkfnQ9U13/4P+Ydf6+ZyGv2c+nfBNbS7BWeG1tkkU/wkOmR+HSt/wAJeL9N8aaRJqOjidYY5mhYToFYMMHsTwQQaq/Ef/kn+pf9sv8A0aldBZ2Fpp0HkafawWsW4t5cEYRcnqcDua3k70033f6GSv7R+i/UnooorA1CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiimtLGhw7qp9zigB1FR/aIf+esf/AH0KPtEP/PWP/voU7MCSioGv7RWIa6hBHUGQUn9oWX/P3B/39X/GizFdFiiq51GyAyby3x/11X/Gov7a0v8A6CVn/wB/1/xo5X2C6LtFUv7a0v8A6CVn/wB/1/xpr67pEa7pNVskUd2uEA/nT5Zdg5l3L9FZf/CTaD/0G9O/8C4/8aP+Em0H/oN6d/4Fx/40+SfYXPHualFZL+KtATGda0/n0uUP8jTf+Et8P/8AQasf+/6/40ezn2Yc8e5sUVj/APCW+H/+g1Y/9/1/xpjeMvDqtg6zafhJn+VHs59mLnj3NuisP/hNPDn/AEGLX/vuj/hNPDn/AEGLX/vun7Kp/Kw9pDublFc8fHnhkHH9rw/98t/hR/wnnhn/AKC8P/fLf4U/Y1P5X9we0h3R0NFc9/wnnhntqsbHsFjck/QAc0f8J34e/wCfyb/wDm/+Io9jU/lf3B7SHdHQ0Vz3/Cd+Hv8An8m/8A5v/iKB450JuIp7iVv7qWUxP/oNHsan8r+4PaQ7o6Giuf8A+E10n0vv/AGX/wCJo/4TXSfS+/8AAGX/AOJpeyqfysPaQ7nQUVz/APwmenN/qrbUpR3KWEvH6Uf8JjZf8+Oq/wDgBJ/hR7Kp2D2kO50FFc//AMJjZf8APjqv/gBJ/hSf8JhCfuaNrbr2ZdPfBo9lPsHtIdzoaK57/hL4/wDoB67/AOC56P8AhL4/+gHrv/guen7KfYPaQ7nQ0Vz3/CWSf9C3rv8A4DJ/8XR/wlkn/Qt67/4DJ/8AF0eymHtInQ0Vz3/CVTNwnhrWy3bdAij899L/AMJLe/8AQs6r+Uf/AMXS9lL+mg9pE6Ciuf8A+Elvf+hZ1X8o/wD4uj/hI9Rb/VeGNSPrveJf/ZqPZS/poOeP9I6Ciuf/ALf1b/oVr7/v/F/8VR/b+rf9Ctff9/4v/iqPZS8vvQc6/pM6Ciue/t3XmOY/ClwV9XvIVP5Zo/tvxD/0Kc3/AIHw/wCNP2UvL71/mHtF5/czoaK57+2/EP8A0Kc3/gfD/jR/a/iY/wDMrxD66mmf/QaPZS8vvX+Ye0Xn9zOhornv7W8Tf9CvD/4M1/8AiKP7V8TngeGYFz3OpKQP/HKPZS8vvX+Ye0Xn9zOhorn/ALf4p/6Adj/4Hn/4ij7f4p/6Adj/AOB5/wDiKXs33X3oOdef3M6Ciuf+2+K34XR9Pj93vWI/RKPtPi3/AKB2lf8AgU//AMRR7N9196DnXZ/cdBRXP/afFv8A0DtK/wDAp/8A4ikMvjB/uWuixj0eeU5/JaPZvuvvDnXZ/cdDRXPbvGX/ADx0L/v7N/8AE0bvGX/PHQv+/s3/AMTT9n5r7w5/JnQ0Vz2PGZ536En+zsmbH45H8qNvjL/ntoX/AH6m/wDiqPZ+aDn8mdDRXPbPGf8Az20L/v1N/wDFUv2bxb/0EdK/8BX/APi6Xs1/Mg532Z0FFc/9m8W/9BHSv/AV/wD4uj7L4sbg6npiD+8to5I/N6ORfzL8f8g5n2Z0FFc/9g8U/wDQcsf/AAAP/wAXR9g8U/8AQcsf/AA//F0ci/mX4/5BzPs/w/zOgornzpnih+viG1ix/c04HP5vSf2T4m/6GiH/AMFi/wDxdPkj/Mvx/wAg5n/K/wAP8zoaK57+yfE3/Q0Q/wDgsX/4uj+xvEbcv4rYH0j0+ID9c/zo5I/zL8f8g5n/ACv8P8zoaK57+xPEP/Q2Tf8AgBD/AIUf2J4h/wChsm/8AIf8KOSP8y/H/IOZ/wAr/D/M6Giuf/sDWD97xTek98W8QH5baP7A1b/oab7/AL8Rf/E0uSP8y/H/ACDmfb8v8zoKK5//AIR/Vjw3im+x3xDED/6DR/wjV7/0M2q/nH/8RRyR/m/MOaXb8joKK5//AIRq9/6GbVfzj/8AiKD4Yun4k8TawV/2JI1P57KOWP8AN+Yc0ux0FFc9/wAInJ/0Mmu/+BKf/EUf8InJ/wBDJrv/AIEp/wDEU+WH8wc0ux5B/wA3n/5/6B9fQFcdafDLSLXxpbeKjd39xqluWPmTPGfN3RGL5yEBOFPHI6CuxrOSSehSu1qFFFFIYUUUUAFFFFABRRRQAUUUUAUNb0iDXtHn028eRIZtu5oiAwwwYYyCOo9Kq6zcXV1cDR9JuGtbx4/Oe5ChhAm7AOD1LHIA46NyMc7Nc8+LH4gG4uTsh1CxS3hc8AyRu7FM+pD5A77T6VSk7pf1/WguVWb/AK3Mmey8QaVdWiap4qmkt7qUQCeK2jj8uQ/cBUhsgnjOepHHORr/APCP6sevim+/78xf/E1F4vX7edL0q2Ie6lv4LgoP4IopA7OfQfLjPqQK6Wr9rJq+n3LyI9nG9v1Zz/8AwjV7/wBDNqv5x/8AxFH/AAjV7/0M2q/nH/8AEV0FFL2sv6SH7OJz58MXbcSeJtXK99rxqfz2Un/CJyf9DJrv/gSn/wARXQ0U/azD2cTnv+ETk/6GTXf/AAJT/wCIo/4RHd/rPEGuv6f6btx/3yoroaKPaz7h7OJz3/CIR/8AQc13/wAGL1kazoz20sOn6TrOtTapcjMayahIUhQdZZMYO0emQWOAMckdu+7Y2zBbHGTxmuS0mz8V6d589xpejXV9dNvuLk6rKu7H3VA+zHaqjgDPqeSSaXtZ9w9nHsVPCehjW/DNrf6lqOpPcyFxI0d7Kqna7LwCxI6eprZ/4Q6y/wCf7Vf/AAPk/wAap/DV7x/Bdv8AbIIIlEkvlmKcyFh5j5yCi45+uevHSuspurO+4lThbY5//hDrL/n+1X/wPk/xo/4QrSe7XxPcm+l5/wDHq6Cil7Wp3H7OHY5//hCtJ9b7/wADpf8A4qg+CdHPDfbGXupvpcH/AMeroKKPa1P5mHs4djnv+EE8Pf8APnN/4GTf/F0f8IJ4e/585v8AwMm/+LroaKftqn8z+8PZw7I5DWfC/hfRtGudRutMknjt0LmM3Er5PbALYH17VTHgDLef9i0Ty8Z+yeRPuzjp53m469/L/Cun8SXMlp4eupYbZbk4CtG6blCFgGYr3AUkkd8VQPh7RG09bn7fd/ZVj4kXVJRAV/3A/lleem3GOMUvbVN+Z/eHs4dkVNI8K+FNY0e21CDRkRLhAwVmbK+o6889xWgngfw1GCF0e3P+8Cf5mrXhu5lu/D1rLNbpbnaVVEXapQEhWA7AqAQPetSm6tS/xP7xKnC2yMP/AIQvw5/0B7X/AL4o/wCEL8Of9Ae1/wC+K3KKXtan8zH7OHYx18I+HlUAaNZfjCDR/wAIl4f/AOgLY/8Afhf8K2KKXtJ92HJHsZH/AAiXh/8A6Atj/wB+F/wp/wDwjOg/9ATTv/ASP/CtSij2k+7HyR7HL22j6edeayvNB0ZE+zCZRFaqxB3YxuIGfyFS6no1latbRaP4e01rq4cqJ3s18uBQCS7bQCfQDIyT1HWrn/M6H/sH/wDtSr93dfZkUIhlmkO2KIHG4/XsB1Jpc8uVa/1dhyx5np/VkYWmWkQ1WfS9X0zTJJ44VnjuLa0CJIhJGNhLFSCP7xzn8K2P7F0v/oG2f/fhf8KLSKK3uXE00cl/MoeQ5AYqOBgdQozgfU9yau0c0u4+VFRNK06PPl2Fqmeu2FRn9Kf/AGfZf8+kH/fpf8KsUUuZhZFf+z7L/n0g/wC/S/4U9bW3RcJBEo9AgFS0UXYWRH9nh/55R/8AfIrK8RTXOm6Nd3mn21mfs9vJMWnBPKrkDaAM5x13CtmsnxX/AMibrP8A14zf+gGk27FwSckjTgbfbxsQBuUHA6DisiS+1PUrqeLQ2tbeC3cxvdXUTSh3H3lVFZeB0LFuuRjitW1/484f+ua/yritG07Zaas+r6vdQT2F5OUWK6aBIEZzIrMoOH3bs5cEdscGiVk2RG7ijuIw4iUSsrOANzKu0E9yBk4/M06q2mzT3GlWk13H5c8kKNKn91ioJH51ZpvR2BaoKKKKQwooooAx7661mfVGsdHihtkjiEkl9eQtJGSScIiKy7jgEk7hjI65p2h6pc3sl7Z6lDHHe2MojlaEkxyBlDK655GQehzgjqetWrq6k80WtkFa4YZLMMrEv95vX2Hf2GSHWMVtbebb28qyTK2+clgXLMPvNjuQPyHHAoQGX9v1fVHnn0SSyitreZ4dtzC7tcshw2GVx5Y3ArkhumcVp6VqMeraVb30KsqzIG2N1U91PuDkfhWN4Ymj0zSdSt76RYXsb25kmLtjajyNKr/Qqw59j6Vb8IxSxeFrPz42ieTfNscYZQ7s4BHY4YUdPuB7/ebNFFFABRRRQAVW1G7ex06a4htpbuRF+SCIZaRugHtz37das0yaaO3haWZtqKMk0AYE+o65pBtrnV/sE9pPNHDJHaxuj25dgqnczESDcQDwvr7VuXt5Dp9jNd3ThIYULux7AVTwJHS91UpBEjjyIpGA2MTtBYn+Ik4A7Z7mqviKx1O+msPsEFpc20MvnTwXNy0PmMuDHysb5APOMDkL70dAQzw1q+p6ldajDq0EMDW7xmOONSGRXTcFcknLAEAkYGa365Xw1LqT+LfEH9oWlpB80BbyLppcN5YwBmNcjHOeMHjB611VABRRRQAUUUUAFV9QujY6dPdJby3LRRllhhXc8hHRQPU1YpssqQRNLKwREGWYngCgDm7nU/EOkQQ6hqy6fLZvJGk9tbRuJLcOwXIkLESYJGRtXjp6HT1nUpbJrO2s1jN1fzmCFps7EIRnLEDBOAp4BGT3HWkbFxtvdUK29pEwaGKU7cHPDvnoc9B26nnGKnilEuG0u0uQq2txeASz7irREIxXa45RiwADAg84HJFHl/X9fiBLZajf22txaTrMlrcTXEDzwz2sLRLhGUMrIzPj764O7nngY52q5qxsYdI8Yx2tg006zWTvcNc3MlxJDtddnzyMzBW3P8ucZXI710tPov66h1CiiikAUUUUAFZt+utyzlNLm0+1hCgia4iedmbnI2KyYHTncfpWlVK8Sy1RZtOkumDqAZEtrtoZU7jlGDD8+aAK2h6rPfre29/HEt3p8/kTGAkxudquGXPIyrDg5wcjJ61ntqPiaTT31eG2s4bdVaRdNuYnW4dBkjMm4CNiOdpQ46E+h4N8q3/tTT7GQXNhaXW2G64JkYqGdWYffZWOC3U9DkgmtOT/AIm6sHwumYO4n/l4Hf8A4B/6F9Oo/IaLljeR6hp9veQbvKuIllTcMHDDIyPxqemQyxTwRy27pJE6hkdCCrKehBHUU+m9yVsFFFFIYUUUUAFYl2fEwEtxby6TEkZYrbSRyOZFHTMu5QhI/wBhse9bdYGvWWj6/o8lxdao8VrEjBri3vikS+u9Q3luOOjgj86T2GtdC/Yaxb33h2DWW/cW0tsLk7z9xSu45+gqnaz+INT8q7hNlptm5DLBcW7zTOnqSJEEZI7YbGfwrPuBqOufCeZYYFjvrnTmEcQTYrHb8uF/hDDHHbOKrQhbbw9Za5DrF5d6jceUBuun8qd2YAxiAnYvcYChhjk5yat25mT9lHa0UUVIwooooAKKKKAMnX9UnsLeKDTljk1G7fZbpKCUXAyzsAQdqjk8jJwM80vh7VZNT8J6fqt95cclxapPL5YIVSVycAknH41l3Vn4hh8QX+ow2GmXiPEIbZ5tQkiaKIDJG0QsMlsknPOF9KZ4Oiurz4V6fBNHHFJJpwjj8uUuCCmFJJUYPtzj1NLXkbW//DlaXSZM+tasmkf8JAfsg0sQ/aGtDC/niHrv8zfjO35tuz2z3rpUdXRXQ5VhkH1Fck18g+FGNp8/+z/sfkA/N5+zy/K/3t/GK6i0iaGygif7yRqp+oFW0k2kQr2Te/8AwxNRRRUjCiiigAooooAKKKKACiiigAqK5toLy3e3u4Y54ZBh45UDKw9CDwalooAp6dpGm6RE0Wk6fa2MbHLJbQLGCfUhQKuUUUAFFFFABRRRQAUUUUAFVdQ0yw1a2+z6rZW17BuDeVcxLIuR3wwIzVqigClpui6XoyyLpGm2dgshBcWsCxByOmdoGau0UUAFFFFABRRRQAUUUUAFZv8Awjeh/wBo/wBof2Np/wBtzn7T9lTzM4xndjPStKigAooooAKKz9Q1/R9JmWLVdWsbKR13KlzcpGWHqAxHFQweLPDt1OsNtr+lzSucLHHeRszfQA0Aa1FRW11b3tslxZzx3EEgyksThlYeoI4NS0AFFFFAGT/wivh4tk6Dpmc5z9jj/wAKs6houl6sIxqum2d6Is+X9pgWTZnrjcDjoKff6nYaVCs2qX1tZRM2xXuJljUt6AsRzVrr0oAoafoOkaTK8mlaVZWUjrtZ7a2SMsPQlQMir9FFABRRRQAUUUUAFUdQ0TStXaM6tplnfGMEIbm3STZnrjcDjpV6mSyxwQvNPIscUalnd2wqgckknoKAK2n6RpukI66Vp9rYrIQXFtAsYYjpnaBmi60jTb66iur3T7W4uIP9VNLArvH/ALpIyPwqzDNFcwJNbyJLFIoZJEYMrA8ggjqKfR1AKKKhmu7a3mhiuLiKKS4YpCjuFMjAZIUHqcAnigCaiiigAoqKW6t4JoYZ54o5Z2KxI7gNIQMkKD1OATxSWt3bXsPm2dxFcRhim+Jww3A4IyO4IwaAKN94Y0DVLo3Op6Hpt5cMADLcWkcjkDpyQTVjTtH0zR43j0jTrSwSQ7nW1gWIMfUhQM1cooApXejaXf3cN1f6baXNxAcwzTQK7x85+UkZH4VdopkM0VxGJIJElQkgMjAg4ODyPcUAPooooAKKKKACoLyytdQtXtr+2hurd8bop4w6tg5GQeDzTprmC2hlluJo4o4V3yPI4UIvqSegp8Usc0KSwuskbqGR0OQwPQg9xQBlReEfDcEyTQeH9KiljYMjpZRhlI5BBC8GtcjIweRRUS3MD3L26zRtOihmiDjcoPQkdQKAKlhoOj6VM02l6VY2UrrtZ7e2SNmHXBKgcVoUUUAFFFFABRRRQAVDd2dtf2sltfW8VzbyDDxTIHRh7g8GpqKAMSPwX4WikWSLw1pCOhDKy2EQKkdCDtrXngiuoHguYkmikG145FDKw9CD1qSigCrp+l6fpNuYNKsbayhJyY7aFY1J9cKAKtUUUAFFFFABRRRQAVS1HRdK1hVXVtMs74IcqLm3WTb9NwNXaKAIorWCC1W2hgjjgVdgiRAFC+mOmKx/+EH8J/8AQsaN/wCC+L/4mt2igBkMMdvCkMEaxRRqFREUBVA4AAHQU+iigAooooAKKKKACs6fw7otzqC31zo9hNeKQVuJLVGkB9mIzWjRQAVRj0TSodUfUotMs479/v3S26CVvq+Mn86vUUAFFFFABRRRQAUUUUAV77T7LVLVrXU7SC8t2IJiuIlkQkdOCCKSw06y0u1Ftplnb2duCSIreJY1BPU4AAqzRQBSGjaWNU/tMabafb8Y+1+Qvm46Y34z+tXaKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAzNX0HSNURptT0qyvJUjKpJcW6SMo5OASDiuQ+HehaOvw603VDo+nvfLDI4uHtUMhIZv4sZ9utd/MpeCRVGSVIH5Vzfg7SL7Svh1aaZfweVeRwSI0W9WwSWIGQSO471Luoyt/W41q1f+tjnNP8AGWsLpvhO10TSNNEmr20zeQiNFFCUxgjBO1RkkjBJ7VbtPEvja9uL/RYNM0caxpzK09y8kgtSjDKhR98sefYY/Co/DvhfWLC48FtdWfljTLS5juz5qHymcDaODzn2zXRaRpd5a+NvEN/PDttrxbYQSbgd+xCG4ByME960la7+f56ER2+45+b4lSf8IvpNxHBZWuqam0sYF9cCK3gMZKuzMecZAwOpzV7wj40n1bWZdG1afSLm8WH7RHcaPc+dDIucFSDyrDI69c1gnwLqY0DSLp9Js76/0y4umfTb1kaO4ilkY43cqG+6Rnp3roPCWlXkepyX134Q0Xw5GI9iR2ypJcMxPJMiAKFx2wTSW5UtNF/WpieNbHVtT+Kvhy1Nto13p/lSukN/G78Db5pK9NwGNh9c5qxYeOte/sfUNf1Kx09dGsmmgSOIuLi4mWXYm3JKqp4HPOQT04rodT0q9uPiDoWpQw7rS0trlJpN4GxnCbRjOTnB6CsW08G3158M7/Qr1VtLya7nnhLMHCnzzJGTtJ4PHvzUrSP3/n/lsPr935f5k1l4k8VaZrGnw+M9O0yKz1WXybaTT5HZreQgsqS7uDnBGV4yKyp/H3iqOw1HWY9K019I0m/lt7sl3E8yLJtzEM4BAIyWPJzgCr8Np4t8T6zpQ8SaNbaPZaTci6eSO8WY3ciqQuwAfIuTk7uelQzeF9Yf4beJtKWzze319czW8Xmp86PKGU5zgZHqRVf1+X/BEui9P1v+ho6T4k8RDxfb6Z4jsNPt7bUreS4sfssjtJFs25SUngnDD7vHHetrxbrE2geEtS1W1SOSa0gMiLICVJHrgj+dUb7SL6bx14f1GODNrZ2txHPJvX5GcJtGM5OcHpVjxvpt3rHgfVtP06Lzrq4tmSKPcF3Me2SQB+NKXw6f1qwhq9fIzBqfjk6D9o/s3RvtdzLuh3XDrFaQFMhpieWYHghBiqWi+N9Xmt/Elpq8elyanotr9oE2nSM9vJlGZRgncCNvIz+VS+OtA1TUrDRWtNKj1uCyYm60iW6ECzkoArbjwdpycHjmsXw74R1y0fxRJN4estJi1TTBFa2tlMhVHCuNjHjL8glunvSltK3mOP2b+X56l3TvGvixZNB1HXNL0yLRtakigjFvI5uInkXKs2fl2nHQZIz1qPX/ABN4l1fSfEE+jaZYy6BaJcWkjSzMLmYqpV3jAG0BTng8nFal74e1SXwj4Rso7bNxp13ZSXSeYv7tY1w5znBx7Zz2rNu9H8XaVZ634f0TSrW907UmuJoL97oI0HmglkaM8sckgEEDkZp1EveS87fh/wAEKb+Fvyv+P/AH6dr+vNo+haB4PtLGW+TR7e5uLjUXcQwoVAUYT5ixwfpiprnx/qdv4YluH0yFdZstTi0+7s95ZGLMvKNkcMrAgnpnnNQQaJ4m8MPpmr6JpMOqTtpMFjfae90sLq8Y4ZZDlTjJBHtxSS+Etdn0KW5u4In1XUdbttQuLeGUbII0dBtDHG4qq8+p6Zq5Wc36/wDt3+RC0ivT9P8AMlTxN46OtXPh5tL0T+1zCt3bzrNL9mjhLFSH43l8gDgAHOeMcyWfi2bV18Jz3em2Qubq/ntp96FzBJGkgZomJ+XJXrzwcVtppV6PidLqxh/0FtJW2Eu9f9YJS23Gc9D1xiuc0nwrrNr/AMI759nt+xazeXU/71Dsjk8zY3B5zuHAyeealdP662/IqXW39aX/ADLOtah8SLC8b7GvhWSGacx2kLC5M0i54zjjIXknoMGrniPVfGVpMRpFvoNrbwxK0l1qtwwWd8ZYRqpyAPVsf1rKh1Xx7baxeXc/gFb6V5GSCYaxBGI4c8KFOcZxknqT9ABR17wzr134ou76bwfYa/8Abo4jbTX18uzTsIA0ZjI+Ybsn5RzU68qt/X9fd+r6u/8AX9f15X4PEH/CUy+AtY8j7O1zd3BaMNuCsIZFOD3GRRYeL78aDZ2ug6Tp41bUr+7ht4VUw26LFI26VwMk9icckmm+GPCmtabpPg62vbJY5NJvLlrrZKhVUZZArDnkHcOByM8gVFa+E/EOl6ZpuqWFlDJq2l397ILKaZVFxDM7HAcZCtjaRn8auVuby/4YnW39eZo/8Jnrmnabr1p4gs7GLW9LsGvomti7W1wmDggHDDDDBGaj07xf4ri1XRZPEOmabBpWtsIrcW0jtPA5TcvmZ+U5weB09eOYJ/D/AIj1+y8Ravq+nRWOoX2lNp9lpsdyshRfmOXk4UksfoBWvqmh6jc2vhBIbfc2m3kMt0N6jy1WJlJ688kDjNJb6+X5v9LA9tPP8l+tzR8Z6hLp3hec2shjuLl0tYXHVHkYIG/DOfwrO1/V7/wxd+HtE8O2NtOLwSQJHMxULsQFTuHQDqeCSBxzVzx5aSXPhOWaFDJJYyxXgQfxCJw5H5A0mqWNxqfirwzqljGJbK2895ZQ4woeLCnBOTk+maS/X8Lf8OP/AC/r9DEt/E3jW8k1HSbbTtG/tjS2U3MzySfZnRl3IEX7+4jPXAGPfiVfHOp6xpujReG9Pt21XVLdrhlu5GENsiHazNjk/NwAK1NG0i+tPGnia/uINltffZ/s771O/bGQ3AORg+uK5vS/DXiTw/pWhanp1hDc6jY201rdadLOqeZG8hcbZBlQwIHXjBo9fL8n+th+n9bf8E1V8X6xZaTr0GtWdnDrWk2Zuk8hmaC4Qg7WUEhsZUgg81VtvF/imB9G1DWtM0yLSNWligRYJXNxE0g+Vmz8uD6DkZ60knh/X9YsPEmq6rZRWuo6lpxsrTT4pxJ5agMQGfhSxZu3FaGv6FqN74d8N21rb75rK+tJbhd6jYqD5jknBx7ZprdX8vzd/wACXtp5/krfjc5Oc66ZviN9uOnm18h/M8rf5m7yf3e3PGNn3vfpxWrpPiXxLo9h4dk1TTtPTRL4W9nGI5XNzGzKArt/Dg4zgcjPWp9T0PXv7R8YW1tpi3FnrVput7lbhFKyiLYIypOeT36D+V3WdB1K78LeGLO3tt89heWctwnmKNixj5zknBx7Z9qI9P8At39bjl/8l+lirqXjHXZfFV7pfh9dDU2LhGtdRuWjubslQ37oDgDnGTnmtHxd9pt9FtfEcELW2o2AV5ItwOY2I3xMRkEc/pkVk+MdG1XVtRngn8FaZrsEny218LsW8kC46Pn5jg5Pynp2zVnWbW8074d6f4bkn+2ardpHaKc53EYLN67QB1+lSr8um+g9ObyO0tLlLyzhuYvuTRrIv0IyKlqCxtRZadb2qnIgiWMH1wMVPVO19CVe2oUUUUhhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAAQCCDyD1qCzs4NPs47Wzj8uCMYRASQo9Bnt7dqnooAKKKKACiiigAooooAKrf2da/2n/aBi3XXl+WJGYnavoATge+OtWaKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/9k=" /></p><p>Figure 1 Kaplan-Meier curves for overall survival (intent-to-treat population)</p><p>The results from the trial were not consistent in the subgroup of patients with a poor performance status (WHO PS=2, n=70), where overall survival and time to progression were similar in both arms. However, no unacceptable risks appear to be present in this patient group.</p><p><u>Recurrent or prorvessive malignant glioma</u><br />Data on clinical efficacy in patients with glioblastoma multiforme (Karnofsky performance status [KPS] &ge; 70), progressive or recurrent after surgery and RT, were based on two clinical trials with oral TMZ. One was a noncomparative trial in 138 patients (29 %received prior chemotherapy), and the other was a randomised active-controlled trial of TMZ vs procarbazine in a total of 225 patients (67 % received prior treatment with nitrosourea based chemotherapy). In both trials, the primary endpoint was progression-free survival (PFS) defined by MRI scans or neurological worsening. In the non-comparative trial, the PFS at 6 months was 19 %, the median progression-free survival was 2.1 months, and the median overall survival 5.4 months. The objective response rate (ORR) based on MRI scans was 8 %.</p><p>In the randomised active-controlled trial, the PFS at 6 months was significantly greater for TMZ than for procarbazine (21 % vs 8 %, respectively-chi-square p = 0.008) with median PFS of 2.89 and 1.88 months respectively (log rank p = 0.0063). The median survival was 7.34 and 5.66 months for TMZ and procarbazine, respectively (log rank p = 0.33). At 6 months, the fraction of surviving patients was significantly higher in the TMZ arm (60 %) compared with the procarbazine arm (44 %) (chi-square p = 0.019). In patients with prior chemotherapy a benefit was indicated in those with a KPS &ge;80.</p><p>Data on time to worsening of neurological status favoured TMZ over procarbazine as did data on time to worsening of performance status (decrease to a KPS of&lt; 70 or a decrease by at least 30 points). The median times to progression in these endpoints ranged from 0.7 to 2.1 months longer for TMZ than for procarbazine (log rank p = &lt; 0.01 to 0.03).</p><p><u>Recurrent anaplastic astrocytoma</u><br />In a multicentre, prospective phase II trial evaluating the safety and efficacy of oral TMZ in the treatment of patients with anaplastic astrocytoma at first relapse, the 6 month PFS was 46 %. The median PFS was 5.4 months. Median overall survival was 14.6 months. Response rate, based on the central reviewer assessment, was 35 % (13 CR and 43 PR) for the intent-to-treat population (ITT) n=162. In 43 patients stable disease was reported. The 6-month event-free survival for the ITT population was 44 % with a median event-free survival of 4.6 months, which was similar to the results for the progression-free survival. For the eligible histology population, the efficacy results were similar. Achieving a radiological objective response or maintaining progression-free status was strongly associated with maintained or improved quality of life.</p><p><u>Paediatric population</u><br />Oral TMZ has been studied in paediatric patients (age 3-18 years) with recurrent brainstem glioma or recurrent high grade astrocytoma, in a regimen administered daily for 5 days every 28 days. Tolerance to TMZ is similar to adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>TMZ is spontaneously hydrolyzed at physiologic pH primarily to the active species, 3-methyl-(triazen-1-yl) imidazole- 4-carboxamide (MTIC). MTIC is spontaneously hydrolyzed to 5-amino-imidazole-4-carboxamide (AIC), a known intermediate in purine and nucleic acid biosynthesis, and to methylhydrazine, which is believed to be the active alkylating species. The cytotoxicity of MTIC is thought to be primarily due to alkylation of DNA mainly at the 0<sup>6</sup> and N <sup>7</sup> positions of guanine. Relative to the AUC of TMZ, the exposure to MTIC and AIC is ~ 2.4 % and 23 %, respectively. In vivo, the t <sub>1/2</sub> of MTIC was similar to that of TMZ, 1.8 hr.</p><p><u>Absorption</u><br />After oral administration to adult patients, TMZ is absorbed rapidly, with peak concentrations reached as early as 20 minutes post-administration (mean time between 0.5 and 1.5 hours). After oral administration of 14C-labelled TMZ, mean faecal excretion of 14<sup>C</sup> over 7 days post-dose was 0.8 % indicating complete absorption.</p><p><u>Distribution</u><br />TMZ demonstrates low protein binding (10% to 20 %), and thus it is not expected to interact with highly proteinbound substances. PET studies in humans and preclinical data suggest that TMZ crosses the blood-brain barrier rapidly and is present in the CSF. CSF penetration was confirmed in one patient; CSF exposure based on AUC of TMZ was approximately 30 % of that in plasma, which is consistent with animal data.</p><p><u>Elimination</u><br />The half-life (t <sub>1/2</sub>) in plasma is approximately 1.8 hours. The major route of 14<sup>C</sup> elimination is renal. Following oral administration, approximately 5 % to 10 % of the dose is recovered unchanged in the urine over 24 hours, and the remainder excreted as temozolomide acid, 5-aminoimidazole-4-carboxamide (AIC) or unidentified polar metabolites. Plasma concentrations increase in a dose-related manner. Plasma clearance, volume of distribution and half-life are independent of dose.</p><p><u>Special populations</u><br />Analysis of population-based pharmacokinetics of TMZ revealed that plasma TMZ clearance was independent of age, renal function or tobacco use. In a separate pharmacokinetic study, plasma pharmacokinetic profiles in patients with mild to moderate hepatic impairment were similar to those observed in patients with normal hepatic function. Paediatric patients had a higher AUC than adult patients; however, the maximum tolerated dose (MTD) was 1,000 mg/m<sup>2</sup> per cycle both in children and in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single-cycle (5-day dosing. 23 days non-treatment). 3- and 6-cycle toxicity studies were conducted in rats and dogs. The primary targets of toxicity included the bone marrow. lymphoreticular system. testes. the gastrointestinal tract and, at higher doses. which were lethal to 60 % to 100 % of rats and dogs tested. degeneration of the retina occurred. Most of the toxicity showed evidence of reversibility, except for adverse events on the male reproductive system and retinal degeneration. However, because the doses implicated in retinal degeneration were in the lethal dose range,and no comparable effect has been observed in clinical studies,this finding was not considered to have clinical relevance.</p><p>TMZ is an embryotoxic, teratogenic and genotoxic alkylating agent. TMZ is more toxic to the rat and dog than to humans, and the clinical dose approximates the minimum lethal dose in rats and dogs. Dose related reductions in leukocytes and platelets appear to be sensitive indicators of toxicity. A variety of neoplasms,including mammary carcinomas. keratocanthoma of the skin and basal cell adenoma were observed in the 6-cycle rat study while no tumours or pre-neoplastic changes were evident in dog studies. Rats appear to be particularly sensitive to oncogenic effects of TMZ, with the occurrence of first tumours within 3 months of initiating dosing. This latency period is very short even for an alkylating agent.</p><p>Results of the Ames/salmonella and Human Peripheral Blood Lymphocyte (HPBL) chromosome aberration tests showed a positive mutagenicity response.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Capsule content</u><br />Lactose Anhydrous<br />Silica. Colloidal Anhydrous Sodium<br />Starch Glycolate (Type A)&nbsp;<br />Tartaric Acid<br />Stearic Acid &nbsp;<br />&nbsp;</p><p><u>Capsule shell,Size 0:</u><br />-5mg: Gelatin,Titanium dioxide (E 171),Yellow iron oxide (E 172),Indigotine-FD&amp; C Blue2 (E132)<br />-20mg: Gelatin,Titanium dioxide (E 171),Yellow iron oxide (E 172),Red iron oxide (E 172).<br />-100mg: Gelatin,Titanium dioxide (E 171),Red iron oxide (E 172),Indigotine-FD&amp; C Blue2 (E132)<br />-140mg: Gelatin,Titanium dioxide (E 171), Indigotine-FD&amp; C Blue2 (E132)<br />-180mg: Gelatin,Titanium dioxide (E 171),Yellow iron oxide (E 172),Red iron oxide (E 172),Black iron oxide( E 172)<br />-200mg: Gelatin,Titanium dioxide (E 171),</p><p><u>Printing ink&nbsp;</u><br />Black Ink:&nbsp;<br />Shellac&nbsp;<br />Propylene glycol&nbsp;<br />Purified water<br />Sodium ammonia solution<br />Potassium hydroxide<br />Black iron oxide (E 172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                HDPE bottles: 2 years
Sachets: 2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>HDPE Bottle presentation<br />Store below 30&deg;C<br />Store in the original bottle in order to protect from moisture. Keep the bottle tightly closed.</p><p>Sachet presentation<br />Store below 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Child proof container, made from white opaque High Density Polyethylene Bottles with Polypropylene child-proof closure, with polyester coil and dessicant desiccant containing 5 capsules.</p><p>Sachets composed of paper on linear low density polyethylene (outermost layer), aluminium and ethylene acrylic acid co-polymer (innermost layer). Each sachet contains 1 hard capsule and is dispensed in a cardboard carton. The carton contains 5 or 20 hard capsules, individually sealed in sachets.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Capsules should not be opened. If a capsule becomes damaged, contact of the powder contents with skin or mucous membrane must be avoided. If Temozolomide comes into contact with skin or mucosa, it should be washed immediately and thoroughly with soap and water.</p><p>Patients should be advised to keep capsules out of the sight and reach of children, preferably in a locked cupboard. Accidental ingestion can be lethal for children.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufacturer and 1ry Packager:
EirGen Pharma Ltd,Ireland
Westside Business Park, Old Kilmeaden Road, Waterford
Ireland

Marketing Authorisation Holder:
Aspen Pharma Trading Limited ,
3016 Lake Drive Citywest Business Campus Dublin 24
Ireland
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Date of Text revision: November 2015
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>